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“Nothing in life is to be feared,  
it is only to be understood.  
Now is the time to understand more,  
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Abstract 
Familial Hypercholesterolaemia (FH) is a common autosomal dominant disorder of 
the defective plasma clearance of LDL-cholesterol (LDL-C). Mutations in three 
genes, LDLR/APOB/PCSK9, can be detected in 60-90% of definite FH patients. 
DNA-based testing for FH mutations has important clinical utility and is 
recommended by the UK and European guidelines to identify affected relatives. This 
thesis aimed to determine the frequency and spectrum of FH mutations in two 
independent cohorts of FH patients (from one Oxford lipid clinic, and of Indian 
background). The FH mutation spectrum was shown to be highly heterogeneous and 
the mutation detection rate was significantly dependent on the pre-treatment total 
cholesterol and triglyceride levels. This project also validated the findings that a 
proportion of clinically diagnosed FH patients have a polygenic cause of 
hypercholesterolaemia due to an accumulation of common mild LDL-C-raising alleles 
by analysing LDL-C gene score in 88 mutation negative and 21 mutation positive FH 
patients, and by replicating the results in further 231 FH patients. A high-throughput 
DNA sequencing method was assessed as a novel diagnostic tool for detection of 
FH mutations, and compared it with the currently used methods. This highlighted the 
need for updating the current FH mutation screening methods as well as the need for 
more efficient bioinformatics for the next generation sequencing data analysis. 
Lastly, whole exome sequencing of 125 definite FH patients with no mutations 
detected in known genes was performed to identify novel monogenic causes of FH. 
Variants in two genes, CH25H and INSIG2, were identified as potential novel FH 
mutations. Overall, the results of this thesis demonstrate the heterogeneous FH 
aetiology and help to understand the genetic architecture of the disease.
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I. CHAPTER ONE - General Introduction 
22 
 
1.1. Lipid metabolism 
1.1.1. Lipids and Lipoproteins 
Lipids are water-insoluble, structurally diverse, organic molecules 
characterized by a hydrocarbon backbone, which can be utilized or 
synthesized from the dietary fats. Several lipid subgroups can be 
distinguished, depending on their chemical composition. Triglyceride (TG) is 
an ester derived from glycerol and three fatty acids, stored in the adipose 
tissue, which is important for energy supply. TG, commonly named as fat, is 
the source of free fatty acids, which are the major substrate for the energy 
production (saturated fatty acids), precursors for tissue hormones 
(unsaturated fatty acids) (Bhathena 2006), or act as ligands for transcription 
factors, influencing gene expression (Lin et al. 1999, Hostetler et al. 2005, 
Hostetler et al. 2006). Cholesterol, the crucial component of cellular 
membranes, is the major sterol in human body, which also functions as a 
precursor for steroid hormones. Cholesterol regulates its own metabolism and 
biosythesis by inducing the activity of sterol regulatory element-binding protein 
(SREBP). Other lipid subgroups include lipophilic vitamins (vitamins A, D, E, 
and K), which also function as ligands for transcription factors and are 
important for regulation of genes involved in energy metabolism (McEwan 
2009), and phospho- and sphingolipids, which are structural membrane 
components. 
In order to be transported in the plasma, hydrophobic lipids are assembled in 
lipoprotein particles. Lipoproteins have a hydrophobic inner core containing 
23 
 
TG and cholesterol esters (CE), covered by a membrane-like structure formed 
by hydrophilic phospholipids, unesterified cholesterol and proteins called 
apolipoproteins. The role of apolipoproteins is to solubilize and stabilize lipids 
in the aqueous environment of plasma. Lipoproteins are divided into five 
classes, according to their origin and density: chylomicrons, very low density 
lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density 
lipoproteins (LDL) and high density lipoproteins (HDL). The plasma 
lipoproteins differ in their composition, as shown in Table 1.  
Lipoprotein trafficking can be divided in three pathways: the exogenous 
pathway, during which dietary cholesterol and fatty acids are absorbed, the 
endogenous pathway, when lipoproteins synthesized in the liver are 
distributed to peripheral tissues, and the reverse cholesterol pathway, which 
mediates transport of excess cholesterol from the periphery to the liver, 
summarized in Figure 1. 
 
Table 1 
Composition of the plasma lipoproteins (% total) (taken from (Feher and 
Richmond 1997)). 
  
Chylomicrons VLDL IDL LDL HDL 
protein 2 10 18 25 55 
TG 85 50 26 10 4 
cholesterol 1 7 12 8 2 
cholesterol 
ester 
3 13 22 37 15 
phospholipid 9 20 22 20 24 
24 
 
Figure 1 
Schematic representation of lipid metabolism. E= Apolipoprotein E, C= Apolipoprotein C, A= Apolipoprotein A, B-48=Apolipoprotein 
B-48, B-100=Apolipoprotein B-100, LPL=lipoprotein lipase, LCAT=lecithin-cholesterol acyltransferase, HTGL=hepatic triglyceride 
lipase (adapted from (Goldstein et al. 1983)).
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1.1.2. Exogenous pathway 
Exogenous transport of cholesterol and fats begins with the absorption of 
dietary lipids in the intestine, during which TGs are hydrolyzed to 
monoacylglycerols and fatty acids. After lipid diffusion across the microvillus 
membrane, cholesterol and fatty acids are re-esterified and packaged with 
apolipoprotein B-48 (ApoB-48), several apolipoproteins A (ApoA-I, ApoA-II, 
ApoA-IV) and other lipids to form chylomicrons. After their synthesis in the 
intestinal wall the chylomicrons enter the blood circulation via the lymphatic 
system where they acquire apolipoproteins E and C (ApoE, ApoC-I, ApoC-II, 
ApoC-III) from HDL-C. ApoC-II activates lipoprotein lipase (LPL), which 
rapidly hydrolyses TGs to produce free fatty acids (FFAs). The FFAs leave 
chylomicrons and are transported to different tissues such as muscle and 
adipose tissue. The remaining chylomicrons, much reduced in size, contain 
the core remnants rich in cholesterol esters, ApoB-48 and ApoE, and the 
surface remnants, mainly composed of phospholipids and Apo-C. The latter is 
transferred to HDL particles, while the core remnants are taken up by the liver 
via the LDL-receptor, an ApoB/E specific receptor, and via the LDL-receptor 
related protein (LRP) (Choi et al. 1991, Rohlmann et al. 1998).  
1.1.3. Endogenous pathway 
To maintain and regulate the energy supply for tissues, the liver is able to 
synthesize TGs from fatty acids produced from acetate of dietary 
carbohydrates (Gibbons 1990). TGs, which can also be derived from the 
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chylomicron remnants produced during the exogenous pathway, are 
packaged together with cholesterol, cholesterol ester, phospholipid, 
apolipoproteins B-100 and A to form VLDL. Newly assembled VLDL particles 
enter the circulation where, similarly to the chylomicrons, acquire more 
apolipoprotein (ApoC and ApoE) from HDL, which activates LPL to hydrolyze 
TGs and to release FFA. The cholesterylester transfer protein (CETP) 
controls the exchange of VLDL lipids with mature HDL, which enriches VLDL 
in cholesterol esters and forms the intermediate density lipoprotein (IDL). 
Further loss of TGs and phospholipids from IDL particles (mainly transferred 
to HDL) is accompanied by a loss of apoliporoteins C and E, which leads to 
an increase in the lipid density of the particles. Apolipoprotein B-100 (ApoB-
100) becomes the major carrier of the assembled LDL particles, which acts as 
a ligand for the LDL-receptors located on the surface of the liver cells or any 
other cells requiring cholesterol supply. Once bound to the receptor, LDL is 
internalized and undergoes lysosomal hydrolysis.  
1.1.4. Reverse cholesterol transport 
Excess cholesterol in peripheral tissues can be transferred back to the liver in 
high density lipoprotein (HDL) particles, in the metabolic pathway of reverse 
cholesterol transport (Glomset 1968). Apolipoprotein A-I produced by the liver 
circulates as pre-beta HDL particles to peripheral cells, where it picks up 
cholesterol and phospholipids. The ATP-binding cassette (ABC) transporter 1 
(ABCA1), described as the gatekeeper of reverse cholesterol transport 
pathway (Oram and Lawn 2001), transports cellular cholesterol and 
phospholipids to the cell surface where they can bind apolipoproteins (Oram 
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and Yokoyama 1996). While in the circulation, HDL accumulates more lipids, 
which reduces its density. It can also acquire ApoE, which enables it to bind to 
the ApoE receptors on hepatocytes. Lecithin-cholesterol acyltransferase 
(LCAT) is an enzyme that esterifies the cholesterol into cholesterol esters that 
accumulate in HDL particle (Roheim 1986). Cholesterol esters can be 
exchanged for TG from TG-rich lipoproteins by CETP or transferred to the 
liver by the scavenger receptor SR-B1 or ABC transporters (Acton et al. 
1996). Once in the liver cholesterol can be recycled to form lipoproteins, used 
for bile acid production or secreted directly into the bile. 
1.1.5. Cholesterol homeostasis  
The concentration of cellular cholesterol is controlled by the regulated 
transport of the ER membrane-bound transcription factor, called the sterol 
regulatory element-binding protein (SREBP), to the Golgi complex 
(Radhakrishnan et al. 2007). Once in the Golgi, SREBP is proteolytically 
processed to release its active fragments, which are imported to the nucleus 
to switch on the transcription of 3-Hydroxy-3-Methylglutaryl-CoA Reductase  
(HMGCR) and Low Density Lipoprotein Receptor (LDLR), and other sterol-
regulated genes (Goldstein et al. 2006). HMGCR encodes the hydroxymethyl-
glutaryl CoA reductase, the rate-limiting enzyme of cellular cholesterol 
biosynthesis, whereas LDLR codes for the LDL-receptor responsible for the 
uptake of LDL-C from plasma. Thus a regulation of the expression of 
SREBP’s target genes enables the cell to maintain a constant level of 
membrane cholesterol, which is important especially during periods of rapid 
cell growth. The activity of SREBP is regulated by the end product, 
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cholesterol, and by oxysterols, which are derivatives of cholesterol 
(Kandutsch et al. 1977, Brown and Goldstein 1974b, Kandutsch et al. 1978). 
Cholesterol and oxysterols can suppress cholesterol biosynthesis and 
cholesterol uptake by binding to Insulin-Induced Gene (INSIG) proteins or to 
Sterol Regulatory Element Binding Protein Cleavage-Activating Protein 
(SCAP, cholesterol only), the escort protein of SREBP (Radhakrishnan et al. 
2007). The excess of cholesterol or oxysterols initiates the formation of an 
INSIG/SCAP complex, which blocks the transport of SREBPs to the Golgi, 
hence HMGCR and LDLR are no longer transcribed (Goldstein et al. 2006). 
Inhibition of SREBP prevents toxic accumulation of cholesterol. 
1.2. Atherosclerosis 
Atherosclerosis derives its name from Greek words ‘sclerosis’ (hardening) and 
‘athere‘ (gruel). The condition remains to be the leading cause of mortality and 
morbidity in developed countries (World Health Organization, 
http://www.who.int/gho/publications/world_health_statistics/2012/en/). The 
process of atherogenesis is driven by many environmental and genetic 
factors. One of the major risk factors is hyperlipidemia, especially increased 
levels of LDL-C in the plasma. Retention of LDL-C in the vessel wall leads to 
oxidation, which promotes the recruitment of monocytes and lymphocytes and 
an increased production of cytokines and growth factors. Monocytes and 
lymphocytes convert to macrophages and take up the oxidized LDL, which 
leads to formation of foam cells (Figure 2(b)). Foam cells form a lesion of 
yellow appearance, also called the fatty streak, which activates inflammation 
by recruiting further inflammatory cells. The lesion’s growth is caused by the 
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infiltration and proliferation of smooth muscle cells (SMCs) and synthesis of 
extracellular matrix containing collagen, elastin and proteoglycans. Some of 
the macrophages go through apoptosis and die, releasing more lipids to the 
core of the lesion forming a so-called necrotic core (Figure 2(c)). Rupture of 
the atherosclerotic plaque causes release of its core components to the 
lumen, which triggers thrombosis and occlusion of the artery (Figure 2(d)), 
which can lead to myocardial infarction resulting in sudden death.   
CVD risk reduction by LDL-C-lowering therapy is well established (Baigent et 
al. 2005). In contrast, HDL-C has been thought to be atheroprotective (Figure 
3), thus low levels of HDL-C were considered to be the risk factor for 
atherosclerosis (Di Angelantonio et al. 2009). However, results of a recent 
mendelian randomization study demonstrated that a gene score including 14 
genetic variants associated with high levels of HDL-C was not associated with 
reduced risk of myocardial infarction, suggesting that HDL-C is not a 
causative factor for CHD (Voight et al. 2012). In addition, the Heart Protection 
Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events 
(HPS2-THRIVE) showed that raising HDL-C with niacin treatment has no 
benefits or can be even harmful for patients at risk of CHD 
(http://www.sciencedaily.com-/releases/2013/03/130311101827.htm accessed 
on 20 Aug 2013). Other CVD risk factors can be divided into the modifiable 
risk factors, such as high blood pressure, smoking, lack of physical activity, 
diet, obesity, diabetes mellitus (including abnormal lipids as mentioned 
before), and the non-modifiable risk factors, including age, gender and genetic 
predisposition, which is reflected by the family history in majority of the 
affected patients (Boer et al. 1999). Other risk factors with a strong genetic 
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component include homocysteine (Rodgers and Conn 1990), haemostatic 
factors (Kannel 2005), lipoprotein(a) (Djurovic and Berg 1997) and systemic 
inflammation (Ross 1999). In the majority of patients, the multistep process of 
atherosclerosis development is likely to be caused by a combination of 
different risk factors, as well as gene-gene and gene-environment interactions 
(Do et al. 2011), however currently the robust statistical evidence to support 
this from single studies and their subsequent replication in larger studies is 
lacking. 
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Figure 2 
Stages in the development of atherosclerotic lesion (taken from (Libby et al. 2011)) and the normal artery (a).
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Figure 3 
Hazard ratios for CHD across quantiles of HDL-C and non-HDL-C plasma levels, based on 302,403 participants (including 12,785 
cases). Adapted from (Di Angelantonio et al. 2009). 
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Familial hypercholesterolaemia (FH) is a monogenic cause of atherosclerosis, 
which starts at a very early age, and eventually results in CHD. It was 
demonstrated that, if untreated, 30% of women and 50% of men patients with 
heterozygous FH will develop CHD by the age of 55 (Slack 1969). FH patients 
have five to eight times higher than average risk of developing CHD (Marks et 
al. 2003). Homozygous FH patients develop CHD very early in life and die 
before the age 20 if no treatment is provided. 
1.3. Overview of the molecular pathogenesis of FH 
Early work by the 1985 Nobel Prize laureates, Michael S. Brown and Joseph 
L. Goldstein, significantly broadened the understanding of lipid metabolism 
and the effect of its inborn errors. Extensive studies of the receptor-mediated 
endocytosis of low-density lipoprotein particles (LDL-C) explained the basis of 
cholesterol regulation within a cell system (Goldstein and Brown 1974). 
Because two thirds of human plasma cholesterol is contained within LDL 
particles, formation of atherosclerotic plaques was correctly linked with 
increased levels of LDL-C. Therefore answering the question: ‘What 
determines blood LDL-C levels in an individual?’ was crucial in order to 
prevent atherosclerosis and premature coronary heart disease (CHD).  
Brown and Goldstein’s biochemical and structural studies resulted in the 
description of the sequential steps of LDL-C uptake by a cell surface receptor, 
called the LDL-receptor (Brown and Goldstein 1979). They discovered that 
LDL-receptors are located in clathrin-coated pits. Binding of the LDL-C 
particle to its receptor initiates internalisation of LDL-LDL-R complexes within 
coated vesicles, which rapidly fuse with lysosomes.  This is followed by the 
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lysosomal hydrolysis of LDL-C, resulting in the release of unesterified 
cholesterol to the cytoplasm while the receptor recycles to the surface. 
Understanding of the LDL-C pathway became the foundation for the 
investigation of FH pathogenesis, which in 1974 led to identification of the first 
FH mutations at the LDLR locus (Brown and Goldstein 1974a). 
Mutation in one of the two inherited genes, the heterozygous form of FH, 
leads to an approximately two-fold increase in plasma cholesterol level. 
However, the homozygous FH is characterised by much greater cholesterol, 
even four- to five-fold the normal level. This occurs when an FH mutation is 
passed to the offspring from both his/her mother as well as from the father. An 
individual with two identical mutations, the true homozygote, or with two 
different mutations (the compound heterozygous FH) suffers extreme lipid 
levels from a very young age and require aggressive lipid-lowering treatment 
to prolong his/hers life.  
1.4. Clinical diagnosis of FH 
There are currently three FH diagnostic algorithms used in lipid clinics around 
the world. In the UK, the Simon Broome Heart Research Trust, which was 
originally founded by Mrs. Katherine Broome, widow of Simon Broome, who 
died prematurely of heart disease, created the Simon Broome register of 
patients suffering from FH. On the basis of the Simon Broome register, its 
Steering Committee ('Risk of fatal coronary heart disease in familial 
hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon 
Broome Register Group'  1991) developed the UK’s clinical diagnostic criteria 
for FH. The criteria distinguish two types of the disease: definite FH (DFH), 
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and possible FH (PFH). Both DFH and PFH patients should have total 
cholesterol (TC) greater than 7.5 mmol/l, and/or LDL-cholesterol (LDL-C) 
greater than 4.9 mmol/l (Table 2). The criteria also account for the difference 
in cholesterol levels between adults and children, thus the pre-treatment 
cholesterol cutoffs are appropriately lowered for patients under the age of 16 
(Table 2). Positive family history of myocardial infarction (MI) is also one of 
the criteria, although the specificity of this criterion depends on the prevalence 
to MI in the studied population. In addition, definite FH patients or their 
relatives (first or second degree) have observable lipid deposition in the 
tendons forming tendon xanthomata, as shown in Figure 4, although these 
are becoming increasingly uncommon due to improvements in early diagnosis 
and treatment. Presence of a variant known or predicted to affect function in 
one of the known FH genes (discussed in section 1.11) also classifies a 
patient as DFH (Marks et al. 2003). Approximately two thirds of all FH patients 
in the UK’s lipid clinics fall under the diagnosis of possible FH (Hadfield et al. 
2008). 
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Table 2 
Simon Broome diagnostic criteria for FH (Marks et al. 2003).  
 
 
 
 
Criteria                   
A 
Plasma cholesterol measurements of 
either:     
 
TC >7.5 mmol/l (adult) or >6.7 mmol/l (child <16 
years)   
 
LDL-C >4.9 mmol/l (adult) or >4.0 mmol/l (child <16 
years)   
B 
Presence of tendon xanthomata in patient or in a relative (first or second 
degree) 
C DNA-based evidence of a mutation in an FH gene 
   
D 
Family history of MI in a second degree relative <50 years or 
in a first degree relative <60 years of age   
E Family history of plasma TC >7.5 mmol/l ina first or second degree relative 
                    
Diagnosis Criteria required 
      
Definite FH A + B or C 
       
Possible FH A +D or A + E 
       
                    
37 
 
Figure 4 
Tendon xanthoma shown in A. is the clinical feature of DFH; xanthelasmas 
and arcus corneae (B) and xanthomata of the extensor tendons (C) are also 
commonly observed in older FH patients, however they are not diagnostic 
features for FH (all taken from (Liyanage et al. 2011) )
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A similar FH diagnostic system has been developed by the Dutch Lipid Clinic 
Network (DLCN). The algorithm uses numerical scores and classifies patients 
into three sub-groups (Marks et al. 2003). The definite FH patients have a 
score greater than 8, the probable FH - between 6 and 8, and the possible FH 
- between 3 and 5 points. No diagnosis is made if the score is below 3. 
Similarly to the Simon Broome FH criteria, DLCNC score is based on a family 
history of premature CHD, LDL-C levels, presence of tendon xanthoma/ 
corneal arcus, and DNA analysis, as summarized in Table 3. A possible 
advantage of the DLCN score over the Simon Broome FH criteria is that the 
DLCN does not require tendon xanthoma to be present for the diagnosis of 
DFH patients (if a mutation has not been identified). As shown in Table 3, a 
definite FH diagnosis can be made on the basis of an extreme LDL-C 
measurement only. 
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Table 3 
The FH diagnostic criteria, as defined by the Dutch Lipid Clinic Network. The DLCN score distinguishes three forms of FH: possible 
(3-5 points), probable (6-8 points), and definite (>8 points) 
Dutch lipid clinic network diagnosis of FH Points 
Family history 
 
A First degree relative with known premature (<55 years men; <60 years women) coronary and vascular disease 1 
B First-degree relative with known LDL-cholesterol >95th percentile and/or2 
 
A First degree relative with tendon xanthomata and/or arcus cornealis 2 
B Children below 18 years with LDL cholesterol >95th percentile 
 
Clinical history 
 
A Patient has premature (<55 years men; <60 years women) coronary artery disease 2 
B Patient has premature (<55 years men; <60 years women) cerebral or peripheral vascular disease 1 
Physical Examination 
 
A Tendon xanthomata 6 
B Arcus cornealis below 45 years 4 
Laboratory analysis 
 
A LDL-cholesterol   > 8.5 mmol/l 8 
B LDL-cholesterol   6.5-8.4 mmol/l 5 
C LDL-cholesterol   5.0-6.4 mmol/l 3 
D LDL-cholesterol   4.0-4.9 mmol/l 1 
 
(HDL-cholesterol and triglycerides are normal) 
 
 DNA analysis  
A Functional mutation  8 
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An early approach to diagnose FH was developed by the MEDPED study 
(Make Early Diagnoses and Prevent Early Deaths), in the USA (Williams et al. 
1993). The MEDPED criteria were based on age- and sex- adjusted total 
cholesterol levels, however it has been demonstrated that in order to avoid a 
high false positive rate the diagnosis of FH should generally not be made 
using total or LDL cholesterol levels alone. The MEDPED cholesterol cut-offs 
for each age group are shown in Table 4. 
The sensitivity and specificity in identifying FH patients with a mutation using 
all three clinical diagnostic algorithms was compared in a study of 408 
patients, which showed that the Simon Broome criteria and the DLCN score 
did not differ much, but both performed better than the MEDPED diagnosis 
(Damgaard et al. 2005). 
Table 4 
MEDPED program TC cut-offs for diagnosis of FH in relatives of a patient and 
their comparison with the general population (Williams et al. 1993).  
  Total cholesterol (mmol/L) 
Age 
(years) 
      
First degree 
relative 
Second degree 
relative 
General 
population 
(Utah) 
<20 5.7 5.9 7.0 
20–29 6.2 6.5 7.5 
30–39 7 7.2 8.8 
>40 7.5 7.8 9.3 
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1.5. Genetic diagnosis of FH 
A DNA-based test can give a definite diagnosis of FH and it is particularly 
useful at identifying affected relatives of a patient, especially those at a young 
age. Because of the difference in the FH mutation spectrum between 
populations, different screening methods have been applied. Methods used in 
the UK, a country with high genetic heterogeneity, originally included the 
commercially available Amplification Refractory Mutation System (ARMS) kit 
(Elucigene FH20, Gen-Probe, Oxford, UK), which was designed to screen for 
the most common UK FH variants including18 LDLR mutations, the APOB 
p.R3527Q, and the PCSK9 p.D374Y. Taylor et al. reported that the ARMS 
assay detected over 44% of the UK FH mutations (Taylor et al. 2010b), with 
the APOB p.R3527Q being the most commonly observed accounting for 12% 
of all detected mutations.  
Because of the wide spectrum of FH mutations in the UK, high resolution 
melting (HRM) of the entire coding region of LDLR, followed by Sanger 
sequencing, has been used to screen patients for less common mutations 
(Whittall et al. 2010b). The method was shown to be effective, however its 
sensitivity decreases in some regions depending on the nucleotide 
composition of the fragment. An additional method was developed to test for 
large deletions and duplications within the LDLR gene (Taylor et al. 2009). 
The multiplex ligation-dependent probe amplification (MLPA) (MRC-Holland) 
is a rather laborious and costly method, but it allows the detection of large 
deletions and insertions, which account for up to 10% of all UK FH mutations 
(Futema et al. 2013). Another commercially available FH diagnostic kit, which 
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test for over 250 FH mutations is LIPOchip (Progenica Biopharma, Spain), 
was shown to detect an FH mutation in 66% of over 800 screened Spanish 
FH patients (Alonso et al. 2009). Although Elucigene FH20 and LIPOchip 
have been widely used as a simple diagnostic tool, a recent review funded by 
The National Institute for Health Research Health Technology Assessment 
programme highlighted the need for novel comprehensive FH mutation 
detection methods, and demonstrated that the off-the-shelf diagnostic kits 
may be less cost-effective in comparison to the novel emerging methods 
(Sharma et al. 2012).  
Next generation sequencing (NGS) has certainly revolutionised molecular 
diagnostic labs, with the costs of custom design targeted deep sequencing 
methods, provided by for example Illumina or Agilent, steadily decreasing. 
Novel NGS approaches, which include PCR-free methods such as the TruSeq 
DNA PCR-free sample preparation kit from Illumina, can provide reliable 
results in two days, however their sensitivity and specificity is still being 
tested.   
The development of more efficient and cheaper screening methods for FH will 
lead to higher mutation detection rate. However, another reason for low 
mutation detection rate in some of the lipid clinics could be due to 
misdiagnosis of the monogenic hypercholesterolaemia with the polygenic form 
of the disease. A recent report demonstrated that at least 20% of the patients 
diagnosed with FH but with no detected mutation may have had high 
cholesterol due to polygenic factors (Talmud et al. 2013).  Finally, the 
detection rate can be low due to a presence of novel FH loci, located outside 
of the screened regions.
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Table 5 
FH mutations included in the ARMS test. The list contains cDNA position 
starting from ATG. 
 
Mutation and protein change 
c.259T>G (p.W87G) 
c.301G.A (p.E101K) 
c.313+1G>A 
c.551G>A (p.C184Y) 
c.654_656delTGG (p.G218del) 
c.680_681delAC (p.D227Gfs*12) 
c.662A>G (p.D221G) 
c.681C>G (p.D227E) 
c.682G>T (p.E228X) 
c.932_933delAA (p.K311Rfs*20) 
c.1048C>T (p.R350X) 
c.1150C>T (p.Q384X) 
c.1285G>A (p.V429M) 
c.1436T>C (p.L479P) 
c.1444G>C (p.D482H) 
c.1444G>A (p.D482N) 
c.2029T>C (p.C677R) 
c.2054C>T (p.P685L) 
APOB c.10580G>A (p.R3527Q) 
PCSK9 c.1120G>T (p.D374Y) 
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1.6. Clinical utility of DNA testing 
DNA testing for FH mutations can provide an unequivocal diagnosis in 
comparison to diagnosis based on clinical observations and lipid 
measurements. This has been confirmed in several studies (Soutar and 
Naoumova 2007, Varret et al. 2008, Campagna et al. 2008). The genetic 
diagnosis overcomes the overlap problem of LDL-C levels between the 
affected and not affected individuals. It was reported that the LDL-C overlap in 
children (5-15 years old) leads to false negative rate of FH diagnosis in 15% 
of patients (Figure 5), and it gets worse with age (Starr et al. 2008).   
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Figure 5 
LDL-C levels in FH patients (with genetic diagnosis) vs. not FH patients aged 5-15 years. The LDL-C overlap leads to 8% mutation 
negative individuals being falsely diagnosed with FH based on their LDL-C level, and 15% of mutation positive patients not being 
diagnosed with FH based on their LDL-C level. Taken from (Starr et al. 2008).
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One of the main benefits of identifying the disease-causing variant is that it 
allows for diagnosis of affected relatives. In a family with a monogenic disease 
like FH, 50% of the first-degree relatives are expected to carry the mutation. 
For comparison, a study showed that only 25.6% of relatives of FH patients 
without a detected mutation were given the FH diagnosis, which suggests a 
polygenic rather than monogenic cause of hypercholesterolaemia (Humphries 
et al. 2006a). The DNA testing has been recommended by the National 
Institute for Health and Clinical Excellence (NICE) as a tool to identify affected 
relatives in cascade testing, as discussed in the next section.  
Genetic diagnosis of FH in children can help to implement life-style changes, 
such as diet, exercise, no smoking, at an early age, which can reduce the risk 
of developing premature CHD. The use of statins in pediatric patients was 
demonstrated to be beneficial (Eiland and Luttrell 2010, Arambepola et al. 
2007, Avis et al. 2007), although its long-term efficacy have not been 
established. The need for a long-term randomized controlled trial in children 
has been highlighted (Vuorio et al. 2010). 
Furthermore, identification of an FH mutation is beneficial for the patients 
monitoring and for the management of LDL-C-lowering therapy (Humphries et 
al. 2006a, Umans-Eckenhausen et al. 2001).   
1.7. Cascade testing to identify FH patients 
 
In 2008, the National Institute for Health and Clinical Excellence (NICE) 
published guidelines and recommendations on the diagnosis and 
management of FH in the UK (CG71) (Wierzbicki et al. 2008). The guidelines 
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state that healthcare professionals should offer a referral for cascade testing 
to every FH patient, in order to identify affected relatives of the patient. This 
should include at least the first- and second- and, when possible, third-degree 
biological relatives. Cascade testing is of high public health interest and its 
goal is to reduce morbidity and mortality from heart disease in persons with 
FH through early diagnosis and effective disease management. A 
combination of DNA testing (for families where the causal mutation is already 
identified), which provides unequivocal diagnosis (Campagna et al. 2008), 
and measurement of LDL-C levels (in the remaining families) has been 
demonstrated as the most cost-effective current approach (Nherera et al. 
2011). This strategy has been successfully applied in the Netherlands in 
families of familial hypercholesterolaemia probands with a detected mutation, 
thus allowing statin treatment of family members at risk of early coronary 
heart disease (Umans-Eckenhausen et al. 2001). A recent case-control study 
on the use of LDL-C SNPs score to identify patients with polygenic 
hypercholesterolaemia (Talmud et al. 2013) suggested to implement the LDL-
C SNPs score calculations (discussed in section 2.3) before beginning the 
cascade testing in the mutation negative patients (Figure 6). The proposed 
strategy needs to be tested further, however it is predicted to increase the 
cost-effectiveness of the cascade testing. Despite clear benefits of the early 
identification of FH patients recently highlighted by the HEART UK charity 
(http://heartuk.org.uk/files/uploads/documents/HUK_HealthEconomics_FINAL
2012_2702.pdf, accessed on 20 Aug 2013), cascade testing has not been 
widely implemented in England. 
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Figure 6 
The proposed diagnostic workflow for cascade testing in patients with FH 
(taken from (Talmud et al. 2013)). *as recommended by NICE (Leren et al. 
2004)
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1.8. Problem of FH underdiagnosis 
 
In 2000, a prospective study in an Oxford based patients registry, highlighted 
the problem of FH underdiagnosis (Neil et al. 2000), which was further 
confirmed in a census estimating that only 15% of FH patients in the UK were 
identified (Marks et al. 2004). A recent report of the European Atherosclerosis 
Society demonstrated that in the majority of studied countries the proportion 
of FH patients being diagnosed is below 1% (Nordestgaard et al. 2013). The 
highest proportion of diagnosed patients was reported in the Netherlands 
(71%), followed by Norway (43%), Iceland (19%), Switzerland (13%), the UK 
(12%) and Spain (6%) (Figure 7). Authors estimated the proportions based on 
the FH prevalence of 1 in 500, however the differences in the frequency 
between some countries were not accounted for. The report suggested that 
there are between 14 and 34 million individuals affected by FH worldwide, 
which highlights the extent of FH underdiagnosis. Early diagnosis should lead 
to the introduction of statin treatment, patient education and advice on diet 
and life-style as well as cascade testing to identify affected relatives. Well-
operated cascade testing system would lead to an increase in the efficiency of 
CHD prevention and safe in the UK only an estimate of £6.9 million per year 
from avoiding cardiovascular events, as stated by the HEART UK charity 
(http://heartuk.org.uk/files/uploads/documents/HUK_HealthEconomics_FINAL
2012_2702.pdf, accessed on 20 Aug 2013). 
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Figure 7 
Estimated per cent of individuals diagnosed with familial 
hypercholesterolaemia in different countries/territories, as a fraction of those 
theoretically predicted based on a frequency of 1/500 in the general 
population. As most countries do not have valid nationwide registries for 
familial hypercholesterolaemia, several values in this figure represent 
informed estimates from clinicians/scientists with recognized expertise in and 
knowledge of familial hypercholesterolaemia in their respective countries. 
Numbers were provided by Michael Livingston, Steve E. Humphries (UK), 
Olivier S. Descamps (Belgium). (Taken from (Nordestgaard et al. 2013). 
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1.9. Treatment of FH 
The most common therapy for FH patients includes daily use of statins, which 
are lipid-lowering compounds, which stimulate expression of the LDL-receptor 
gene (LDLR) by inhibiting HMG-CoA (hydroxymethylglutaryl co-enzyme A) 
reductase activity. Although use of statins in FH patients was shown to be the 
most effective (see the next paragraph), alternative medications are available, 
when a patient does not tolerate the statin treatment. These include bile acid 
sequestrants, fibrates, nicotic acid, all in conjunction with low-fat diet. Lifestyle 
changes, in particular quitting of smoking, are advised to every FH patient. A 
combined FH therapy is also in use. Ezetimibe is a recently introduced lipid-
lowering drug, which acts by decreasing cholesterol absorption in the intestine 
(Toth and Davidson 2005). Ezetimibe can be used in combination with statins, 
which can result in additional cholesterol reduction (Morrone et al. 2012), and 
it has been recommended as an alternative and additional therapy by the 
NICE guidelines (2007), although a recent study of over 3,800 patients 
showed no significant mortality benefit over the use of statins alone (Patel et 
al. 2013). 
The efficacy of statins in heterozygous FH patients was assessed by the 
Simon Broome Scientific Steering Committee in a study of over 3,000 FH 
individuals, who were followed up for 26 years, until the end of 2006 (Neil et 
al. 2008). The standardized mortality ratio (SMR), which was expressed as a 
percentage (%), was compared between different age groups of patients 
before and after the statin treatment was introduced in 1992. The authors 
reported that the statins, when used as the primary prevention, reduced the 
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SMR for CHD over 59% in the middle age group (40-59) of participants (Table 
6). There was also a beneficial effect in the younger age group; however the 
result may be imprecise because of the small sample size hence large 
confidence intervals. In addition, it was shown that the secondary prevention 
reduced the number of deaths from the CHD in the whole group by 25%, with 
a larger effect in women. Overall, the study validated the significant impact of 
the early identification and treatment of heterozygous FH patients, and 
confirmed the importance of the early identification of FH patients for example 
by cascade testing (discussed in section 1.7.). 
 
Table 6 
The effect of the use of statins (primary prevention) in heterozygote FH 
patients (SMR for CHD, SMR=100 for the reference population) [adapted from 
(Neil, Cooper et al. 2008)]. 
Age 
groups 
(years) 
1980-1991 1992-2006 
SMR 95% CI P-value SMR 95% CI P-value 
20-39 3750 773-10 959 <0.001 1153 238-3372 <0.01 
40-59 342 148-674 <0.01 141 75-242 0.28 
 
Similar findings were reported by Versmissen et al., who mimicked a statin 
clinical trial by following up around 2,000 FH patients, for an average of 8.5 
years, before and after the statin treatment (Versmissen et al. 2008). The 
authors observed a 76% reduction in the risk of CHD in treated versus 
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untreated FH patients, which led to a significant improvement of the event-
free survival. Even more, when the risk of myocardial infraction (MI) in statin-
treated FH patients (older than 55) was compared with the data of a general 
population (the Rotterdam study), the event-free survival of FH individuals 
was not different from the general population (Figure 8). 
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Figure 8 
Kaplan-Meier curve of cumulative MI-free survival among FH patients (older than 55) according to the statin treatment (the 
Rotterdam study represents the general population) (Versmissen et al. 2008).
55 
 
Although most patients respond well to currently available treatments, the 
development of novel pharmacotherapies specific to particular defects in the 
LDL-C pathway is on its way. Inhibition of PCSK9 by human monoclonal 
antibodies (REGN727 and AMG 145), which prevent the degradation of LDL-
receptors, has been recently demonstrated as a safe, well-tolerated and 
effective way of lowering plasma LDL-C (Koren et al. 2012, Stein et al. 2012b, 
Dias et al. 2012, Raal et al. 2012). The promising outcomes of PCSK9 
targeting led to further developments of the antisense oligonucleotide (ASO) 
(Graham et al. 2007), locked nucleic acid (LNA)-ASO (Gupta et al. 2010), 
siRNAs (Frank-Kamenetsky et al. 2008), and mimetic peptides (Shan et al. 
2008), all aiming to silence the activity of PCSK9. The safety and efficacy of 
these new therapeutic approaches is currently being tested. 
Targeting ApoB as a novel FH treatment has also shown some signs of 
success. The overproduction of ApoB in FH patients can be lowered by an 
antisense oligonucleotide (known as Mipomersen) or by microsomal transfer 
protein (MTP) inhibitor (known as Lomitapide). A recent clinical trial showed 
that Mipomersen can effectively reduce ApoB-containing lipoproteins in FH 
patients, when used in combination with statins (Stein et al. 2012a) and in 
statin-intolerant patients (Visser et al. 2012). The use of an MTP inhibitor also 
resulted in a significant LDL-C reduction, despite an increased hepatic fat 
accumulation in some of the treated individuals (Cuchel et al. 2007), 
Lomitapide together with Mipomersen have recently been approved by the 
Food and Drug Administration (FDA) for use as an adjunct to diet and statin 
therapy in homozygous FH patients. 
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The emerging novel therapies target specific defects in the cholesterol 
metabolism, thus knowing the precise mutation, hence the defect in the 
pathway, may be required for choosing the effective therapy. For example, 
patients carrying a mutation affecting the LDL-receptor recycling process are 
less likely to respond to the PCSK9 inhibitors. The same prediction applies to 
homozygous FH patients with a null mutation in the LDLR gene. 
1.10. FH frequency  
The estimated frequency of FH in most populations is 1 in 500 for 
heterozygous individuals, and about 1 in 1 million for homozygotes (Goldstein 
et al. 1973). However significant differences have been observed between 
populations. A recent study on a general population in Denmark population 
using the DLCN diagnostic score above 5 (the lowest point for probable FH) 
found an FH frequency of 1 in 137, which is much higher than commonly 
perceived (Benn et al. 2012). A study performed on a cohort of Afrikaners 
living in the region of Johannesburg, in South Africa, revealed a much higher 
prevalence of the disease, estimating its heterozygous frequency to be 
around 1 in 100 (Seftel et al. 1980). Similar observations were made by 
Khachadurian et al (Khachadurian and Uthman 1973), who reported an even 
higher heterozygote frequency (1 in 85) in the Christian Lebanese population, 
with projected occurrence of homozygotes higher than 1in 100,000. On the 
other hand, Japanese citizens appear to have much lower incidence of FH, 
calculated to be approximately 1 in 900 individuals (Mabuchi et al. 1977). 
These clear differences in FH frequency are mainly due to founder effects, 
which occur when a small cohort is genetically isolated during evolution, 
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leading to a so-called population bottleneck. Such isolation can be caused by 
for example linguistic, geographical or religious barriers. The frequency of FH 
in South-Indian population remains unexamined. A study of Indians living in 
South Africa suggested the prevalence to be even higher than 1 in 100 but 
this would be due to a founder effect specific to the Indians in South Africa 
who derived from 150,000 South and East Indian immigrants, who settled 
there between 1860 and 1911 (Rubinsztein et al. 1993). However, the number 
of deaths from CVD is steeply increasing in India (Yusuf et al. 2001, Setia et 
al. 2012) and there is an urgent need for identification of FH mutations in the 
Indian population (Setia et al. 2012).  
When molecular diagnoses of FH were developed it became clear that in 
populations with a higher prevalence, FH is caused by a much smaller 
number of LDLR mutations. For instance, almost 90% of FH patients in the 
North Karelian region of Finland carry the same mutation, which has been first 
seen in Finland around 400 years ago (Vuorio et al. 1997). Several other 
cohorts with higher FH frequency are caused by just a few mutations including 
western Scotland (Lee et al. 1998), northwestern Greece (Miltiadous et al. 
2001), people in central and southern Tunisia (Jelassi et al. 2009) and Iceland 
(Gudnason et al. 1997). Countries with a much lower population stratification, 
such as those in central Europe, have in contrast a much bigger variety of 
LDLR mutations (Dedoussis et al. 2004).  
Knowing the FH frequency and spectrum of the mutations can help to design 
a simple and cost-effective strategy to identify affected individuals, specially in 
isolated populations. Over 1,200 unique LDLR variants known to cause FH 
have been logged into a database maintained by Dr Sarah Leigh, at UCL, 
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which can be accessed at http://www.ucl.ac.uk/fh (Leigh et al. 2008). 
1.11. FH genes 
1.11.1. Low Density Lipoprotein Receptor gene (LDLR) 
The first identified FH mutations were found to affect the function of the low-
density lipoprotein receptor (LDL-R), encoded by the LDLR gene. LDLR, 
which is located on chromosome 19p13.2, was called the “mosaic of exons 
shared with different proteins” (Sudhof et al. 1985). It comprises of 18 exons 
that are transcribed and translated into several distinct domains, which 
together form a cell surface receptor for the LDL particle, as shown in Figure 
9. Exon one (not shown in Figure 9) codes for a 21-amino-acid-long signal 
domain, which is cleaved from the mature protein during its synthesis in the 
endoplasmic reticulum. Exons 2-6 code for the cysteine-rich region, which 
once translated forms disulfide bridges and functions as the ligand-binding 
domain for ApoB- the major protein of LDL-C (discussed later).  Exons 7-14 
are highly similar to the human epidermal growth factor (EGF) precursor 
gene, and the domain encoded by this region acts during receptor recycling, 
when lipoproteins dissociate from the LDL-R in the endosome. Davis et al. 
(Davis et al. 1987) also shown that the EGF precursor homology domain 
positions the ligand-binding domain of LDL-R to the cellular surface and 
therefore enables it to bind LDL-C. Exon 15 encodes 58 amino acids, mainly 
threonine and serine, which function as an attachment site for O-linked 
carbohydrate chains. However, a study on cultured hamster fibroblasts 
suggested that the O-linked carbohydrate chains domain is not essential for 
59 
 
the normal functioning of LDL-R (Davis et al. 1986).   The LDL-R membrane-
spanning domain is composed of 22 hydrophobic amino acids, and is 
encoded by exon 16 and the 5’ of exon 17. The final 50 amino acids function 
to localise the receptor into coated pits on the cell surface, and are encoded 
by exons 17(3’) and 18 (Chen et al. 1990). 
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Figure 9 
Domain structure of the human LDLR protein and its relation to the exon 
organisation of the gene [adapted from (Hobbs et al. 1990)]. The signal 
peptide encoded by exon 1 of LDLR is not shown. 
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To date, over 1,200 LDLR mutations have been identified (Usifo et al. 2012) 
and they account for the majority of all FH cases. The distribution of the 
reported FH variants across the gene is not even, as shown in Figure 10A. 
The highest frequency of FH mutations was observed in exon 4, which could 
be explained by its large size but also by the frequent occurrence of CpG 
sequences, which are highly mutable (Hobbs et al. 1990, Day et al. 1997b, 
Leigh et al. 2008). Austin et al. suggested that selection bias could also be 
one of the reasons for the higher number of exon 4 mutations (Austin et al. 
2004). They concluded that patients with mutations in the ligand-binding 
domain of LDLR are overrepresented in the lipid clinic, due to the highly 
detrimental effect of such variants on the gene function and therefore more 
severe FH phenotype. 
On the other hand, the FH-causing mutation frequency in exons 15 and 16 
are relatively low. Considering conservation scores for each of the LDLR 
exons, exons 15 and 16 are the least conserved (apart from the signal peptide 
domain encoded by exon 1) along the gene, as shown in Figure 10B, which 
suggests their minor importance in the whole functionality of LDL-R.  
Although the LDLR gene has been studied extensively, the functional effect of 
every detected base change must still be thoroughly evaluated. Several 
bioinformatics tools are available to predict the effect of nonsynonymous 
variants (e.g. PolyPhen, SIFT, Mutation Taster), however the assessment of 
intronic changes or variants that may affect the splicing process require 
further investigation, including in vitro and family co-segregation studies.
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Figure 10 
A. Percentage of reported LDLR variants in 2008  (Leigh et al. 2008) (black 
bars) and in 2012 (Usifo et al. 2012) (white bars). There was an increase in 
the prevelance of mutations reported in the promoter, exons 10, 12, 13 and 
16, and in the intronic variants between the UCL FH database updates. B. 
Conservation scores for all LDLR domains, based on the allignments of 
functionally similar proteins with the same domain types. (Both taken from 
(Usifo et al. 2012)) 
 
B. 
A. 
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1.11.2. Apolipoprotein B gene (APOB) 
The second locus found to be causing FH is the APOB gene, located on 
chromosome 2. The gene encodes apolipoprotein B (ApoB), which, once 
synthesised in the liver, is the major apolipoprotein of VLDL, IDL, and LDL 
particles. ApoB also functions as a ligand to the LDL receptor. A thorough 
study by Boren and colleagues identified the LDL-R binding site in ApoB, 
which is located between residues 3,386-3,396 (Boren et al. 1998). The 
interaction between the receptor and the ligand is known to be modulated by 
the carboxyl tail of ApoB, as demonstrated in Figure 11. The APOB defect 
was first discovered in FH patients with normal LDL-R activity, but with 
reduced ApoB affinity to the LDL receptor (Innerarity et al. 1987). Soria et al. 
(Soria et al. 1989), followed by further studies (Ludwig and McCarthy 1990), 
which demonstrated that the Familial Defective Apolipoprotein B (FDB), also 
called Type B Familial Hypercholesterolaemia, occurs due to G to A transition 
at nucleotide 10580, in exon 26 of APOB, which leads to the substitution of 
Glutamine 3527 to Arginine (p.R3527Q). The mutation accounts for 
approximately 6-10% of all FH defects in the UK and it is mainly limited to 
individuals of European descent. It was hypothesised that the mutation 
originated from an European ancestor about 7,000 years ago and since then it 
has been moved across the continent due to migration (Myant et al. 1997). 
Carriers of the p.3527Q are usually characterised by slightly lower pre-
treatment TC and LDL-C than carriers of any LDLR mutation, but the risk of 
developing premature CHD (at the age of 50) was estimated to be 40% for 
males and 20% for females (Tybjaerg-Hansen and Humphries 1992).
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Figure 11 
Schematic representation of A. Apo-B100 (full length) wrapped around the 
LDL particle and the carboxyl tail of ApoB as the modulator of LDL-receptor 
binding. B.FH mutation p.R3527Q (the figure shows old numbering without 
the signal peptide (27 amino acids)) is predicted to disrupt the interaction of 
p.R3527 residue with the carboxyl tail, which blocks the LDL-R-binding site 
(B-site) and ApoB can no longer bind to LDL-receptor. C. Deletion of the 
carboxyl modulator site allows Apo-B80 (80% of the full length) enhances 
binding of ApoB to the receptor despite the FH mutation p.R3527Q being 
present. Adapted from (Boren et al. 1998).
A. B. C. 
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APOB is a very large and polymorphic gene, encoding 4,563 amino acids. 
Thus the majority of FH studies examined only a portion of exon 26, which is 
known to influence the binding of ApoB to the LDL-receptor (Figure 11). A 
recent study, which applied next generation sequencing (NGS) methodology, 
has identified two novel APOB variants, p.R3059C and p.K3394N, which were 
demonstrated to co-segregate with the FH phenotype in a family (Motazacker 
et al. 2012). However, these variants are predicted to be very rare as to date 
no further reports confirming the mutations have been published. Several 
studies associated the APOB variant p.R3531C with FH (Pullinger et al. 1995, 
Rabès et al. 1997, Wenham et al. 1997), however its effect was not consistent 
within examined families and the variant was later concluded as not FH-
causing (Rabès et al. 2000). Furthermore, some rare APOB variants, which 
lead to premature truncation of the peptide, were found to lower lipid levels in 
FH patients who were found to carry an FH-causing mutation at a different 
locus. FH patients with a nonsense APOB variant had 56% lower LDL-C 
levels when compared to FH patients without premature stop codons in APOB 
(Huijgen et al. 2012).  
1.11.3. Proprotein Convertase Subtilisin/Kexin type 9 gene 
(PCSK9) 
A third FH locus, the PCSK9 gene located on chromosome 1p32, was found 
by linkage analysis of a large Utah family with strong FH history, but with no 
LDLR or APOB mutation detected (Abifadel et al. 2003). PCSK9, also known 
as NARC1-neural apoptosis regulated convertase, encodes proprotein 
convertase subtilisin/kexin type 9, which enhances degradation of LDL-Rs 
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during endocytotic recycling back to the cell surface (Qian et al. 2007). 
PCSK9 residues between 367 and 381 and its catalytic site (residues 153-
155) bind directly to the N terminal of the EGF-like domain A (Figure 9) of 
LDL-R (Kwon et al. 2008).In 2003, a co-segregation study of a families with 
autosomal dominant hypercholesterolaemia identified a PCSK9 variant 
p.D374Y as a novel cause of FH (Abifadel et al. 2003), which was followed by 
functional analyses (Sun et al. 2005). P.374Y was later found to increase the 
affinity of PCSK9 for the LDL-R, and therefore behaved as a ‘gain-of-function’ 
mutation (Kwon et al. 2008). Patients with the p.374Y mutation have more 
severe form of the disease than those with LDLR or APOB mutations, so that 
their pre-treatment cholesterol is even higher and their response to statin 
treatment is not so effective (Naoumova et al. 2005). Approximately 2% of all 
UK FH patients with a detected mutation have the PCSK9 variant in the UK 
population (Humphries et al. 2006c). University College London hosts a 
publically available database of published PCSK9 variants (www.ucl.ac.uk/fh), 
which contains nearly 100 independent PCSK9 variations, some of those are 
shown in Figure 7. A quarter of the reported variants are predicted to be loss-
of-function, half are common polymorphisms and 23 seem to be gain-of-
function, however further studies are needed to establish their effect (Leigh et 
al. 2009). Loss-of-function variants are known to have a beneficial effect on 
LDL-C levels (Hooper et al. 2007, Yue et al. 2006). A study found that two of 
the nonsense variants, p.Y142* and p.C679*, which can reduce LDL-C by 
40%, are much more common in the African American population (combined 
frequency 2%) in comparison to Americans of European background 
(frequency less than 0.1%) (Cohen et al. 2005). Positive selection pressure 
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has been suggested to be the reason for such high frequency of the loss-of-
function variants in individuals of African ancestry. 
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Figure 12 
Summary of functional variants identified in PCSK9 and their position in relation to gene’s domains. SP=signal peptide, 
Pro=prosegment (both cleaved-off in the ER). Adapted from (Berge et al. 2006) 
 
Gain-of-func on	
Loss-of-func on	
LDL-C-lowering	
LDL-C-raising	
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1.11.4. Low Density Lipoprotein Receptor Adaptor Protein 1 gene 
(LDLRAP1) 
In the mid-nineties, a condition of very similar characteristics to the 
homozygote FH was observed, however the inheritance pattern did not agree 
with the dominant model (Zuliani et al. 1999). The condition, called Autosomal 
Recessive Hypercholesterolaemia (ARH), occurs when a patient inherits two 
recessive variants, which in 2001 were mapped to the ARH gene, later named 
Low Density Lipoprotein Receptor Adaptor Protein 1 (LDLRAP1) (Garcia et al. 
2001).  LDLRAP1 encodes an adaptor protein, which is necessary for 
internalisation of the LDL-LDLR complex and for efficient binding of LDL to its 
receptor (Michaely et al. 2004). Because of the recessive model of ARH, the 
disease is relatively rare, and LDLRAP1 mutations are more common in 
founder populations, such as those of Sardinian origin. 
The LDLRAP1 gene, originally named ARH (Autosomal Recessive 
Hypercholesterolaemia), was linked with the rare pathogenesis of 
hypercholesterolaemia inherited in a recessive manner (Garcia et al. 2001). 
Mutations in LDLRAP1 are more common in the Sardinian population and the 
majority of patients are characterized by bulky xanthomas from early 
childhood, although their plasma LDL-C appears to be lower than in patients 
with homozygous FH (Soutar et al. 2003). The gene is located on the short 
arm of chromosome 1 and it codes for the adaptor protein characterized by 
the presence of the phosphotyrosine-binding domain (PTB), which is known to 
bind NPXY motifs found in the cytoplasmic domain of signaling receptors 
(Forman-Kay and Pawson 1999). LDLRAP1 interacts with the cytoplasmic 
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domain of the LDL-receptor, which promotes the receptor endocytosis via the 
clathrin-coated pits on the cell surface, demonstrated in Figure 13.   
 
 
 
Figure 13 
Schematic overview of LDLRAP1 function. The LDL receptor adaptor protein 
functions to engage the LDL receptor with the clathrin-coated pit machinery 
for endocytosis (taken from (Soutar and Naoumova 2007)). 
 
 
 
 
 
 
 
In a recent study, it has been thoroughly demonstrated that the LDLRAP1 
interacts with the “I-7xF-5xNPxY0QK+2” domain of the LDL-R tail (Dvir et al. 
2012). The domain is located between residues p.I821 (named as I-7) and 
p.K830 (named as K+2), and the crystal structure of the LDLRAP1-LDL-R 
complex is shown in Figure 14. The presented model will allow for analysis of 
point mutations in LDLRAP1 as well as mutations affecting the LDLR 
cytoplasmic domain, which are of ambiguous effect.  
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Figure 14 
The structure of PTB domain of LDLRAP1 and LDL-R tail complex. LDL-R tail 
shown as cyan sticks with the core LDLRAP1-interacting residues in yellow.
72 
 
1.11.5. Other loci causing FH 
Since an FH-causing mutation can be detected in only 60-90% of definite FH 
patients (Graham et al. 2005, Taylor et al. 2010b, Futema et al. 2013) several 
studies on patients without a reported mutation were conducted in order to 
find a monogenic cause for hypercholesterolaemia in the unexplained FH 
cases. In 2010, a study of a large French family with FH led to linkage of 
16q22.1 region with the disease (Marques-Pinheiro et al. 2010). The genomic 
region containing 154 genes, and was named HCHOLA4, however after the 
extensive analysis the causal variant was not identified. A year later, family 
linkage analysis of three pedigrees mapped an FH locus to 8q24.22 cytoband 
in one of the studied families (Cenarro et al. 2011). The identified region 
contains approximately 30 genes, however the authors could not pinpoint the 
functional variant. No linkage was found in the remaining two families. Shortly 
after, another study reported linkage of FH with two different chromosomal 
regions, 3q25-26 and 21q22, in one Chinese FH pedigree (Wang et al. 2011). 
The authors selected two genes, ABCA1 and LSS, for further sequencing 
however no mutations were identified. All three studies are summarized in 
Table 7.
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Table 7 
Summary of genome-wide linkage studies of families with clinical diagnosis of FH.
Publication 
Number of 
studied 
families 
Number of studied members of 
the family 
Locus Follow up 
Marques-
Pinheiro A., et 
al. (2010) 
1 
30 individuals over 4 generations 
(10 affected, 20 unaffected) 
16q22.1 (HCHOLA4) 
57 (out of 154) genes 
sequenced 
Cenarro A., et 
al. (2011) 3 
Family 1: 21 individuals over 3 
generations (10 affected, 11 
unaffected) 
8q24.22 
no genes sequenced  
 
Family 2: 9 individuals (5 
affected, 4 unaffected) 
No linkage detected 
  
  
Family 3: 6 individuals (4 
affected, 2 unaffected) 
No linkage detected 
Wang X., et al. 
(2011) 
1 
17 individuals over 4 generations 
(11 affected, 6 unaffected) 
3q25.1-26.1 and 21q22.3 
(possible multiplicative 
interaction between the loci) 
ABCG1 and LSS 
sequenced (out of 92 
and 113 genes, 
respectively) 
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Analysis of loci identified by genome wide association studies (GWAS) for 
lipid traits might also help to explain some of the FH cases. In 2010, GWAS 
meta-analysis of over 100,000 individuals reported association of 95 loci with 
lipids in European population (Teslovich et al. 2010). Associated loci are 
shown in Figure 15. This was followed by a larger study of over 180,000 
individuals using genome-wide and custom genotyping arrays (Willer et al. 
2013a). Single Nucleotide Polymorphisms (SNPs) located in the regions of 
LDLR/APOB/PCSK9/LDLRAP1 showed significant association with LDL-C, 
thus one could hypothesise that other genes, within which common variants 
were having a moderate effect on LDL-C, may contain rare FH-causing 
variants. To date, no reports on the analysis of rare variants in the GWAS hits 
for the LDL-C have been published.  
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Figure 15 
 
Venn diagram of genes associated with lipids as reported in meta-GWAS on over 100,000 individuals (Teslovich et al. 2010). 
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1.12. Polygenic Hypercholesterolaemia 
Polygenic hypercholesterolaemia is thought to be a condition of uncertain 
aetiology. It may occur in the absence of a positive family history (sporadic), it 
may be associated with a familial component of unclear mode of inheritance 
or it may be interpreted as being the result of the interaction of multiple genes 
with a small effect (polygenic). High cholesterol may also result from one or 
more environmental factors (e.g. high saturated fat/cholesterol diet, obesity, 
pregnancy) interacting with a genetic predisposing factor or susceptibility 
gene (multifactorial). 
The Global Lipid Genetic Consortium (GLGC) meta-analysis of genome-wide 
association studies identified several loci where common variants affect LDL-
C concentration (Teslovich et al. 2010) and results of another study (Talmud 
et al. 2009) showed that a proportion of individuals carrying several LDL-C-
raising single nucleotide polymorphisms (SNPs) have LDL-C concentrations 
that exceed the diagnostic LDL-C threshold for FH of 4·9 mmol/l. Using this 
information a recent report demonstrated that individuals clinically diagnosed 
with the familial form of hypercholesterolaemia are likely to express the same 
phenotype due to polygenic causes (Talmud et al. 2013). Authors selected 
only the lead SNP from each locus reported by Teslovich et al., and if a SNP 
was associated with more than one lipid fraction, they included it if LDL-C was 
the lead trait for the SNP. They composed a score using the weighted sum of 
the LDL-C-raising allele for each of the 640 (321- mutation negative, 319-
mutation positive) studied FH patients and for 3,020 controls from the 
Whitehall II study (WHII). The major observation was that the mutation 
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negative patients with clinical diagnosis of FH had significantly higher SNP 
score than the control population (Figure 16(A)). They also found that 
mutation positive FH patients had a higher SNP score than the controls 
(Figure 16(B)), which may explain heterogeneity in LDL-C cholesterol 
between patients with the same mutation. The difference between the 
mutation negative and mutation positive FH patients was also significant 
(Figure 16(C)). High SNPs score explained hypercholesterolaemia in at least 
20% of patients with no identified mutation. The overlap of clinical features of 
both forms of hypercholesterolaemia highlights the importance and clinical 
utility of genetic testing for FH, discussed in section 1.7.  
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Figure 16 
 Distribution of weighted LDL-C gene scores(A) Whitehall II controls (WHII) 
versus patients with familial hypercholesterolaemia without a known mutation 
(FH/M–). (B) WHII controls versus patients with familial 
hypercholesterolaemia with a known mutation (FH/M+). (C) FH/M– versus 
FH/M+. In both patients with definite familial hypercholesterolaemia (DFH) 
and those with possible familial hypercholesterolaemia (PFH), patients without 
a detected mutation had a significantly higher mean weighted LDL-C gene 
score than did those with a detected mutation (taken from (Talmud et al. 
2013)   
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II. CHAPTER TWO – Materials and Methods 
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2.1. Patient selection criteria 
2.1.1. Oxford FH 
The Oxford FH cohort comprised individuals who attended sequentially the 
Oxford Lipid Clinic, in England over the period 2009-2011. All participants 
were Caucasian, aged 18 or over, and were diagnosed with either definite FH 
(DFH) or possible FH (PFH) using the Simon Broome clinical diagnostic 
criteria ('Risk of fatal coronary heart disease in familial hypercholesterolaemia. 
Scientific Steering Committee on behalf of the Simon Broome Register Group'  
1991, Neil et al. 2004), or as having unclassified hypercholesterolaemia (UH) 
which was defined as a total cholesterol and/or LDL-C concentration above 
the Simon Broome criteria cut off (respectively >7.5 mmol/l and/or >4.9 
mmol/l) but with no family history of early CHD or with no such family history 
that could be elicited. The Simon Broome diagnostic criteria for FH exclude 
subjects with a triglyceride level of > 4.5mmol/l and none of the patients 
exceeded this level. There were a total of 289 patients in the cohort, of which 
272 probands were apparently unrelated. 
 
The Simon Broome British Heart Foundation study (SBBHF) of 409 
individuals was used for the replication of the FH clinical diagnosis methods 
comparison between the Simon Broome FH criteria and the Dutch Lipid Clinic 
Network (DLCN) score, and for the testing of the mutation detection 
association with TC and TG quartiles. This was a cross-sectional comparison 
of white patients aged 18 years or more with treated DFH with and without 
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clinically documented CHD recruited from clinics in London, Oxford and 
Manchester. Recruitment methods, inclusion and exclusion and diagnostic 
criteria have been described previously (Neil et al. 2004). The cohort 
consisted of 328 FH-mutation positive (FH/M+) and 81 FH-mutation negative 
(FH/M-) patients. 
2.1.2. South-Asian FH 
Blood samples of FH patients with South-Asian origin were collected across 
several lipid clinics in England, including the Royal Free Hospital and the 
Newham Hospital in London, the University Hospital of Coventry and 
Warwickshire, and the Leeds Teaching Hospital, over the period of three 
years (2010-2013). In total, 34 samples (33 probands) were collected, of 
whom four presented with or had a family history of tendon xanthomas. The 
Simon Broome diagnostic criteria LDL-C cutoff of 4.9 mmol/l for adults was 
lowered to 4.2 mmol/l. 
In addition to the samples collected in the UK, eight members of a 
consanguineous hypercholesterolaemic family from Kokilaben Dhirubhai 
Ambani Hospital in Mumbai, India, were studied. The extreme TC and LDL-C 
levels observed in the family proband - nine years old boy, were suggestive of 
homozygous FH.
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2.1.3. Whole exome sequencing cohort 
The whole exome sequencing cohort was comprised of 125 unrelated patients 
diagnosed using the UK Simon Broome criteria as DFH on the basis of the 
presence or family history of tendon xanthomas. The majority of patients 
(n=65) were originally from the Simon Broome British Heart Foundation study 
(SBBHF), which used the High Resolution Melting (HRM) method to screen 
the entire promoter and coding region, including splice sites, of the LDLR 
gene (Whittall et al. 2010b). SBBHF patients were tested for presence of the 
APOB mutation, p.(R3527Q), using a restriction enzyme digest (Mamotte and 
van Bockxmeer 1993), and the entire coding region of the PCSK9 was 
examined by HRM (Humphries et al. 2006b). Fragments with a shifted melting 
curve were analysed further by direct sequencing. Screening for large 
rearrangements within the LDLR gene was done using the MLPA SALSA 
P062 LDLR kit from MRC-Holland (Amsterdam) (Taylor et al. 2009). The final 
cohort also included 14 DFH patients with no detectable mutation selected 
from the Oxford FH cohort, studied in Chapter Three. The FH mutation 
screening methods were as described in the ‘Molecular genetic analysis’ 
section.  
The remaining 45 samples sequenced in this study were provided by several 
collaborators. These included: 16 from Australia (PI: Frank Van Bockxmeer), 
10 from Israel (PI: Eran Leitersdorf), 10 from Nothern Ireland (PI: Colin 
Graham), five from Great Ormond Street Diagnostic Laboratory (PI: Nicholas 
Lench), three from Modena in Italy (PI: Sebastiano Calandra) and one from 
Cairo Montenotte in Italy (PI: Stefano Bertolini). The initial FH mutation 
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screening methods varied between the labs and are summarised in Appendix 
Table I. 
2.2. Molecular genetic analysis 
The FH mutation testing workflow overview is shown in Figure 17. 
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Figure 17 
The FH mutation screening overview 
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2.2.1. Whole blood DNA extraction 
The whole blood DNA extraction method was adapted from Miller et al. 
“salting-out” method (Miller et al. 1988) 
 
Solutions: 
Reagent A: 0.32M sucrose, 5mM MgCl2, 10mM Tris-HCl pH 7.5, 1% 
Triton-X-100, in deionised water. 
Reagent B: 10mM Tris-HCl pH 8.2, 0.4M NaCl, 2mM Na2EDTA pH 8.0, 
10X 1% SDS, in deionised water. 
TE Buffer: 10mM Tris, 1mM EDTA, in deionised water, pH7.6 
Blood samples were collected into 4.5 ml tubes, containing anticoagulation 
agent EDTA. 
Cell Lysis: 3-5 ml of blood was thoroughly mixed with 20 ml of ice-cold 
reagent A, and centrifuged at 10,000 rpm (13,000 g) for 10 minutes, at 4°C. 
The supernatant was discarded into a waste tube without disturbing the pellet. 
The pellet was resuspended and washed in 20 ml of ‘reagent A’, and the 
centrifugation step repeated. 
Nuclear Lysis: The pellet was resuspended in 2 ml of ‘reagent B’. 
Deproteinisation: 1 ml of 5 M sodium perchlorate was added, mixed 
thoroughly and incubated on a shaker for 15 minutes. 
Extraction: 2 ml of ice-cold chloroform was added, mixed and centrifuged at 
10,000 rpm (13,000 g) for 3 minutes, to separate the DNA into upper aqueous 
phase. 
86 
 
Precipitation: The aqueous phase was transferred, without disturbing the 
organic phase, to a fresh 30 ml polypropylene tube. 10 ml of ice-cold 100% 
ethanol was slowly added to the tube and incubated on a bench for 3 minutes. 
The tube was then inverted several times to precipitate the DNA. 
Washing: Precipitated DNA was removed from the solution with a sterile 
Pasteur tip, washed briefly in 70% ethanol, and placed in a nuclease-free tube 
containing 0.5-1.0 ml of TE buffer (pH 7.6). Samples were then incubated 
overnight at 37°C to dissolve.  
Concentration and purity of each sample were measured using the Nanodrop 
ND8000 spectrophotometer, supplied by Labtech International. The ratios of 
absorbance at 260/280 nm and 260/230 nm, indicating the purity of a sample, 
were accepted at values 1.8-2.0 and 1.8-2.0, respectively. 
DNA was standardised to concentration of 30ng/µl and stored at 4°C. 
2.2.2. Amplification Refractory Mutation System (ARMS) 
Patients’ DNA were first screened for the 20 most common UK mutations with 
a commercially available ElucigeneTM FH20 (Gen-Probe Life Sciences, UK) 
Amplification Refractory Mutation System (ARMS) kit. The ARMS assay is 
based on a principle of multiplex allele-specific PCR, allowing to test for the 
presence of 18 of the most common LDLR mutations, one PCSK9 
(p.(Asp374Tyr)) and one APOB (p.(Arg3527Gln)) mutation in only three 
reactions. The full list of the mutations is shown in Table 8. 
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Table 8 
The list of FH mutations tested by each ARMS primer mix (LDLR residue 
numbering includes the signal peptide). 
 
  
PRIMER MIX A PRIMER MIX B PRIMER MIX C 
p.D374Y (PCSK9) p.R3527Q (APOB) p.W87G 
p.P685L p.IVS3+1G>A p.V429M 
p.L479P p.D482H p.D227E 
p.R350X p.G218del p.C677R 
p.E228X p.D227GfsX12 p.K311RfsX20 
p.D221G p.Q384X p.C184Y 
p.E101K  p.D482N 
 
 
 
Reaction set-up 
Enzyme Dilution (for 10 reactions, for each Primer Mix: A, B, and C): 
21 µl sterile deionised H2O 
6 µl dilution buffer 
30 µl loading dye 
3 µl AmpliTaq Gold 
 
Reaction Mix (for 10 reactions): 
55 µl enzyme dilution 
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165 µl TA/TB or TC primer mix 
Loading a PCR plate: 
20 µl reaction mix (TA, TB or TC) 
2 µl 30ng/µl DNA 
3 µl sterile deionised H2O 
 
Cycling conditions on a standard thermocycler 
94°C for 20 minutes (Taq activation) 
35 cycles of:  
94°C for 30 seconds (denaturation) 
61°C for 1 minute (annealing) 
72°C for 1 minute (elongation) 
72°C for 30 minutes (final elongation) 
 
Agarose gel electrophoresis 
Visualisation of PCR products was achieved with 2% Agarose gel 
electrophoresis (120V for 60 minutes), with addition of Ethidium Bromide 
(5g/l), in 1 x TBE buffer (1x, 18mM Tris-borate and 4mM EDTA, pH8). 
Loading dye for PCR products was Bromophenol Blue.  
2.2.3. High Resolution Melting (HRM) 
High Resolution Melting (HRM) is a post-PCR method, based on thermal 
denaturation of double stranded PCR products. It enables the detection of 
genetic variations (including small deletions or insertions) by comparing 
melting patterns of DNA fragments. HRM was shown to be a sensitive and 
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robust screening method for FH mutations, which is able to sense all four 
classes of DNA base pair changes (Whittall et al. 2010b, Liew et al. 2004), 
although the class four DNA changes (A>T or T>A variants) were shown to be 
the most difficult to detect (Whittall et al. 2010b). 
 
Reaction set-up 
Most of the HRM reactions in this project were performed using AccuMeltTM 
HRM SuperMix (Quanta Biosciences). Each 20 µl reaction contained: 
10 µl AccuMelt HRM SuperMix (containing the Syto9 saturating dye at 
2X concentration) 
0.8 mM Forward/Reverse Primer 
2 µl DNA template at 30 ng/µl 
Nuclease-free H2O up to 20 µl 
 
Exon 4.4 was amplified using LightScanner® Master Mix (BioFire Diagnostics, 
Inc.), which incorporated the LCGreen® saturating dye formulated at 2.5X 
concentration. Each 10 µl reaction contained: 
4 µl Master Mix (2.5X) 
0.8 mM Forward/Reverse Primer 
2 µl DNA template at 30 ng/µl 
Nuclease-free H2O up to 10 µl 
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Cycling conditions 
HRM was performed on Rotor-Gene6000 realtime rotary analyser. Reaction 
cycling conditions and HRM temperature gradient are presented in Table 9. 
Primer sequences for each fragment are shown in Appendix Table II. 
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Table 9 
A summary of PCR cycling conditions and the HRM melting temperature 
range for the LDLR promoter, each LDLR exon, APOB exon 26 and PCSK9 
exon 7.   
Gene (Exon) 
Enzyme 
activation 
Amplification 
conditions 
N° of 
cycles 
HRM T 
Gradient 
LDLR  95°C 5 min 95°C 5 sec 
40 x 80-94°C 
(Promoter, 1, 3, 4.1, 4.2, 
4.3, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15, 16, 17, 18) 
 60°C 10 sec 
  70°C 20 sec 
LDLR 95°C 5 min 95°C 5 sec 
40 x 80-94°C (2)  55°C 10 sec 
    70°C 20 sec 
LDLR 95°C 5 min 95°C 10 sec 
45 x 80-94°C (4.4)  66°C 10 sec 
    72°C 20 sec 
LDLR 95°C 5 min 95°C 10 sec 
40 x 80-94°C (12)  56°C 20 sec 
    70°C 30 sec 
APOB 95°C 5 min 95°C 5 sec 
40 x 85-95°C (26)  60°C 10 sec 
    70°C 20 sec 
PCSK9 95°C 5 min 95°C 10 sec 
45 x 80-94°C (7)  66°C 10 sec 
    72°C 20 sec 
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2.2.4. Restriction Fragment Length Polymorphism (RFLP) 
Restriction Fragment Length Polymorphism (RFLP) was used to genotype 
commonly occurring polymorphisms in LDLR exons. Table 10 contains a list 
of all common LDLR SNPs, restriction enzymes, and amplification primers 
used for the genotyping. 
 
PCR amplification of each fragment was performed in 30 μl reaction: 
 
  Volume  
 
Concentration 
30ng/μl DNA 2 μl 60ng/30μl 
10x Polmix 3 μl 1x 
100mM dNTPs 0.24 μl 0.8 mM 
100pmoles/μl Primers 0.12/0.12 μl 12 pmol/30μl  
50mM Mg2+ 1.2 μl 2 mM 
5u/μl Taq 0.12 μl 0.6 units 
 H2O 25.2 μl  
 
 
Cycling conditions on a standard thermocycler 
Heated Lid 
96oC for 3 minutes 
35 cycles of:  
94oC for 30 seconds 
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       60oC for 40 seconds* 
      65oC for 10 minutes 
72oC for 30 minutes 
16oC for 2 minutes 
*Exon 2 annealing temperature was 57oC 
PCR products were checked on 2% agarose gel. 
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Table 10 
Commonly occurring LDLR SNPs, the RFLP primers and enzymes used to distinguish between the alternative alleles.    
LDLR 
exon 
SNP ID SNP position 
Enzyme used 
for RFLP 
Primer 
direction 
Amplification Primers (5' to 3')   
2 rs2228671 c.81C>T HhaI Forward TGATCGGATGACATTTCTGG *forced site 
        Reverse GGCACTGGAACTCGTTTCTTGC   
7 rs12710260 c.1060+10C>G SmaI Forward GGCGAAGGGATGGGTAGGGG 
 
        Reverse CCCCTACCCATCCCTTCGCC   
8 rs11669576 c.1171G>A StuI Forward CATTGGGGAAGAGCCTCCCC 
 
        Reverse GCCTGCAAGGGGTGAGGCCG   
105' rs5930 c.1413G>A BsmAI Forward AGATGAGGGCTCCTGGTGC 
 
        Reverse GCCCTTGGTATCCGCAACAGAGACA   
11 rs5929 c.1617C>T AciI Forward TCCTCCCCCGCCCTCCAGCC 
 
        Reverse CTGGGACGGCTGTCCTGCG   
12 rs1799898 c.1725C>T BsmAI Forward CTCCTCAGTGGCCGTCT *forced site 
        Reverse ATCCGCCACCTAAGTGCTTG   
12 rs688 c.1773C>T HincII Forward GCACGTGACCTCTCCTTATCCACTTG 
 
        Reverse CACCTAAGTGCTTGCATCTCGTACG   
13 rs5925 c.1959C>T AvaII Forward GTCATCTTCCTTGCTGCCTGTTTAG 
 
        Reverse GTTTCCACAAGGAGGTTTCAAGGTT   
15 rs5927 c.2232A>G MspI Forward GAAGGGCCTGCAGGCACGTGGCACT 
 
        Reverse CTAGGGAGGGCCCAGTCTTT   
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Restriction enzyme digest (13 μl) 
  Volume  
 
Concentration 
 PCR product 8 μl  
10x Buffer 1.3 μl 1x 
 Restriction Enzyme As required 3u 
100x BSA 0.13 μl 
 
1x 
 H20 Make up to 13 μl  
 
The incubation temperature and time were dependent on the enzyme. 
2.2.5. Microtitre Array Diagonal Gel Electrophoresis (MADGE) 
The DNA fragments produced by restriction enzyme digest were separated using 
electrophoresis on a non-denaturing polyacrylamide gel, using Microtitre Array 
Diagonal Gel Electrophoresis (MADGE). Utilisation of this technique makes it 
possible to electrophorese the entire 96 wells of a standard PCR plate on a single 
gel, by allowing the samples to run diagonally. Use of MADGE was an essential 
part of the project as it allowed high throughput screening of the PCR product, and 
allowed the 96 well DNA array format to be retained throughout the screening 
process (Day et al. 1996). Standard 7.5% MADGE gels were made up in batches 
for economy of time.  
MADGE consists of an open arrangement of 8x12 wells each 2mm deep. The wells 
are arranged at an angle of 71.2o to the short axis of the array, but perpendicular to 
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the long-axis of the Perspex formers used. Thus the maximum track length is 
26.5mm allowing sufficient travel for genotype resolution. 
Glass plates of appropriate size (160 x 100 x 2mm) were rigorously cleaned and 
hand dried. Once dry, 5 drops of -methacryloxypropyltrimethoxysilane (“sticky” 
silane) were spread across the plates and left to air-dry. Silane was used to ensure 
that the MADGE gel would adhere to the glass plates. 
 
Gel solution 
5mls of 10xTBE (10x Tris-Boric acid-Ethylenediaminetetraacetic acid 
contained: 0.9M Tris, 0.9M Ortho-boric acid, 0.2M 
ethylenediaminetetraacetic acid) 
12.2mls 30% acrylamide-bisacrylamide (in a ratio of 19:1)  
32.5mls of distilled dH2O 
150l N’-tetramethylethylenediamine (TEMED)  
150l 25% ammonium per sulphate (APS) 
 
Polymerisation was initiated by the addition of APS, which was added last (as 
the combined solution begins to set within thirty seconds of mixing) before the 
solution was mixed and quickly poured into the three-dimensional former. A 
glass plate was then gently placed over the mould (silanised side facing 
downwards) taking care not to trap any air bubbles. This was then left for 
fifteen minutes to set, using a small weight to ensure that the glass did not slip 
whilst the gel was setting. Excess gel was trimmed from the edges of the 
MADGE former before the glass plate and attached gel were then prized 
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away from the plastic former. MADGE gels were stored in a plastic Stuart box 
containing neat TBE (1x concentration).  
 
Gel staining and loading 
Prior to loading a gel with digested PCR product, each gel was stained with 
Ethidium Bromide (EtBr). This was achieved by placing them individually in a 
Stuart box, shielded from direct light, containing 100ml of 1x TBE and 10l 
EtBr for 20 minutes.  
Whilst the gels were being stained, the PCR-digest product was prepared for 
loading onto the MADGE gel. 2l of formamide dye (98% formamide, 
10mmol/l EDTA, 0.025% xylene cyanol, 0.025% bromophenol blue) was 
added to each well of a new, round-bottomed, loading tray, followed by 5l of 
each digested sample, using a multi-channel pipette to pick up the samples 
from the microtitre plates. After placing the stained MADGE gel into an 
electrophoresis tank containing 1000ml of 1xTBE, a multi-channel pipette was 
then used to transfer 5l of this digest/dye mixture to the wells of the gel. At 
all times the samples were kept in the same layout as on the PCR tray, 
allowing each sample to be easily identified without being re-labelled. The gel 
was electrophoresed at 150 volts for 40 minutes. 
Following electrophoresis the gel was viewed and photographed under 
ultraviolet light using the UVP Gel Documentation System. Care was once 
more taken to ensure the correct orientation of the MADGE under UV. This 
was ensured by always placing the well corresponding to grid-reference “A1” 
in the bottom left-hand corner of the UV-viewing box. The image produced 
was used for genotyping.  
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Genotyping quality control 
All genotyping was performed in a double blind fashion using both positive 
and negative controls. Two individuals rechecked the results at the time of 
MADGE imaging and during data entry into the computer database. Any 
apparent genotype differences were resolved by repeat PCR. An example of 
RFLP and MADGE gel results are shown in Figure 18. 
 
 
Figure 18 
A typical MADGE gel image demonstrating BsmAI RFLP digests of rs5930 
polymorphism located in exon 10 LDLR. Different fragment lengths indicate 
different genotypes of the SNP.
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2.2.6. PCR product purification 
Prior to the Sanger sequencing of fragments that showed a shift in the melting 
during the HRM, PCR products were purified to remove any remaining 
enzyme or dye from the reaction mix. The DNA purification was performed 
using the Illustra GFX PCR DNA and Gel Band Purification kit from GE 
Healthcare Life Sciences. Briefly, the PCR volume was mixed with 500 μl of 
the Capture Buffer (type 3) and loaded onto the assembled GFX MicroSpin 
column and collection tube. The sample was then centrifuged at 16,000 x g 
for 30 seconds. The flow through was discarded and the column was placed 
back inside the collection tube. Next, 500 μl of the Wash Buffer (type 1) 
containing 70% ethanol was added onto the column and the centrifugation at 
16,000 x g for 30 seconds was repeated. The collection tube was discarded 
and the column was placed on a fresh DNase-free 1.5 ml microcentrifuge 
tube. The PCR product was eluted from the column with 30 μl of sterile 
nuclease-free water by another centrifugation step, 16,000 x g for 1 minute. 
DNA concentration of the eluted product was measured on the NanoDrop 
ND8000 spectrophotometer and aliquoted to 1 ng/μl per 100 bp of product in 
volume of 15 μl, for Sanger sequencing. 
2.2.7. Sanger sequencing 
Every variant detected by ARMS and/or a melting curve shift on HRM was 
confirmed by standard Sanger sequencing (in the forward and reverse 
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direction), service provided by Source Bioscience LifeSciences. Primers for 
the fragment amplification and sequencing are shown in Appendix Table X. 
All produced sequencing reads were then analysed manually on FinchTV 
(Geospiza Inc.). 
2.2.8. Multiplex Ligation-dependent Probe Amplification (MLPA) 
Multiplex Ligation-dependent Probe Amplification (MLPA) SALSA P062-C1 
LDLR kit (MRC-Holland, Amsterdam) was used to screen for large deletions 
and insertions in the LDLR gene of definite FH patients (Taylor et al. 2009). 
The kit contains probes for all 18 LDLR exons, producing fragments of 
different length, as well as 15 reference probes located on different 
chromosomes. The experiment requires DNA samples to be aliquoted to 
standard concentration, which in this case was 60 ng/µl.  
 
DNA denaturation 
5 µl of each 60 ng/µl DNA sample was loaded into 96-well AB-0800 plate. 
DNA was then denatured on thermocycler for 5 minutes at 98°C (with a 
heated lid) and cooled to 25°C. 
 
Hybridisation 
3 µl of the hybridisation mix containing (per reaction): 
1.5 µl MLPA buffer 
1.5 µl probemix 
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was loaded into each denatured sample and mixed by pipetting up and down. 
Reactions were incubated for 1 minute at 95°C, and then for 16-20 hours at 
60°C. 
 
Ligation 
Ligase mix contained (per reaction): 
3 µl Ligase-65 buffer A 
3 µl Ligase-65 buffer B 
25 µl dH2O 
1 µl Ligase-65 
32 µl of the ligase mix was mixed into each reaction during a pause at 54°C 
on the thermocycler. This step was then followed by 15 minutes incubation at 
54°C (ligation), and 5 minutes heat inactivation of Ligase enzyme at 98°C. 
Completed ligation reactions were cooled down to 15°C. 
 
Amplification 
PCR buffer mix (per reaction): 
4 µl SALSA PCR buffer 
26 µl dH2O 
30 µl of the PCR buffer mix was loaded into each reaction well on a new plate 
and mixed with 10 µl of ligation product. The plate was then incubated at 60°C 
on a thermocycler and each reaction was mixed with 10 µl of Polymerase 
master mix, which contained (per reaction): 
2 µl SALSA PCR-primers 
2 µl SALSA enzyme dilution buffer 
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5.5 µl dH2O 
0.5 µl SALSA Polymerase 
 
PCR cycling conditions: 
60°C pause 
35 cycles: 
95°C for 30 seconds 
60°C for 30 seconds 
72°C for 60 seconds 
72°C for 20 minutes 
15°C pause 
 
 
Fragment separation 
1 µl of each PCR product was mixed with 12.5 µl of Hi-Di Formamide and 0.5 
µl of Size Standard. Fragments were separated on ABI-3730XL with 36 cm 
capillary length.  
Results, normalized with synthetic control, were analysed on GeneMarker® 
software. A typical MLPA result graph is shown in Figure 19.
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Figure 19 
A typical MLPA results can be evaluated by comparing a peak patterns of separated fragments between the tested samples (vlue 
peaks) and the reference data (red peaks). Each peak represents a probe for a specific region of LDLR or for a control (located at 
outside of the gene). Probes are labeled in grey boxes under the graph. 
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2.3. Global Lipids Genetic Consortium gene score calculation 
The GLGC reported SNPs that were significantly associated with LDL-C, with 
a p-value cut-off of less than 5x10−8 (Teslovich et al. 2010). For the purpose of 
the gene score calculation only the lead SNP from each locus was selected 
and if a SNP was associated with more than one lipid fraction it was only used 
in this score calculation if LDL-C was the lead trait (most strongly associated 
trait) for the SNP. For each individual, the LDL-C-specific gene scores were 
calculated using the weighted sum of the risk allele (i.e. the LDL-C-raising 
allele). The weights used were the corresponding per-risk-allele beta 
coefficients reported by the GLGC. Although the GLGC consortium included 
healthy subjects and CAD cases, any individuals taking statins were excluded 
from the estimates of the effect size associated with the SNPs. Since the 
beta-coefficients reported by GLGC are for the effect of each minor allele, 
where the effect was LDL-lowering, the other allele was considered the risk 
allele and the absolute effect size was used as the weight. APOE is a major 
determinant of LDL-C levels and the effect of the APOE haplotype was 
included in the LDL score calculation. For APOE the previously reported effect 
of the APOE haplotypes on LDL-C from a meta-analysis in 61,463 healthy 
participants was used (Bennet et al. 2007). Based on the latter study, using 
ε3/ε3 individuals as reference, the APOE haplotype was scored as follows: 
ε2ε2=-0.9, ε2ε3=-0.4, ε2ε4=-0.2, ε3/ε3=0, ε3ε4=0.1 and ε4ε4=0.2. A total of 
10 SNPs plus two APOE SNPs were used for the LDL-C score calculation, 
shown in Table 11. 
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Table 11 
The top LDL-rising SNPs and their effects (as reported by the GLGC) used for 
the LDL-C gene score genotyping and calculation. 
   
 
SNP ID 
Nearest 
gene 
Risk Allele 
Beta 
coefficient 
(mmol/l) 
rs2479409 PCSK9 G 0.051978278 
rs629301 CELSR2 T 0.146108094 
rs1367117 APOB A 0.104732351 
rs4299376 (rs6544713) ABCG8 T 0.071114559 
rs3757354 MYLIP C 0.036979571 
rs1800562 HFE G 0.057408844 
rs1564348 SLC22A1  T 0.01448151 
rs4055111 (rs11220462) ST3GAL4 G 0.050426687 
rs8017377 NYNRIN A 0.029480217 
rs6511720 LDLR G 0.180760279 
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2.3.1. LDL-rising SNPs genotyping 
2.3.1.1. KASP genotyping 
The KASP (Kbiosciences, UK Hoddesdon, Herts, UK) genotyping was used 
for genotyping of all SNPs shown in Table 11. Probes for two of the SNPs, 
rs4299376 (in the ABCG5/ABCG8 region) and rs11220462 (in the ST3GAL4 
region), could not be designed because of an occurrence of other 
polymorphisms in the surrounding region, therefore proxies (SNPs in high 
Linkage Disequilibrium (LD)) were used instead, rs6544731 and rs4055111, 
respectively. 
The method utilises a form of competitive allele-specific PCR. Bi-allelic 
discrimination was achieved by the competitive binding of two allele-specific 
primers, each with a unique tail sequence that corresponded with two 
universal FRET (fluorescence resonant energy transfer) cassettes. Each 
allele-specific primer was labelled, one with FAM dye and the other with HEX 
dye, which enabled the discrimination between alleles. The reverse primer 
was universal (common) for both forward allele-specific primers. 
The genotyping reactions were carried out in a 384-well plate format. 5 ng of 
DNA was transferred from a standardized array, using the Biomek 2000 
Laboratory Automation Workstation, into a 384-well plate and centrifuged at 
3000rpm for 1 minute before being air-dried. Each plate contained at least two 
no-template-control (NTC) wells.   
   
KASP Master Mix (5 μl per each reaction): 
2.5 μl KASP Reaction Mix (2X) 
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0.07 μl KASP-by-Design (KBD) assay 
2.5 μl dH2O 
 
Cycling conditions on a standard thermocycler: 
94°C for 15 minutes (hot-start enzyme activation) 
10 cycles (dropping 0.8°C per each cycle): 
94°C for 20 seconds 
65-57°C for 60 seconds 
26 cycles: 
94°C for 20 seconds 
57°C for 60 seconds 
 
2.3.1.2. TaqMan Genotyping 
The APOE ε2/ε3/ε4 haplotype is made up of two SNPs (rs429358 and 
rs7412) and resulting in different isoforms of the ApoE protein, is an important 
genetic determinant of LDL-C levels. Off-the-shelf TaqMan probes (Life 
Technologies, Carlsbad, California, US) for the APOE genotyping were 
available. 
Each ABI TaqMan Genotyping Assay (40x) contained two target SNP specific 
primers for the region of interest and two allele-specific TaqMan MGB probes. 
Each allele specific probe has three main elements: a reporter dye (at the 5’ 
end), a minor groove binder (MGB), and a non-fluorescent quencher (NFQ, at 
the 3’ end). Two commonly used reporter dyes, VIC and FAM, enabled to 
distinguish between each allele. The MGB was added in order to increase the 
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melting temperature for a given probe length, which increases the efficiency of 
allelic discrimination. The NFQ does not fluoresce and will quench the 
fluorescent signal in any reporter dye linked to the 5’ end for as long as the 
probe remains intact. 
ABI TaqMan Genotyping reactions were carried out in a 384-well plate format. 
5 ng of DNA was transferred from a standardized array, using the Biomek 
2000 Laboratory Automation Workstation, into a 384-well plate and 
centrifuged at 3000rpm for 1 minute before being air-dried. Each plate 
contained at least two no-template-control (NTC) wells.     
The TaqMan genotyping reaction was carried out as per the TaqMan 
Genotyping mastermix manufacturer’s instructions. Each plate was 
centrifuged at 3000rpm for 1 minute and PCR reactions were carried out 
using the 7900HT Fast Real-Time PCR system.  
 
Cycling conditions: 
95°C for 10 minutes (AmpliTaq Gold activation) 
40 cycles: 
92°C for 15 seconds 
60°C for 60 seconds 
 
2.3.1.3. Genotyping signal detection 
The standard allelic discrimination program assigned genotypes automatically 
to a plate coordinate in a text output file and in the form of an allelic 
discrimination plot based on the fluorescent signal detected. The light source 
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from the cycler excites the reporter dyes by fluorescence resonance energy 
transfer. The dyes used in KASP or TaqMan genotyping have significantly 
different excitation and emission wavelengths, which allows them to be 
differentially detected. An example of the allelic discrimination plot is shown in 
Figure 20. Each dot on the scatterplot represents one well of the plate (either 
DNA sample or an NTC). Samples that did not reach the threshold fluorescent 
signal level for any of the genotypes (undefinable samples) were marked by 
an ‘X’. Results of each SNP were checked manually by study personnel using 
SNPviewer software.  
The distribution of each genotype frequency was checked using the Hardy-
Weinberg equation. 
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Figure 20 
Allelic discrimination plot. This plot represents KASP genotyping results for 
rs629301A>C SNP in part of the Oxford FH study. Samples with a significant 
FAM signal are called homozygous for the A (blue cluster). Samples with an 
even distribution of HEX and FAM signals are heterozygotes (green cluster). 
Homozygotes for the rare allele are those with a significant HEX signal (red 
cluster). NTCs are represented by black squares.  
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2.3.2. Healthy comparison group 
A healthy comparison group of white men and women was drawn from the UK 
Whitehall II study (WHII) (Marmot et al. 1991). This study recruited 10,308 
participants (70% men) between 1985 and 1989 from 20 London-based Civil 
service departments. Clinical measurements were taken at 5-year intervals. 
Phase 3 (1991-1993) provided the first comprehensive phenotyping and is 
considered the baseline phase, and lipid measurements from this phase were 
used in this analysis. Blood samples for DNA extraction were collected from 
5066 individuals at a follow-up screening in 2003-2004. From those that had 
DNA available, 642 subjects who developed either T2D (N=383) or CHD 
(N=193) or both (N=66) over phase 3-7 were selected and matched with two 
healthy participants (total 1926), and an additional 1482 subjects were 
selected at random for genotyping with the Metabochip platform (Illumina Inc, 
San Diego, CA, USA), a custom Illumina iSelect genotyping array comprising 
approximately 200,000 SNPs at regions identified by meta-analyses of GWAS 
for cardio-metabolic endpoints and traits. After removal of samples for quality 
control purposes (outliers, low call rate, gender ambiguity, cryptic relatedness, 
non-Caucasians) and for missing data for the SNPs required for generating 
LDL score, 3020 individuals were used as controls for this analysis. These 
samples were a subset of a previous random selection of 5059 WHII 
individuals that were genotyped using the Illumina Cardiochip platform.  
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2.3.3. Replication cohorts 
Several FH cohorts provided by close collaborators were used to replicate the 
LDL-C gene score findings. The replication cohort included 78 adult FH 
individuals from Canada (39 patients with an identified FH mutation and 39 
mutation negative patients). Two groups of FH children were also studied, 
which included 130 patients from Greece (70 mutation positive and 60 
mutation negative), and 23 patients from Holland (all mutation negative). A 
cohort of FH patients with South-Asian background (studied in Chapter Four, 
26 mutation negative, and 8 mutation positive) was also genotyped for the 12 
SNPs. 
2.4. Whole exome sequencing 
2.4.1. Genomic DNA purification 
Prior to the whole exome sequencing each genomic DNA sample was purified 
using a chloroform-based method. Briefly, 500 μl of each sample was mixed 
with 20 mg/ml Proteinase-K and incubated for 2 hours at 55°C. 1 μl of 
RNaseA was then added, followed by an incubation at 37°C for 15 minutes. 
510 µl of chloroform was thoroughly mixed with the sample and centrifuged at 
16,000 x g for 3 minutes. The DNA-containing top phase was divided (250 µl 
each) between two fresh 1.5 ml microcentrifuge tubes, whereas the remaining 
pellet (containing the chloroform) was discarded with care using the 
hazardous waste facility. 25 µl of NaAc (3M solution) was mixed with each 
pellet. DNA was then precipitated by adding 825 µl of ice-cold 100% absolute 
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ethanol and by slowly inverting the tube. DNA was spooled, washed briefly in 
70% ethanol and dissolved in appropriate volume of TE buffer (100-250 µl).   
Genomic DNA samples were aliquoted to concentration of 100 ng/µl in 
volume of 50 µl. DNA purity was thoroughly assessed by repeated readings 
on NanoDrop ND8000 spectrophotometer, and only samples with absorbance 
readings of 260/280 nm = 1.8 and 260/230 = 2.0 were sent for exome 
sequencing.  
Prior to the sequencing, samples went through several quality control steps 
and cherry-picked for sequence capture. 
2.4.2. Library preparation and sequence capture 
The library preparation and deep sequencing was performed at the Wellcome 
Trust Sanger Institute in Cambridge, as a part of the UK10K sequencing 
project (http://www.uk10k.org). The methods used were as below: 
DNA (1-3 μg) was shared to 100-400 bp fragments using Covaris E210 or 
LE220 (Covaris, Woburn, MA, USA). Shared DNA was subjected to Illumina 
paired-end DNA library preparation and enriched for target sequences 
(Agilent Technologies; Human All Exon 50 Mb – ELID S02972011) according 
to manufacturer’s recommendations (Agilent Technologies; SureSelectXT 
Automated Target Enrichment for Illumina Paired-End Multiplexed 
Sequencing). The set of target regions for the human exome was based on 
the GENCODE project annotations, which provide the most recent human 
protein-coding region with alternatively transcribed variants, non-coding loci 
with transcript evidence, and pseudogenes (Coffey et al. 2011). The exome 
capture was performed by a liquid-phase hybridization method, summarized 
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in Figure 21. Enriched libraries were sequenced using the HiSeq 2000 
platform (Illumina) as paired-end 75 base reads according to manufacturer’s 
protocol. 
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Figure 21 
An overview of the insolution (a liquid-phase) sequence capture. Fragmented 
genomic DNA was hybridised with biotinylated bait probes (blue/black boxes 
with an asterisk) in solution. Streptavidin beads (black circles) were used to 
separate the bead-bait complexes, which were then washed followed by the 
captured DNA (light blue fragments) elution. Adapted from (Teer and Mullikin 
2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genomic DNA fragmentation 
Bait probe hybridisation 
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2.4.3. Whole exome sequencing  control cohort 
A cohort of 1,926 samples, with no lipid abnormalities, was used as a 
comparison group for the rare variant association gene-based burden test 
(see ‘Gene-based burden test’ section). The control sample consisted of eight 
groups of different rare diseases (with no abnormal cholesterol metabolism), 
which were a part of the UK10K project and therefore were sequenced in 
parallel with the FH cohort using exactly the same methods. Variants called in 
the controls were processed together with the cases using the same pipeline.   
2.4.4. Variant calling and informatics 
All the exome sequencing data were produced and annotated together with 
the controls at the Wellcome Trust Sanger Institute in Cambridge as a part of 
the UK10K sequencing project. The variant calling pipelines were as follows: 
2.4.4.1. Single-sample calling release 
To improve raw alignment BAMs for SNP calling, calls were realigned around 
known (1000 Genomes pilot (Abecasis et al. 2010)) indels, and the base 
quality scores was recalibrated using GATK. BAQ tags were added using 
SAMtools calmd. BAMs were merged to sample level and duplicates were 
marked using Picard. Variants (SNPs and Indels) were called on each sample 
individually with both SAMtools mpileup (version 0.1.17) and GATK 
UnifiedGenotyper (version 1.3-21), restricted to exon bait regions plus or 
117 
 
minus 100 bp window. Various quality filters were applied to each of the call 
sets separately (Table 12). Calls were then merged, giving preference to 
GATK information when possible. Calls were annotated with 1000 Genomes 
allele frequencies, dbSNP132 rs IDs and earliest appearance in dbSNP. 
Functional annotation was added using Ensembl Variant Effect Predictor 
(version 2.2) against Ensembl 64 and included coding consequence 
predictions, SIFT, PolyPhen and Condel annotations, and GERP and 
Grantham Matrix scores. 
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Table 12 
Quality filters settings used for the filtering of the whole exome sequencing calls.
Filters for mpileup variants 
all DP <4 MinDP Minimum depth at locus 
all DP >2000 MaxDP Maximum depth at locus 
all MQ <=25 MQual Minimum mapping quality 
snp GQ <=25 GQual Minimum genotype quality 
snp QUAL <=30 MinQ Minimum quality at locus 
indel GQ <=60 iGQual Minimum indel genotype quality 
indel QUAL <=60 iMinQ Minimum quality at indel locus 
Filters for GATK variants 
snp QUAL <30 MinQ Minimum quality at locus 
snp QD <5 MinQD Minimum quality by depth at locus 
snp HRun >5 MaxHRun Max homopolymer run length 
snp SB >-0.1 StrBias Max strand bias 
snp FS >60 MaxFS Max Fishers p-value 
indel FS >200 iMaxFS Max indel Fishers p-value 
indel QD <2 iMinQD Minimum indel quality by depth 
indel ReadPosRankSum <-20 iMinRank        Minimum Z-score 
indel InbreedingCoeff <-0.8 iMinInbreed      Minimum inbreeding coefficient 
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2.4.4.2. Multi-sample calling release 
Calls were made from sets of merged BAMs containing multiple samples per 
BAM. This set of merged BAMs contained the data for all 4,732 exome 
samples in this UK10K release. A BCF file was created with SAMtools 
mpileup, calculating genotype likelihoods for every site in the bait (+/-100bp) 
regions file, then variants (SNPs and Indels) were called by bcftools. 
Variant Quality Score Recalibration (VQSR) was used to filter SNPs. The 
GATK (v1.6-13-g91f02df) UnifiedGenotyper was used to recall the 
sites/alleles discovered by SAMtools in order to generate annotations to be 
used for recalibration. The GATK VariantRecalibrator was then used to model 
the variants, followed by GATK ApplyRecalibration, which assigns VQSLOD 
(variant quality score log odds ratio) values to the variants. 
Variants, based on their VQSLOD score, were assigned to 'truth sensitivity' 
tranches, e.g. s truth sensitivity of 99% means that with variants above this 
minimum VQSLOD score, one retains 99% of truth sites. 
Each VCF contained the following filters applied to SNPs: 
- LowQual,Description="Low quality variant according to GATK (GATK)" 
- MinVQSLOD,Description="Minimum VQSLOD score [SNPs:-1.8768, truth 
sensitivity 99.48]" 
All SNP sites which do not fail these filters will be marked as PASS in the  
VCF.  
Indels were left-aligned using GATK LeftAlignVariants. The following soft 
filters were applied to indels using vcf-annotate: 
120 
 
 StrandBias,Description="Min P-value for strand bias (INFO/PV4) 
[0.0001]" 
 BaseQualBias,Description="Min P-value for baseQ bias (INFO/PV4) 
[1e-100]" 
 EndDistBias,Description="Min P-value for end distance bias 
(INFO/PV4) [0.0001]" 
 GapWin,Description="Window size for filtering adjacent gaps [3]" 
 MaxDP,Description="Maximum read depth (INFO/DP or INFO/DP4) 
[8000000]" 
 MinAB,Description="Minimum number of alternate bases (INFO/DP4) 
[2]"> 
 MinDP,Description="Minimum read depth (INFO/DP or INFO/DP4) 
[16000]" 
 MinMQ,Description="Minimum RMS mapping quality for SNPs 
(INFO/MQ) [10]" 
 Qual,Description="Minimum value of the QUAL field [10]" 
 RefN,Description="Reference base is N []" 
 
The calls were annotated using vcf-annotate. Variant consequence 
annotations are called using the Ensembl Variant Effect Predictor 
(http://www.ensembl.org/info/docs/variation/vep/index.html), v2.4 against 
Ensembl 66. This provides coding consequence predictions and SIFT, 
PolyPhen and Condel annotations. Ensembl also provides GERP 
conservation scores. Grantham matrix values come from a simple lookup. 
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2.4.5. Filtering of variants 
Variants were flagged as somewhat-rare and rare according to their frequency 
in publicly available databases including 1000 Genomes and NHLBI Exome 
Sequencing Project (ESP6500) (http://evs.gs.washington.edu/EVS/). The 
somewhat-rare flag was used to filter out all variants with frequency higher 
than 0.5%, whereas the rare flag was more stringent, selecting variants that 
were novel (i.e. absent from the above databases). In addition to the 
frequency filters, a functional flag was added, which prioritised variants that 
are most likely to affect a protein’s function, i.e. non-synonymous SNVs, stop 
gain SNVs, stop loss SNVs, frameshift deletions and insertions, and splice 
site variants. 
Variants within Tier 1 genes (LDLR, APOB, PCSK9, and LDLRAP1) were 
assessed on the bases of their frequency in 1000 Genomes and 6500ESP, 
and manually by looking at their annotations in the UCL FH mutation 
database (Usifo et al. 2012). Sanger sequencing was used to confirm all 
called mutations. Samples with known FH mutations and therefore an 
explained cause were removed from further analysis. 
The Tier 2 gene list consisted of genes associated with LDL-C as a lead trait 
in the largest (at the time) available Global Lipid Genetic Consortium (GLGC) 
meta-analysis of genome-wide association studies (Teslovich et al. 2010), 
which included: APOE, SORT1 (CELSR2, PSRC1), ABCG5/ABCG8, MYLIP, 
HFE, LPA, PLEC, ABO, ST3GAL4, NYNRIN, OSBPL7, TOP1, PLEC1. 
PLEC1 appeared to be highly polymorphic in both groups, showing an excess 
of variants in the controls as opposed to cases, therefore variants in genes 
122 
 
sharing the LD block with PLEC1 were also considered (LD block is shown in 
Appendix Figure X). These included: PARP10, GRINA, SPATC1, OPLAH, 
EXOSC4, GPAA1, KIAA1875, CYC1, SHARPIN, MAF1. 
Genes that encode proteins, which are directly involved in the lipid 
metabolism were also closely analysed, by looking for variants with strong 
predicted effect on the gene function. These included: SREBP1, SREBP2, 
HMGCR, SCAP, INSIG1, INSIG2, NPC1L1, CETP, LPL, LIPC, ANGPTL4.   
In the past few years, several loci have been demonstrated to be associated 
with FH in family linkage studies, however none was able to map the 
association to a specific gene (Cenarro et al. 2011, Marques-Pinheiro et al. 
2010, Wang et al. 2011). In this study, genes located in the associated 
regions were also analysed for loss-of-function variants.  
2.4.6. Copy Number Variant (CNV) calling 
The ExomeDepth package for R (freely available at the Comprehensive R 
Archive Network (CRAN)) was used to call Copy Number Variants (CNVs) 
(Plagnol et al. 2012). ExomeDepth is based on an algorithm designed to 
compare the read count data from exome sequencing experiments across a 
batch of sequenced samples. The model builds an optimised reference set 
from the input data, which increases the CNV detection power. The 
ExomeDepth approach has been demostrated to overcome biases associated 
with sequence capture and high throughput sequencing when used on 
samples sequenced at the same time in the same manner (Plagnol et al. 
2012). The package uses the February 2009 human genome reference 
sequence (GRCh37, or hg19) for exon annotations, which was produced by 
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the Genome Reference Consortium 
(http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/). The CNV 
calling was performed on BAM files in batches of 24 or 25 samples, since they 
were sequenced at different time points of the project. Common CNVs were 
annotated using published data from Conrad et al. (Conrad et al. 2010). CNVs 
called by ExomeDepth can be visualised using a plot function, which shows 
the ration between observed and expected read depth, as well as the 95% 
confidence interval generated for the studied batch of samples. 
Observed/expected ratios of around 1.5 indicate heterozygous duplication, 
ratios above 2.0 suggests a homozygous CNV. Deletions are characterised 
by values smaller than 0.5. 
The R script for the CNV calling using the ExomeDepth package can be found 
at https://github.com/marta10/PhD_Thesis_MF/blob/master/cnvs_calling.R.  
In addition to ExomeDepth, CNVs were also called using an alternative 
method – ConVex, which was provided by the UK10K project. ConVex 
analysis is also based on the read depth information, which was compared to 
a reference set generated for 50 random whole exome samples from the 
UK10K project. The algorithm detects CNVs with the log2 ratio of depth over 
median depth, using an error-weighted score and the Smith-Waterman 
algorithm. 
2.5. In silico mutation analysis 
2.5.1. Integrative Genomic Viewer (IGV)  
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Integrative Genomic Viewer (IGV) is a visualisation tool of large-scale 
sequencing genomic or exomic data sets (Robinson et al. 2011), which 
supports wide variety of data types, including genomic annotations and 
sequence alignments, such as BAM files. IGV was freely available from: 
http://www.broadinstitute.org/igv/. The tool was used for a visual assessment 
of a candidate variant call quality, for example by analysing the depth of 
coverage, read clonality, or forward/reverse primer bias. 
2.5.2. PolyPhen-2 
Polymorphism Phenotyping 2 (PolyPhen-2) is a web-based tool that predicts 
possible impact of an amino acid substitution on the structure and function of 
a human protein by using 11 predictive features, such as PSIC score, the 
sequence identity to the closest homologue, CpG context, and structural 
features (Adzhubei et al. 2010). PolyPhen can be accessed via 
http://genetics.bwh.harvard.edu/pph2/. The mutation prediction algorithm 
classifies variants into three groups: Benign, Possibly Damaging and Probably 
Damaging. 
2.5.3. SIFT 
Sorting Intolerant From Tolerant (SIFT) is a web-based amino acid change 
prediction tool, which can be found at http://sift.jcvi.org/ (Ng and Henikoff 
2003). SIFT examines a conservation of the studied amino acid change in the 
protein family it belongs to, the positive/negative charge, its hydrophobic or 
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hydrophilic character, and summarizes the data into probability score resulting 
in the outcome of either: Tolerated or Not Tolerated. 
2.5.4. Mutation Taster 
Mutation Taster is a free web-based tool designed to assess the effect of a 
single nucleotide change and/or deletion/insertion in a human gene (Schwarz 
et al. 2010). A studied variant is evaluated according to its evolutionary 
conservation, its ability to cause splice-site alterations, the protein features 
that it may affect, as well as interactions with other molecules. Results are 
assessed by naive Bayes classifier, which predicts the pathogenicity of a 
given variation. A variant can be predicted as Disease Causing or as a 
Polymorphism.  
2.5.5. HOPE 
Have (y)Our Protein Explained (HOPE) is a Web server that can be accessed 
at http://www.cmbi.ru.nl/hope/ . HOPE is a fully automated program that 
analyses DNA base pair changes (including insertions and deletions), by 
considering not only amino acid properties and conservation, but also 
interactions of the sequence with other molecules (e.g. ligands, metals, 
hydrogen bonds, disulphide bridges), modifications that can affect post-
translational processes (e.g. phosphorylation), splice site effects, and 
functionality of structural domains (Venselaar et al. 2010). In addition, the 
report produced by HOPE contains visualisation of each amino acid change in 
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3D-structure of the analysed protein (if available in Protein Data Bank, PDB), 
which can help to understand the effect of a particular change.  
2.5.6. Human Splicing Finder (HSF) 
Human Splicing Finder (HSF) version 2.4.1 was used for assessment of 
single base pair changes that occur in the region in or around intronic/exonic 
boundaries and have ambiguous effect on the amino acid composition of a 
given protein. HSF is freely available on http://www.umd.be/SSF/. The tool 
uses an algorithm, which calculates the strength of a potential splice site and 
the strength of splicing branch points and compares them between the wild 
type and the mutated state (Desmet et al. 2009).  
2.6. Statistical analysis 
All statistical analyses were carried out using R (R Foundation for Statistical 
Computing, Vienna, Austria, ISBN 3-900051-07-0). 
2.6.1. Oxford FH 
Matched pre- and post-treatment LDL-C values were available for 104 
patients (69 mutation negative, 35 mutation positive). Concentrations of 
serum cholesterol, LDL-C, HDL-C and triglyceride were not normally 
distributed, and were presented as geometric means with an approximate 
standard deviation. Matched pre-treatment TC and TG values were available 
for 159 patients (62 mutation positive). Dutch scores were calculated using 
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the weights for diagnostic traits as described in Table 3. SBBHF study 
subjects were scored zero for arcus cornealis since there was no information 
available for this item. SBBHF LDL-C measures were post-treatment and we 
therefore estimated pre-treatment values for use in the score assuming a 
reduction of 40% in LDL-C with treatment. The ability of the criteria to 
discriminate between mutation carriers and non-carriers was assessed by the 
area under the ROC curve using combined data from both studies. Areas 
were compared using the method described by Delong (DeLong et al. 1988). 
Dutch scores were adjusted for study differences before construction of the 
ROC curves. A p value of <0.05 was taken as significant. 
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2.6.2. South-Asian FH 
Matched pre- and post-treatment LDL-C values were available for 19 patients 
(2 mutation positive). Concentrations of serum cholesterol, LDL-C, HDL-C and 
triglyceride were not normally distributed, and were presented as geometric 
means with an approximate standard deviation. Matched pre-treatment TC 
and TG values were available for 24 patients (6 mutation positive). A p value 
of <0.05 was taken as significant.  
2.6.3. LDL-C gene score association testing 
LDL-C gene score for each individual was calculated by summing the weights 
of each of the ten risk alleles the individual was carrying and by adding the 
weight of the observed ApoE isoform. The scores were compared by Welch 
Two-sample T Test between the mutation negative FH and the mutation 
positive FH, the mutation negative and the healthy control, and the healthy 
control and the mutation positive FH. ANOVA test was used to test the LDL-C 
gene score distribution difference between the three groups together.    
2.6.4. Whole exome sequencing gene-based burden test  
Analysis of the rare variant association with FH cohort was performed using a 
gene-based burden test. A gene-based burden test groups variants into 
genes, which increases the power of detecting the association in comparison 
to a single-variant association tests. The increase in power is a great 
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advantage of the burden test however it depends on the number of associated 
variants, the number of neutral variants diluting the signal, and the direction of 
the effect of the associated gene. In this study variants were flagged by their 
frequency as somewhat-rare or rare (see ‘Filtering of variants’ section) and by 
their function (as functional) in cases and controls. Flagged variants were then 
counted per gene in the cases and controls. The imbalance of functional 
somewhat-rare or functional rare variants was assessed using a binomial 
probability test (pbinom) in R. The R script for the association testing can be 
found at: 
https://github.com/marta10/PhD_Thesis_MF/blob/master/association_updated
_aug_2013.sh . 
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III. CHAPTER THREE - Analysis of the frequency and 
spectrum of FH mutations in patients from 
Oxford 
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3.1. Introduction 
The clinical phenotype of FH is known to be due to mutations in three genes 
encoding proteins involved in the uptake of LDL-C from the plasma, LDLR, 
APOB and PCSK9. Mutations in LDLRAP1 are known to cause recessive 
form of FH. In the UK, the Simon Broome Register criteria are used for the 
clinical diagnosis of FH, whereas other European countries may use a score 
developed by the Dutch Lipid Clinic Network (DLCN) ('Risk of fatal coronary 
heart disease in familial hypercholesterolaemia. Scientific Steering Committee 
on behalf of the Simon Broome Register Group'  1991, Marks et al. 2003). To 
date, there are over 1,200 different LDLR mutations reported (Usifo et al. 
2012) but only one common APOB (c.10580G>A, p.(Arg3527Gln)) and one 
PCSK9 (c.1120G>T, p.(Asp374Tyr)) (Humphries et al. 2006a). The spectrum 
of FH mutations in Europe varies between countries, from Greece with only 
six mutations, which account for 60% of FH in the country, to the Netherlands 
with one of the most heterogeneous spectrum (Glynou et al. 2008, Dedoussis 
et al. 2004). In the UK there are over 200 different mutations reported (Leigh 
et al. 2008), which is similar to other western countries. LDLR mutations 
include mainly single nucleotide changes, which alter the amino acid 
composition of the mature protein, affect the correct splicing of the transcript, 
or binding of key transcription factors, if located in the promoter region 
(Khamis A 2012). Large deletions and insertions account for approximately 5-
6% of all FH genetic defects (Taylor et al. 2010b, Leigh et al. 2008).  
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Statin drug therapy significantly reduces the morbidity and mortality from 
premature coronary disease in FH, particularly if affected individuals are 
identified and treated in childhood or early adulthood (Neil et al. 2008, Gill et 
al. 2012, Nherera et al. 2011). The UK National Institute for Health and 
Clinical Excellence (NICE) guidelines published in 2008 recommended that all 
FH patients be offered a DNA test to confirm the diagnosis and that identified 
mutations should be used as the basis for cascade testing of first-degree 
relatives of index cases. Patients newly identified by such screening can then 
be offered treatment to reduce the risk of premature cardiac events 
(Wierzbicki et al. 2008).  DNA testing for FH has also been shown to 
complement cholesterol measurement in the management of affected 
individuals (Humphries et al. 2006c). 
 
This study aimed to assess the frequency and spectrum of mutations 
recognised to cause FH among patients attending the Oxford Lipid Clinic. The 
LDLRAP1 gene was not analysed since all patients had the dominant pattern 
of FH inheritance. The frequency of specific mutations in the UK differs 
between areas, with p.(Glu101Lys) being the most common in Manchester 
(Webb et al. 1992), p.(Arg350*) in South of England (Day et al. 1997a), and 
p.(Cys184Tyr) in Glasgow (Lee et al. 1998). This study examined whether 
there are any specific mutations that occur with an unexpected frequency 
among patient attending the Oxford lipid clinic, which is a specialist clinic with 
a catchment population of over 620,000 people (Neil et al. 2000). The 
correlation between the measured pre-treated cholesterol, pre-treated 
triglycerides and the mutation detection rate was also assessed to test the 
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hypothesis that the individuals carrying a FH mutation have higher pre-
treatment cholesterol levels and lower triglyceride level compared to those 
with no mutation. The likelihood of identifying mutation carriers was compared 
using two different clinical diagnostic criteria: the Simon Broome criteria and 
the DLCN score. In addition, the study examined whether the effectiveness of 
lipid-lowering therapy varied between patients with different genetic causes of 
FH. 
3.2. Results 
3.2.1. Patients characteristics 
In total, 289 (272 probands) FH patients were screened for FH mutations in 
three genes, LDLR, APOB and PCSK9. Characteristics of the patients 
recruited for the study is shown in Table 13. The majority (52%) of individuals 
had the clinical diagnosis of PFH, with 23% being DFH. 26% of the patients 
could not be classified (UH) due to a lack of family history of early CHD or the 
patient was unaware of the family history. There was no significant difference 
in age or in the male/female ratio between the groups. The mean pre-
treatment cholesterol differed significantly between groups (p<0.0001), with 
DFH having the highest TC (9.79 mmol/l) and LDL-C (6.93 mmol/l) levels, 
while PFH and UH groups had similar pre-treatment TC and LDL-C levels. 
The highest mean pre-treatment TG levels (2 mmol/l) was observed in the UH 
patients, and it was significantly different between the groups (p=0.004), 
however similar to PFH (p=0.162). There was no difference in the HDL-C 
distribution between the groups. 
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A well-phenotyped cohort studied by Neil et al. (Neil et al. 2004) was used for 
the comparison and replication. The SBBHF study comprised 409 DFH 
patients, diagnosed using the Simon Broome criteria for FH, of whom the 
majority (80%) had a reported FH-causing mutation. The baseline 
characteristics of this cohort are shown in Table 14. Briefly, mutation positive 
patients were significantly younger (p=0.01), had higher pre- and post-
treatment TC and LDL-C (p=3x10-5, p=0.03, p=4x10-5). The post-treatment TG 
levels were significantly lower in the mutation carriers (1.25 mmol/l vs. 1.62 
mmol/l, p=3.136x10-6). The replication SBBHF patients were younger than the 
DFH Oxford FH participants. There was no significant difference in pre-
treatment TC levels between the groups, however the SBBHF patients had 
significantly higher post-treatment TC, TG and LDL-C (Table 15). These 
differences are likely to be due to the different lipid-lowering treatment that 
was available for the cohorts. The replication cohort is historic and post-
treatment lipid levels were recorded before Atorvastatin treatment was 
approved in 1996. There was no difference in the male/female ratio between 
the cohorts.
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Table 13 
Baseline characteristics of the Oxford FH cohort. Lipid levels (in mmol/l) are shown as geometric means (with approximate 
standard deviation), because they were not normally distributed. P value between two groups was calculated on log transformed 
data using Welch Two Sample t-test. The overall p values were obtained using ANOVA test. 
Variable DFH (N=65) 
p value 
(DFH vs. PFH) 
PFH 
(N=150) 
p value 
(PFH vs. UH) 
UH (N=74) 
p value 
(overall) 
Gender 
 
 
 
 
 
 
% Male (N) 47.7 (34)  46.7 (70)  58.1 (43) 0.25 
Mean age (SD) 58.0 (12.7)  53.8 (14.1)  54.2 (14.9) 0.12 
  
 
 
 
  
Pre-treatment TC 9.79 (1.66) 7.6x10-06 8.71 (1.27) 0.391 8.47 (1.92) <0.0001 
Pre-treatment HDL-C 1.38 (0.35) 0.302 1.46 (0.40) 0.634 1.39 (0.39) 0.62 
Pre-treatment TG 1.22 (0.56) 0.008 1.53 (0.72) 0.115 2.00 (0.81) 0.004 
Pre-treatment LDL-C 6.93 (1.61) 0.005 6.12 (1.15) 0.074 5.45 (1.72) 0.0002 
  
 
 
 
  
Post-treatment TC 5.95 (1.01) 0.003 5.46 (1.13) 0.604 5.36(1.17) 0.008 
Post-treatment HDL-C 1.31 (0.36) 0.05 1.44 (0.32) 0.866 1.40 (0.46) 0.1 
Post-treatment TG 1.12 (0.52) 0.188 1.25 (0.60) 0.848 1.21 (0.38) 0.42 
Post-treatment LDL-C 4.1 (1.04) 7.7x10
-06 3.29 (1.00) 0.596 3.65 (1.57) 0.0001 
            
Detected mutations (in probands only)  
 
 
  LDLR (%) 43(71.7)  30(21.1)  9(12.9) 
<0.0001 APOB (%) 1(1.7) 1.94x10
-09 8(5.6) 0.062 1(1.4) 
None (%) 16(26.7)  104(73.2)  60(85.7) 
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Table 14 
Baseline characteristics of the SBBHF study used for the replication and comparison with the original results in Oxford FH cohort. 
Lipid levels (in mmol/l) are shown as geometric means (with approximate standard deviation), because they were not normally 
distributed.
Variable 
Mutation -ve 
(N=81) 
Mutation +ve 
(N=328) 
Total 
(N=409) 
P value 
% male 
 
Age 
 
Pre-treatment TC 
 
Post-treatment TC 
 
Post-treatment LDL-C 
 
Post-treatment HDL-C 
 
Post-treatment Triglycerides 
50.6% (41) 
 
52.4 (13.6) 
 
9.22 (1.71) 
 
6.39 (1.41) 
 
4.06 (1.27) 
 
1.37 (0.33) 
 
1.62 (0.76) 
51.5% (169) 
 
48.3 (13.5) 
 
10.35 (1.88) 
 
6.74 (1.29) 
 
4.67 (1.24) 
 
1.34 (0.37) 
 
1.25 (0.55) 
51.3% (210) 
 
49.1 (13.6) 
 
10.13 (1.90) 
 
6.67 (1.32) 
 
4.54 (1.28) 
 
1.34 (0.36) 
 
1.32 (0.60) 
0.88 
 
0.01 
 
0.00003 
 
0.03 
 
0.00004 
 
0.49 
 
3.136x10-6 
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Table 15 
 
Baseline characteristics comparison of the Oxford definite FH patients and the SBBHF replication study. Lipid levels (in mmol/l) are 
shown as geometric means (with approximate standard deviation). P value between two groups was calculated on log transformed 
data using Welch Two Sample t-test.  
 
Variable Oxford DFH (N=65) SBBHF (N=409) p value 
Gender 
 
 
 
% Male (N) 47.7 (34) 51.3 (210) 0.99 
Mean age (SD) 58.0 (12.7) 49.1 (13.6) 1.2 x10
-7 
 
   
Pre-treatment TC 9.79 (1.66) 10.13 (1.90) NS 
 
   
Post-treatment TC 5.95 (1.01) 6.67 (1.32) 5.5 x10
-6 
Post-treatment HDL-C 1.31 (0.36) 1.34 (0.36) NS 
Post-treatment TG 1.12 (0.52) 1.32 (0.60) 0.03 
Post-treatment LDL-C 4.1 (1.04) 4.54 (1.28) 0.01 
 
 
NS = not significant 
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3.2.2. Mutation spectrum 
A FH-causing variant was found in 101 individuals, of which the most 
frequently observed was APOB p.(Arg3527Gln), present in 11 individuals (10 
probands). There were 54 different LDLR mutations, which were found in 90 
patients and accounted for 89% of all observed mutations. The most 
commonly observed mutations in LDLR were c.301G>A (p.(Glu101Lys)) 
present in six probands, c.259T>G (p.(Trp87Gly)), c.313+1G>A, 
c.680_681delAC (p.(Asp227Glyfs*12)), c.681C>G (p.(Asp227Glu)), 
c.1116_1119dupGGGT (p.(Glu374fs*8)), and c.2054C>T (p.(Pro685Leu)), all 
observed in three FH probands. Most of the changes occurred in exons 4 and 
10, which are the longest LDLR exons. There were no FH-causing variants 
found in exons 1, 12, 16 and 18 of the LDLR. The MLPA analysis of LDLR 
detected large gene rearrangements in 11 probands, which accounted for 
over 10% of all Oxford FH mutations. All observed mutations are summarised 
in Table 16. There were no patients with the PCSK9 p.(Asp374Tyr) mutation 
in this cohort. There were no compound heterozygotes for mutations in LDLR 
and APOB.
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Table 16 
All FH mutations found in the Oxford FH cohort, ordered by their frequency. Variants marked in bold were novel. Predicted 
consequence: A=amino acid change, B=splicing defect, C=peptide truncation due to a frame shift, D=large in frame indel, 
E=premature stop codon formation, F=gene expression effect, G=structure/folding defect, H=peptide elongation.  
Gene Base pair change 
Predicted  
amino acid change 
Number of 
carriers 
(number of 
probands) 
Predicted 
consequence 
APOB c.10580G>A p.(Arg3527Gln) 11(10) A 
LDLR c.301G>A  p.(Glu101Lys) 6(6) A 
LDLR c.313+1G>A N/A 4(4) B 
LDLR c.681C>G  p. (Asp227Glu) 4(3) A 
LDLR c.1444G>A p.(Asp482Asn) 4(3) A 
LDLR c.259T>G  p.(Trp87Gly) 3(3) A 
LDLR c.680_681delAC p.(Asp227Glyfs*12) 3(3) C 
LDLR c.1116_1119dupGGGT p.(Gly374fs*8) 3(3) C 
LDLR c.2054C>T p.(Pro685Leu) 3(3) A 
LDLR c.191-?_1186+?del N/A 3(2) D 
LDLR c.2187_2197del p.(Leu729Leufs*39) 3(2) C 
LDLR c.2089G>C p.(Ala697Pro) 3(1) A 
LDLR c.662A>G p.(Asp221Gly) 2(2) A 
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LDLR c.682G>T p.(Glu228*) 2(2) E 
LDLR c.695-?_817+?del N/A 2(2) D 
LDLR c.912C>G p.(Asp304Glu) 2(2) A 
LDLR c.1846-?_2140+?del  N/A 2(2) C 
LDLR c.667_693del p.(Lys223_Cys231del) 2(1) G 
LDLR c.-121T>C N/A 1(1) F 
LDLR c.68-?_1186+?dup N/A 1(1) D 
LDLR c.118delA p.(Ile40Serfs*166) 1(1) C 
LDLR c.139G>A p.(Asp47Asn) 1(1) A 
LDLR c.191-?_1186+?dup N/A 1(1) D 
LDLR c.191-?_313+?del N/A 1(1) D 
LDLR c.361T>A  p.(Cys121Ser) 1(1) A 
LDLR c.502G>A  p.(Asp168Asn) 1(1) A 
LDLR c.621C>T p.(Gly207Gly) 1(1) A 
LDLR c.629T>A p.(Ile210Asn) 1(1) A 
LDLR c.654_656delTGG p.(Gly219del) 1(1) A 
LDLR c.859G>A p.(Gly287Ser) 1(1) A 
LDLR c.889A>C p.(Asn297His) 1(1) A 
LDLR c.898A>T p.(Arg300*) 1(1) E 
LDLR c.933delA p.(Lys311fs*59) 1(1) C 
LDLR c.1048C>T p.(Arg350*) 1(1) E 
LDLR c.1049G>C p.(Arg350Pro) 1(1) A 
LDLR c.1135T>C p.(Cys379Arg) 1(1) A 
LDLR c.1215C>G p.(Asn405Lys) 1(1) A 
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LDLR c.1230G>T p.(Arg410Ser) 1(1) A 
LDLR c.1246C>T p.(Arg416Trp) 1(1) A 
LDLR c.1285G>A p.(Val429Met) 1(1) A 
LDLR c.1369_1372dupGACA  p.(Arg458fs*10) 1(1) C 
LDLR c.1379_1402delinsCAGCTTGACCCGC p.(His460Profs*3)  1(1) C 
LDLR c.1436T>C p.(Leu479Pro) 1(1) A 
LDLR c.1466A>G p.(Tyr489Cys) 1(1) A 
LDLR c.1567G>A p.(Val523Met) 1(1) A 
LDLR c.1574A>T p.(Asp525Val) 1(1) A 
LDLR c.1587-?_1845+?del N/A 1(1) C 
LDLR c.1587-?_1845+?dup N/A 1(1) C 
LDLR c.1646G>A p.(Gly549Asp) 1(1) A 
LDLR c.1694G>C p.(Gly565Ala) 1(1) A 
LDLR c.1897C>T p.(Arg633Cys) 1(1) A 
LDLR c.1941_1944delins1922_1934 N/A 1(1) C 
LDLR c.2098G>A p.(Asp700Asn) 1(1) A 
LDLR c.2393_2401del p.(Leu799_Phe801del) 1(1) A 
LDLR c.2476C>A p.(Pro826Thr) 1(1) A 
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3.2.3. Novel LDLR variants 
There were 12 novel LDLR variants, summarized in Table 17, which were not 
reported on the UCL FH database. These included one promoter variant (c.-
121T>C), which was further studied and proved to affect a transcription factor 
binding site and reduced luciferase activity by 50±8% suggesting strongly that 
this variant is FH-causing (publication in revision, Khamis A, et al.). Six non-
synonymous changes were identified of which two were located in exon 4 of 
the gene, one nonsense mutation (c.898A>T, p.(Arg300*)), three small 
rearrangements, of which two lead to a frame shift and premature termination, 
and one large gene rearrangement - duplication of exon 11, predicted to 
cause frame shift and premature termination. Using in silico tools, all novel 
variants were predicted to be protein damaging suggesting that they are likely 
to be pathogenic.  
Deletion of nine amino acids in c.667_693del (p.(Lys223_Cys231del)) was 
assessed using conservation and structure analysis (Usifo et al. 2012). This 
region includes the highly conserved D-x-S-D-E motif (residues 224-228) in 
exon 4. The secondary structure of this region and the coordination of a 
calcium cation are crucial for pH dependent recycling of the LDL-R peptide. 
Therefore, deletion of residues 227 and 228, which are directly involved in 
calcium coordination and removal of the disulphide bridge formed between 
residues 231and 216, is very likely to have a pathogenic effect (shown in 
Figure 22). All novel mutations were submitted to the UCL FH database (Usifo 
et al. 2012). 
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Table 17 
Novel LDLR variants identified in the Oxford Lipid Clinic patients and the in silico prediction of their effect. 
Mutation 
type/Exon 
Variant position PolyPhen  SIFT 
Mutation 
Taster 
Conclusion 
Promoter           
  c.-121T>C NA NA D 
Transcription factor binding site disruption 
(publication in preparation) 
Missense           
4 c.361T>A (p.(Cys121Ser)) D D D FH-causing 
4 c.629T>A (p.(Ile210Asn)) D D D FH-causing 
6 c.859G>A (p.(Gly287Ser)) D D D FH-causing 
9 c.1230G>T (p.(Arg410Ser)) D D D FH-causing 
14 c.2098G>A (p.(Asp700Asn)) P D D FH-causing 
17 c.2476C>A (p.(Pro826Thr)) D D D FH-causing 
Nonsense           
6 c.898A>T (p.(Arg300*)) NA NA D Formation of premature stop codon 
Small rearrangements 
  
        
4 c.667_693del (p.(Lys223_Cys231del)) NA NA NA Deletion of 9 highly conserved residues  
10 
c.1379_1402delinsCAGCTTGACCCGC 
(p.(His460Profs*3)) 
NA NA NA Frame shift   premature stop codon 
15 c.2187_2197del (p.(Leu729Leufs*39)) NA NA D Frame shift   premature stop codon 
Large rearrangements         
11 c.1587-?_1845+?dup NA NA NA Frame shift   premature stop codon 
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Figure 22 
3D structure of LDL-R extracellular domains (Protein Database 1N7D, 
http://www.ebi.ac.uk/pdbsum/1N7D) viewed using Jmol, overlaid with 
conservation scores. Red indicates high conservation, purple moderate 
conservation, blue poor conservation. Calcium cations are shown as black 
dots.  Residues deleted in p.(Lys223_Cys231) are shown by yellow dotted 
line, disulphide bridge broken by the deletion shown as green line. 
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3.2.4. Mutation detection rate and patients’ lipid levels 
An FH-causing mutation was detected in 73% DFH and in 27% PFH patients 
(probands), with 10 mutations found in the unclassified hypercholesterolaemia 
group (14% of probands) and overall this difference in detection rate was 
highly statistically significant (p < 0.0001).  The mutation detection rate was 
significantly different by pre-treatment TC levels quartile (p=9.83 x 10-5), and 
in the top quartile (pre-treated TC of 10.0-15.0mmol/l) an FH mutation was 
found in 74% of patients, as shown in Table 18. The mutation detection rate 
also differed significantly depending on pre-treatment TG levels (p=0.0005). 
Individuals with the lowest TG levels (0.4-1.0mmol/l) had the highest detection 
rate (60%), which decreased to 20% for patients in the top quartile (2.16-4.3 
mmol/l). When combined, the mutation detection rate was 100% in individuals 
whose TG levels were in the lowest quartile and TC levels in the top quartile 
compared to a less than 5% detection rate in those with TG levels in the 
highest quartile and TC levels in the lowest quartile, demonstrated in Figure 
23. These findings were replicated in the SBBHF cohort, where the highest 
mutation detection rate of 90% was observed in patients with pre-treatment 
TC above 11.6 mmol/l, which decreased to 68% in those with TC equal to or 
below 8.7 mmol/l, confirming the association of pre-treatment TC levels with 
the mutation detection rate (p=0.0001). Because pre-treatment TG levels 
were not available, the post-treatment TG levels were used and this also 
showed high association (p=1.8x10-6) (Table 18).  
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Table 18 
FH mutation detection rate by quartile of pre-treatment TC and pre-treatment TG. (Pre-treatment TG levels for SBBHF study were 
not available). 
 
  Oxford FH study   
Quartile of Pre-treatment 
TC (mmol/l) 
N Mutation +ve (%) 
Quartile of Pre-treatment 
TG (mmol/l) 
N 
Mutation +ve 
(%) 
Q1   <= 8.0 40 10 (25) Q1   <= 1.0 42 25 (60) 
Q2   8.1-8.7 41 12 (29) Q2   1.10-1.32 38 15 (40) 
Q3   8.8-9.9 44 15 (34) Q3   1.33-2.15 39 14 (36) 
Q4   >10.0 34 25 (74) Q4   2.16-4.30 40 8 (20) 
P value (trend)   p = 9.83 x 10-5     0.000458 
  Replication SBBHF study   
Quartile of pre-treatment 
TC (mmol/l) 
N Mutation +ve (%) 
Quartile of post-treatment 
TG (mmol/l)* 
N 
Mutation +ve 
(%) 
Q1    <=8.7 76 52 (68.4) Q1    <1 105 92 (87.6) 
Q2    8.8-10.1 82 66 (80.5) Q2    1-1.3 123 109 (88.6) 
Q3    10.2-11.6 69 62 (89.9) Q3    1.4-1.8 90 70 (77.8) 
Q4    >11.6 72 65 (90.3) Q4    >1.8 91 57 (62.6) 
P value (trend)   0.0001     P= 1.80 x 10-6 
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Figure 23 
FH mutation detection rate by quartiles of pre-treatment TC and pre-treatment 
TG levels combined in Oxford FH patients.
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The specificity and sensitivity of correctly identifying mutation carriers by using 
the Simon Broome FH criteria was compared to the Dutch Lipid Clinic 
Network (DLCN) score. 220 Oxford FH patients had data available to allow 
the DLCN Score to be calculated. As shown in Table 19 the mutation 
detection rate significantly increased (p=0.004) with rising DLCN Score. The 
number of DFH individuals diagnosed using the Simon Broome criteria was 
significantly correlated with the DLCN score (2.6 x 10-7), indicating high 
similarity of both methods. When we compared the discriminatory power of 
the two methods using the AROC statistic, both methods performed well (ROC 
values for SB= 0.73 (95% CI = 0.68-0.77) vs. DLCN = 0.72 (95% CI = 0.69-
0.77), p values for difference = 0.68), confirming that the sensitivity and 
specificity of both clinical diagnostic approaches were not different (Figure 
24). 
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Table 19 
The FH mutation detection rate in patients diagnosed using the DLCN score, 
with the percentage of DFH diagnosed by the Simon Broome FH criteria in 
each score group. 
 
DLCN Score 
Patient 
Count 
Mutation +ve (%) DFH (%) 
< 3 13 3 (23) 2 (15) 
3 - 5 69 19 (28) 9 (13) 
6 - 8 49 19 (39) 8 (16) 
> 8 89 48 (54) 45 (51) 
P value for the trend 
(Fisher's exact) 
  0.004 2.6 x 10-7 
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Figure 24 
Receiver Operating Characteristic (ROC) curve comparing the accuracy of the 
Simon Broome FH criteria (SB) vs. the Dutch Lipid Clinic Network criteria 
(Dutch score) in Oxford Lipid Clinic patients and the SBBHF study combined. 
Chi square test p value of the area under the curve was not significant (p > 
0.68).
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3.2.5. Mutation carriage and lipid levels pre- and post-treatment 
The mean level of pre-treatment TC in patients with any detected FH-causing 
mutation was significantly higher than in those with no mutation (p=2.15 x 10-
08, Welch Two Sample t-test) (Figure 25). The highest pre-treatment TC was 
seen in the patients with any LDLR mutation (9.81 mmol/l, SD=1.52), followed 
by the familial defective ApoB (FDB) patients (9.12 mmol/l, SD=0.85), while 
the mutation-negative patients had the lowest pre-treatment TC (8.47 mmol/l, 
SD=1.36), as shown in Figure 26. The difference between the TC levels in 
LDLR and APOB mutation carriers was significantly different (p=0.03) as well 
as the overall difference between the three groups (ANOVA test, p=3.31x10-
8). This result confirms previous findings (Humphries et al. 2006c). 
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Figure 25 
Mean pre-treatment and post-treatment TC levels in mutation negative (-ve) 
vs. mutation positive (+ve) patients. P values shown from Welch Two Sample 
t-test. NS = not significant.
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Figure 26 
Pre-treatment LDL cholesterol in patients with mutation in LDLR or APOB 
genes, or with no mutation identified. The difference between the groups was 
significant (ANOVA p = 7.76 x 10-05).
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The TC level was significantly reduced by treatment in both mutation positive 
and mutation negative groups by at least 35% (see Table 20). The UK 
guidelines on management of FH dyslipidaemias recommend that the 
treatment goal for FH should be to reduce LDL-C by at least 50% from 
baseline (Wierzbicki et al. 2008), while guidelines on management of 
dyslipidaemias recommend that LDL-C in high risk subjects should be 
reduced below 2.5 mmol/l and for individuals with CVD (very high risk) below 
1.8 mmol/l (Catapano et al. 2011).  Data on pre- and post-treatment LDL-C 
was available for 104 individuals, and the 50% LDL-C reduction was achieved 
in 47% of the patients. This was similar to the study from 2008, when 64% 
patients had 45% reduction in LDL-C (Hadfield et al. 2008), and to the 
findings of the National Audit of the Management of Familial 
Hypercholesterolaemia 2010, when 44% of patients achieved 50% reduction 
(http://www.rcplondon.ac.uk/resources/audits/FH). 
 Post-treatment LDL-C values were available for 176 patients of whom 26 
(14.8%) had LDL-C reduced below 2.5 mmol/l and 1 patient (0.6%) had LDL-
C below 1.8 mmol/l. The pre- and post-treatment LDL-C distribution is shown 
in Figure 27. 
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Table 20 
Total cholesterol reduction after treatment in patients with or without an 
identified FH mutation, in DFH, PFH and UH.
  DFH PFH UH 
Mutation -ve 
-37.5%  
(-47.0 to -26.3) 
-38.1%  
(-41.3 to -34.7) 
-35.2%  
(-39.5 to -30.6) 
Mutation +ve 
-39.9%  
(-44.0 to -35.5) 
-41.8%  
(-45.3 to -38.0) 
-41.0%  
(-52.2 to -27.3) 
All 
-39.3% 
(-43.1 to -35.3) 
-39.1%  
(-41.6 to -36.4%) 
-36.5%  
(-40.5 to -32.2) 
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Figure 27  
LDL-C levels distribution before and after treatment. Dashed lines at 1.8 mmol/l and 2.5 mmol/l indicate the recommended post-
treatment levels for FH individuals with CVD and with high risk of CVD, respectively. 
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3.3. Discussion 
This study has identified marked genetic heterogeneity among patients with 
heterozygous familial hypercholesterolaemia attending a single UK lipid clinic 
with a catchment population of more than 620,000 people in the Oxfordshire 
region. Amongst 272 unrelated patients 54 different LDLR mutations in 90 
subjects were identified, which is comparable with the 107 different mutations 
identified in 232 subjects in the UK Cascade pilot project who were from five 
geographically dispersed sites (Taylor et al. 2010b). There were 12 previously 
unreported mutations found in the Oxford cohort, which accounted for 22% of 
all LDLR mutations found in this study. This is also substantially higher than 
the 7% novel variants found in the previous UK study (Taylor et al. 2010b). 
While this may be a result of the increased sensitivity of the current mutation 
detection methods, it may also reflect the genetic heterogeneity of this Oxford 
sample. Overall, the mutation spectrum was similar to the rest of the UK, 
however the most commonly occurring LDLR mutation in Oxford was 
c.301G>A (p.(Glu101Lys), which accounted for 6% of all observed mutations, 
as opposed to 1% in the whole of the UK study (Taylor et al. 2010b). The 
frequency of gross deletions/duplications within the LDLR was higher (10%) 
than previously reported (5-6%), however this was not statistically different 
(Fisher’s exact test, p = 0.06). The PCSK9 (p.(Asp374Tyr)) mutation, which is 
associated with a higher CHD risk than other FH-causing  mutations 
(Humphries et al. 2006a), was not observed in the Oxford cohort.  
 
 158 
A striking finding was the importance of high pre-treatment cholesterol and 
low triglyceride levels as predictors of the likelihood of detection of an FH-
causing mutation.  The detection rate of 73% in DFH compared to the 27% in 
PFH in patients attending the Oxford clinic was similar to that reported 
previously in UK patients (Humphries et al. 2006c, Heath et al. 2001, Graham 
et al. 1999, Damgaard et al. 2005).  
Additionally, this study examined the utility of the Dutch Lipid Clinic Network 
(DLCN) score, in identifying patients with a high or low probability of carrying 
an FH-causing mutation. In patients with a DLCN score indicative of Definite 
FH (>8), Probable FH (>5 and <8) and Possible FH (>3 and <5), the mutation 
detection rates were 54% vs. 39% vs. 28%, respectively, and using the AROC 
statistic the two approaches were not significantly different in discrimination. 
Combining pre-treatment TC and TG levels gave the highest likelihood of 
finding patients carrying FH mutations, with 100% mutation detection rate in 
patients with pre-treated TC above 10.0 mmol/l and with TG below 1.0 mmol/l, 
compared to >5% detection rate in those with pre-treated TC below 8.0 
mmol/l and with TG above 2.15 mmol/l.  
A proportion of the studied patients (26%) did not fulfil the Simon Broome 
criteria for FH as there was either no family history of hypercholesterolaemia 
or premature CHD or, alternatively, the family history was unknown or 
incomplete. There were 10 FH-causing mutations found among probands of 
the unclassified hypercholesterolaemic individuals (14%), and the 
identification of an FH-causing mutation therefore changed the diagnosis to 
DFH, which would have warranted cascade testing of their first-degree 
relatives. This finding supports the clinical utility of DNA testing, even in 
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individuals with a low probability of being affected. We can speculate as to the 
likely genetic cause of the elevated cholesterol and triglyceride levels seen in 
the mutation negative subjects examined in this study. As recently 
demonstrated (Talmud et al. 2013) and discussed further in Chapter Three, in 
a significant proportion of mutation negative patients with a clinical diagnosis 
of FH, the elevated LDL-C can be explained by the “polygenic” contribution of 
12 common LDL-C-raising variants, in genes identified through Genome Wide 
Association studies. Similarly it has been demonstrated that the frequencies 
of common triglyceride-associated variants are also significantly higher in 
groups of patients with different Fredrickson classification forms of 
hypertriglyceridaemia (Johansen et al. 2011) compared with controls. Thus, it 
is likely that the elevated levels of lipids seen in the Oxford no-mutation group 
have a polygenic and not a monogenic explanation. Several of the mutation 
negative DFH patients from Oxford were genotyped for the 12 LDL-C-rising 
SNPs in Chapter Five.  
 
A limitation of the study was that pre-treatment TC measurements were not 
available for 31 out of 289 participants, and pre-treatment TG levels were not 
recorded for 130 individuals. This was because some patients who met the 
criteria in other respects (e.g. personal family history of premature CHD or 
tendon xanthomas) were referred to the lipid clinic whilst on diet or lipid-
lowering medication, and it would not have been ethical to stop medication to 
collect data for this study. Although both the SB and DLCN clinical diagnostic 
methods performed well, the clinical utility of the Simon Broome diagnostic 
criteria may be questioned since they require tendon xanthomata to be 
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present for a diagnosis of DFH, and these are increasingly uncommon as 
patients are diagnosed at a younger age. Although the methodology used for 
the mutation screening is appropriate and was shown to be sensitive and 
robust (Whittall et al. 2010a), a recent report exposed some limitations to the 
current methods, which included false negative calling due to human error in 
data and sample handling (Futema et al. 2012), which is discussed further in 
Chapter Six. 
 
The UK 2008 NICE guidelines for the management of FH recommends a 
target reduction in LDL-C with treatment of greater than 50% from baseline, 
which was achieved in less than half of patients in this study. Furthermore, 
reduction of LDL-C below the ESC/EAS guideline of 2.5 mmol/l for moderate 
risk subjects (Catapano et al. 2011) was achieved in only about 15% of the 
patients, and only one patient had post-treatment LDL-C below the 1.8 mmol/l 
target for individuals at a very high risk. The mechanism of action of statins 
drives the expression of the SREBP transcription factor, which activates the 
expression of LDLR but also activates expression of PCSK9, which results in 
greater degradation of LDL-receptors. Inadequate  LDL-C reduction in most 
patients highlights the need for more effective lipid-lowering drug therapy, and 
novel treatments, such as PCSK9 inhibition, may offer new therapeutic 
opportunities to achieve this (Raal et al. 2012).
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IV. CHAPTER FOUR - Mutation detection, spectrum 
and frequency in FH patients of South-Asian 
background 
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4.1. Introduction 
The World Health Organization (WHO) has recently reported that the leading 
cause of death in India is cardiovascular disease (CVD) ((WHO) 2011), and 
the number of deaths from CVD is steeply increasing with 17.8% rise between 
1990-2004 (Yusuf et al. 2001, Setia et al. 2012). FH is a monogenic risk factor 
for premature CVD, which can be identified by DNA testing. The urgent need 
for identification of FH mutations in the Indian population has been recently 
highlighted and the importance of the cascade testing to identify affected 
relatives has been emphasized (Setia et al. 2012). The FH mutation 
frequency and spectrum in the Indian population is highly unexplored with 
only a handful of studies reporting mutations characteristic to patients of 
Indian origin (Kotze et al. 1997, Ashavaid et al. 2000, Taylor et al. 2010b).  
This study aimed to assess the FH mutation frequency and spectrum in 
hypercholesterolaemic patients of Indian origin. Patients’ samples were 
collected across several lipid clinics in England. A number of reports 
demonstrated that individuals of Indian origin manifest CVD at lower levels of 
risk factors, including plasma lipid levels, than other populations (Mohan et al. 
2001, Goel et al. 2003). It has been suggested that variations in cultural and 
environmental factors such as diet, physical activity, and body weight may be 
responsible for the difference (Mohan et al. 2001). For the above reason, the 
Simon Broome criteria LDL-C cutoff for FH (4.9 mmol/l) has been lowered to 
4.2 mmol/l during the patient’s recruitment for this study. Thus this study 
aimed to assess if South-Asian patients carrying an FH-causing mutation 
present with lower plasma LDL-C levels than individuals of European descent.  
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The second part of this study reports a case of homozygous FH in a large 
consanguineous family from Mumbai, India. The aim of this investigation was 
to test the severely affected proband who was diagnosed with multiple 
xanthomas and seven of his relatives for mutations in FH genes. Genetic 
characterization of the family members would provide an early diagnosis and 
help to introduce the appropriate treatment.  
4.2. Results – South-Indian patients living in England 
4.2.1. Patients characteristics 
The objective of this study was to test 100 hypercholesterolaemic patients 
from Indian Sub-continent for FH mutations. However, only 34 samples were 
collected across several lipid clinics in England and referred for the molecular 
genetic testing. 32 of the patients were adults, with mean age of 45 years. 
None of the patients presented with tendon xanthoma thus according to the 
Simon Broome clinical criteria for FH all patients were diagnosed as possible 
FH (PFH). One of the patients was seven years old at the time of the study 
and therefore was excluded from the overall lipid analysis of adult patients. 
Her pre-treatment lipid values were: TC = 7.6mmol/l, LDL-C = 5.8 mmol/l, 
HDL-C = 1.4 mmol/l and TG = 0.9 mmol/l. The patient’s elevated cholesterol 
was not treated at the time of the study because of the young age of the 
patient. In addition, a 17 years old female (patient’s ID 2011) was referred as 
a suspected homozygous FH case. She presented with pre-treatment lipid 
levels of TC = 16.9mmol/l, LDL-C = 14mmol/l, HDL-C = 2mmol/l, and pre-
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treatment TG = 1.9 mmol/l, with family history of hypercholesterolaemia in 
both parents and was also excluded from the cohort baseline characteristics 
analysis. Overall, the South-Asian patients’ cohort had significantly lower pre-
treatment TC (7.68mmol/l ±0.9) than the DFH (9.79mmol/l, p=8x10-12), PFH 
(8.71mmol/l, p=6x10-6) and UH (8.47mmol/l, p=5x10-3) patients from the 
Oxford FH study. The pre-treatment LDL-C of the South-Asian cohort 
(5.33mmol/l ±1.1) was similar to patients categorised as unclassified 
hypercholesterolaemia in the Oxford FH cohort, however significantly lower 
than the DFH (6.93mmol/l, p=8x10-6) and PFH (6.12mmol/l, p=2x10-3). 
Baseline characteristics of South-Asian patients in comparison to the Oxford 
FH cohort are shown in Table 21.
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Table 21 
Baseline characteristics of the South-Asian FH cohort in comparison to the Oxford FH. Lipid levels (in mmol/l) are shown as 
geometric means (with approximate standard deviation), because they were not normally distributed. P value between two groups 
was calculated on log transformed data using Welch Two Sample t-test. Significant p values are in bold.  
Variable 
South-Asian 
FH (n=32) 
Oxford DFH 
(n=65) 
South-Asian 
vs. Oxford 
DFH 
Oxford PFH 
(n=150) 
South-Asian 
vs. Oxford 
PFH 
Oxford UH 
(n=74) 
South-Asian 
vs. Oxford 
UH 
Gender  
 
 
    % Male (N) 44% (14) 48% (34)  
47% (70) 
 
58% (43) 
 Mean age (SD) 45 (14) 58 (13)  
54 (14) 
 
54 (15) 
 
 
      
 Pre-treatment TC 7.68 (0.9) 9.79 (1.66) 8x10
-12 8.71 (1.27) 6x10-6 8.47 (1.92) 5x10-3 
Pre-treatment HDL-C 1.37 (0.4) 1.38 (0.35) 0.91 1.46 (0.40) 0.32 1.39 (0.39) 0.92 
Pre-treatment TG 1.79 (0.7) 1.22 (0.56) 5x10
-3 1.53 (0.72) 0.23 2.00 (0.81) 0.53 
Pre-treatment LDL-C 5.33 (1.1) 6.93 (1.61) 8x10
-6 6.12 (1.15) 2x10-3 5.45 (1.72) 0.47 
 
      
 Post-treatment TC 5.47 (1.3) 5.95 (1.01) 0.15 5.46 (1.13) 0.91 5.36(1.17) 0.71 
Post-treatment HDL-C 1.48 (0.5) 1.31 (0.36) 0.11 1.44 (0.32) 0.53 1.40 (0.46) 0.76 
Post-treatment TG 1.53 (0.8) 1.12 (0.52) 0.03 1.25 (0.60) 0.12 1.21 (0.38) 0.10 
Post-treatment LDL-C 3.13 (1.2) 4.1 (1.04) 3x10
-3 3.29 (1.00) 0.62 3.65 (1.57) 0.45 
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4.2.2. Mutation spectrum 
South-Asian patients were screened for mutations in the promoter and coding 
region of LDLR, for the APOB p.R3527Q mutation and for the PCSK9 
p.D374Y mutation. The LDLRAP1 gene was not analysed since all patients 
had a dominant pattern of FH inheritance. Eight patients were found to have 
an FH mutation, all of which were located in the LDLR gene. Three of the 
patients were heterozygous for the c.2054C>T (p.P685L) allele, also called 
Gujarati FH, whereas patient 2011 was found to be homozygous for the 
variant. The mutation is positioned within the EGF precursor homology 
domain repeat C and it has been shown to affect the intracellular transport of 
the LDL receptor as well as the ligand binding (Soutar et al. 1989). Another 
mutation located in the EGF precursor homology domain, found in one of the 
patients, was a non-synonymous change at c.1285G>A, which mutates the 
Valine 429 residue to Methionine. The p.M429 allele, also known as FH 
Afrikaner-2, has been demonstrated to increase the rate of LDL receptor 
degradation (Leitersdorf et al. 1989). Two nonsense mutations were identified, 
one in exon 3 of the gene (c.285C>A  p.C95*), and one in exon 9 
(c.1257C>G  p.Y419*), which was found in the seven years old patient of 
Indian Punjabi origin. Both variants predicted to cause a formation of the 
truncated peptide have been reported before (Hirayama et al. 1998, 
Zakharova et al. 2001, Van Gaal et al. 2001). There was one splice site 
mutation found in intron 10 of LDLR. The c.1587-1G>A variant mutates the 
first nucleotide of the 3’ splice acceptor, and it has been reported in a 
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Japanese cohort (Yu et al. 2002). All identified mutations and their in silico 
predictions are summarised in Table 22.
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Table 22 
Summary of FH mutations identified in the South-Asian cohort. 
 
Mutation 
type/Exon 
Variant position PolyPhen  SIFT 
Mutation 
Taster 
Number of 
carriers 
Nonsense 
     
3 c.285C>A (p.(Cys95*)) NA NA Disease causing 1 
9 c.1257C>G (p.(Tyr419*)) NA NA Disease causing 1 
Missense 
     
9 c.1285G>A (p.(Val429Met) Probably damaging Not tolerated Disease causing 1 
14 c.2054C>T (p.(Pro685Leu) Probably damaging Not tolerated Disease causing 3 + 1 homozygote 
Splicing 
     
intron 10 c.1587-1G>A NA NA Disease causing 1 
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4.2.3. Mutation carriage and patients’ lipid levels 
An FH mutation was detected in 17.6% of 34 Indian patients. The mutation 
detection rate was similar to the Unclassified Hypercholesterolaemia cohort 
(14.3%, p= 0.8) studied in Chapter One. The mean pre-treatment TC and 
LDL-C values in the mutation positive patients were higher than in the 
mutation negative (8.46 vs. 7.51 mmol/l, and 6.26 vs. 5.11 mmol/l, 
respectively), however the difference was not statistically different. Baseline 
characteristics of both groups are summarized in Table 23. In comparison to 
the FH patients from Oxford, the pre-treatment LDL-C level in the mutation 
positive patients did not differ between the cohorts, however it was 
significantly lower in the mutation negative Indians (p=0.002) Figure 28. All 
but one mutation positive patient had the pre-treatment TC and LDL-C levels 
above the Simon Broome FH criteria cutoff (>7.5 mmol/l and >4.9 mmol/l, 
respectively). One of the patients (22 years old) who was identified to carry 
the p.P685L mutation had pre-treatment TC and LDL-C levels below the 
defined cutoff, TC = 6.7 mmol/l and LDL-C = 4.6 mmol/l. Lipid measures were 
not available for the carrier of the p.C95* (c.285C>A) mutation. 
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Table 23 
 
Baseline characteristics of South-Asian FH cohort by presence of a mutation. 
Lipid levels (in mmol/l) are shown as geometric means (with approximate 
standard deviation), because they were not normally distributed. P value 
between two groups was calculated on log-transformed data using Welch Two 
Sample t-test.   
 
 
 
 
Variable 
Mutation 
positive (n=6) 
Mutation 
negative 
(n=26) 
p value 
Gender 
  
 % Male (N) 50% (2) 48% (12) 
 Mean age (SD) 37 (14.1) 47 (13.3) 0.17 
 
  
 Pre-treatment TC 8.46 (1.6) 7.51 (0.6) 0.23 
Pre-treatment HDL-C 1.31 (0.3) 1.38 (0.4) 0.70 
Pre-treatment TG 1.50 (0.6) 1.89 (0.7) 0.30 
Pre-treatment LDL-C 6.26 (1.6) 5.11 (0.8) 0.14 
 
  
 Post-treatment TC 6.13 (1.9) 5.38 (1.2) 0.57 
Post-treatment HDL-C 1.53 (0.1) 1.47 (0.5) 0.63 
Post-treatment TG 1.44 (0.3) 1.54 (0.8) 0.71 
Post-treatment LDL-C 3.84 (1.8) 3.04 (1.1) 0.53 
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Figure 28 
Pre-treatment LDL-C levels in mutation positive and mutation negative FH patients of Indian origin in comparison to FH patients 
from Oxford. NS= not significant  
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Using the Oxford FH study quartile cutoffs for pre-treatment TC and TG, the 
mutation detection rate in Indian FH patients increased with each pre-
treatment TC quartile and decreased with increasing pre-treatment TG level, 
as shown in Table 24, which agreed with the findings reported in Chapter 
One.  
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Table 24 
FH mutation detection rate in South-Indian FH cohort by quartile of pre-treatment TC and pre-treatment TG levels (the quartiles 
used came from the Oxford FH study from Chapter Three). P values were calculated using logistic regression. 
 
 
Quartile of pre-
treatment TC (mmol/l) 
N Mutation +ve (%) 
Quartile of pre-
treatment TG (mmol/l) 
N Mutation +ve (%) 
Q1 <=8.0 14 2 (14) Q1 <=1.0 2 1 (50) 
Q2 8.1-8.7 5 1 (20) Q2 1.10-1.32 3 1 (33) 
Q3 8.8-9.9 2 1 (50) Q3 1.33-2.15 11 2 (18) 
Q4 >10 1 1 (100) Q4 2.16-4.30 6 1 (17) 
  
 p value    0.03 
 
    0.3  
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4.3. Results – Consanguineous family from Mumbai, India. 
4.3.1. Family characteristics 
In addition to the samples collected in England, DNA from a consanguineous 
Indian (from Mumbai) family of eight was collected. The family proband 
(referred here as FH13), a nine years old boy was diagnosed with severe 
cholesterol levels (TC = 22.1mmol/l and LDL-C = 19mmol/l) and multiple 
xanthomas around his elbow and at the back of his legs, as shown in Figure 
29. Both of his parents were said to be hypercholesterolaemic. An extensive 
family history of myocardial infarction, coronary bypass surgeries and sudden 
cardiac deaths was reported in relatives of both parents. Available baseline 
characteristics of the family are shown in Table 25. 
 175 
Figure 29 
Images of physical examination of FH13 patient, nine years old boy with 
severe plasma cholesterol levels (TC = 22.1mmol/l and LDL-C = 19mmol/l). 
Both A and B show a typical of severe DFH or homozygous FH physical 
manifestation of cholesterol deposition within the skin. A: multiple xanthomas 
on the patient’s elbow; B: eruptive xanthoma on the back of both legs and 
on the buttocks of the patient. 
 
A. 
B. 
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Table 25 
Baseline characteristics of the Mumbai consanguineous family. Other measurements were not available. 
 
 
 
 
 
 
 
 
N/A = not available 
 
 
Relation Gender Age (years) Sample ID 
TC 
mmol/l 
LDL-C 
mmol/l 
Proband M 9 FH13 22.1 19 
Mother F 35 FH10 7.4 5.7 
Father M 38 FH4 7.7 N/A 
Father's brother M 42 FH11 8.5 6.2 
Cousin F 12 FH12 N/A N/A 
Father's brother M 48 FH14 20 N/A 
Cousin M 23 FH15 5.4 3.63 
Cousin M 17 FH16 7.8 6.7 
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4.3.2. FH mutation spectrum  
Mutation testing of the consanguineous family members identified two 
variants in the LDLR gene. HRM detected changes of the melting temperature 
in fragments of exons 7 and 11 LDLR in several family members, as shown in 
Figure 30. Exons 7 and 11 were examined further by Sanger sequencing. A 
previously unreported variant in exon 7 (absent from the UCL FH mutation 
database and other publically available databases), c. 948C>G, was identified 
in four relatives, however it was absent from the proband and proband’s 
parents. The variant changes Asparagine to Lysine at the position 316, which 
was predicted as ‘probably damaging’ by PolyPhen, ‘not tolerated’ by SIFT 
and ‘disease causing’ by Mutation Taster. The other variant was located in 
intron 11, within the consensus splice site at the position c.1705+1G>C, which 
is predicted to alter the protein splicing as shown in Figure 31. The intronic 
mutation has been previously observed in a Japanese family, where it 
reduced the LDL-C uptake by 66%, in comparison to a control (Hattori et al. 
2002). Family members FH11 and FH14 were heterozygous for both variants, 
whereas FH12 and FH15 were found to carry only the exon 7 variant. The 
c.1705+1G>C mutation on its own was identified in FH4 (proband’s father), 
FH10 (proband’s mother), and FH16. The family proband FH13 was found to 
be homozygous for the splice site mutation and didn’t carry the p.N316K in 
exon 7.
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Figure 30 
Normalised melting curve of fluorescence (F, Y axis) and temperature (T, X axis) of A: exon 7 LDLR. Samples FH11, FH14 and 
FH15 in addition to the c. 948C>G are also heterozygous for rs12710260 SNP; B: exon 11 LDLR. Sample FH4 in addition to the 
c.1705+1G>C is also heterozygous for rs5929 SNP. Insets ‘i’ and ‘ii’ represent difference graphs for the fragments with 
deltaF/deltaT (on Y axis) and T (on X axis).
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i ii 
 179 
Figure 31 
Splice site analysis of c.1705+1G>C variant in intron 11 of LDLR. Scores for each predicted donor and acceptor splice site were 
calculated using the Human Splicing Finder. Marked in blue are the naturally occurring (wild type) splice sites for LDLR exon 11. 
Marked in red are changes in splice site score when c.1705+1G is mutated to C. When mutated, the donor splice site is no longer 
recognised, which may lead to exon skipping of the entire exon, which will cause a frame shift.
AATTCGTTGCACGCATTGGCTGGGATCCTCCCCCGCCCTCCAGCCTCACAGCTATTCTCTGTCCTCCCACCAGCTTCATGTACTGG
ACTGACTGGGGAACTCCCGCCAAGATCAAGAAAGGGGGCCTGAATGGTGTGGACATCTACTCGCTGGTGACTGAAAACATT
CAGTGGCCCAATGGCATCACCCTAGG/CTATGTTCGCAGGACAGCCGTCCCAGCCAGGGCCGGGCAC		
Exon	11	
Intron	11	
Predicted Wild Type Donor splice site 
   
  Score    Exon   Intron 
 1.00     accctaggtatgttc 
Predicted Wild Type Acceptor splice site 
 
Score               Intron                        Exon 
0.56     ggatcctcccccgccctccagcctcacagctattctctgtc 
0.73     ccccgccctccagcctcacagctattctctgtcctcccacc 
0.50     tattctctgtcctcccaccagcttcatgtactggactgact 
0.57     tcaccctaggtatgttcgcaggacagccgtcccagccaggg 
0.89     tttgttttttctttttttgagatgaggtcttggtctgtcac 
Predicted Donor splice site for c.1705+1G>C 
   
  Score    Exon   Intron 
 None 
Predicted Acceptor splice site for c.1705+1G>C 
 
Score               Intron                        Exon 
0.56     ggatcctcccccgccctccagcctcacagctattctctgtc 
0.73     ccccgccctccagcctcacagctattctctgtcctcccacc 
0.50     tattctctgtcctcccaccagcttcatgtactggactgact 
0.80     tcaccctaggtatgttcgcaggacagccgtcccagccaggg 
0.89     tttgttttttctttttttgagatgaggtcttggtctgtcac 
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4.3.3. Mutation carriage and lipid levels 
Pre-treatment TC and LDL-C measurements were available for seven 
members of the Mumbai consanguineous family, whereas post-treatment 
values were not available at all. A summary of the mutation carriage and lipid 
levels within the family is presented in Figure 32. One of the proband’s 
cousins, FH15, was found to carry the novel variant in exon 7 (c.948C>G), 
however exhibited normal plasma cholesterol levels. Two family members, 
brothers FH11 and FH14, were compound heterozygotes for both identified 
variants, but only FH14 presented with extreme pre-treatment TC levels, 
characteristic of homozygous FH. The family doctor was contacted to confirm 
the initial pre-treatment cholesterol measurements for FH15 and FH11 
patients, whose clinical information did not agree with the molecular 
diagnosis. Further clinical assessment was requested for the family members, 
however due to a difficult access to the patients to date no tests have been 
carried out. 
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Figure 32 
A family pedigree of a nine years old homozygous FH proband (in red) from Mumbai. Available values of total cholesterol (in 
mmol/L) are shown in yellow boxes.  
 
FH13 
FH11 FH10 FH4 
FH16 FH15 
FH12 
FH14 
c.1705+1G>C 
homozygote 
c.1705+1G>C c.1705+1G>C 
c.948C>G and 
c.1705+1G>C  
c.948C>G and 
c.1705+1G>C  
c.1705+1G>C c.948C>G  
c.948C>G  
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4.4. Discussion 
This study of FH mutations in patients from the Indian Sub-Continent 
identified five different FH-causing variants in the LDLR gene, in eight out of 
34 studied patients. There were no APOB and no PCSK9 FH mutations 
observed in this cohort. A heterozygous mutation was detected in 17.6% of 
unrelated patients, which was low is comparison to the 73% rate in the DFH 
and 27% in the PFH patients from Oxford (studied in Chapter One), however 
similar to the 14.3% mutation detection rate in UH group from Oxford. One of 
the reasons for the low mutation detection rate could be the sample size of 
this study. The initial target of collecting 100 unrelated samples has not been 
achieved in the time of my PhD course, which remained to be the main 
limitation of the analysis. The TC/LDL-C cutoff used for the clinical diagnosis 
of FH could also be the reason for low mutation detection rate. The Simon 
Broome FH criteria cutoffs have been lowered from 7.5 mmol/l to 6.7 mmol/l 
for TC, and from 4.9 mmol/l to 4.2 mmol/l for LDL-C, because of the evidence 
for lower levels of CVD risk factors in Indian populations (Mohan et al. 2001, 
Goel et al. 2003). However, this study demonstrated that there was no 
difference between pre-treatment LDL-C levels of the mutation positive 
patients of Indian origin and the mutation positive FH patients from the Oxford 
cohort, thus the Simon Broome clinical diagnostic criteria for FH are suitable 
for patients of Indian background. As shown in Chapter One, the mutation 
detection rate highly depends on the pre-treatment TC and TG levels. In this 
study, 13 of the recruited patients did not reach the Simon Broome 7.5 mmol/l 
diagnostic cutoff for the pre-treatment TC. Furthermore, pre-treatment TC 
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level was not available for five of the participants. The mean pre-treatment TG 
in Indians (1.53 ± 0.8 mmol/l) was higher than the levels observed in the 
Oxford cohorts (1.12 ± 0.52 in DFH, 1.25 ± 0.6 in PFH and 1.21 ± 0.38 in UH), 
although the difference was statistically significant only between the Oxford 
DFH and the Indian FH (p=0.03). This study also confirmed the finding from 
Chapter One, of the importance of high pre-treatment cholesterol and low 
triglyceride levels as predictors of the likelihood of detection of an FH-causing 
mutation, since the proportion of patients carrying an FH mutation increased 
with higher pre-treatment TC and decreased with higher pre-treatment TG.  
The most commonly observed mutation in the South-Indian cohort was the 
p.Pro685Leu (found in 43% of probands), which is known as the Gujarati FH 
mutation. However overall, the mutation spectrum in South-Indians living in 
the UK differed from the spectrum reported in Indians from South Africa 
(Rubinsztein et al. 1993). None of the detected mutations was observed in the 
studied South Africans of Indian origin. Although this study did not identify any 
novel mutations, none of them were previously associated with Indian 
populations (apart from the p.Pro685Leu). Two of the variants (c.285C>A 
(p.Cys95*) and c.1587-1G>A) were initially found in Japanese patients, 
whereas c.1257C>G (p.Tyr419*) was reported in Belgium and c.1285G>A 
(p.Val429Met) is an Afrikaner FH mutation. The difference in FH mutation 
spectrum could be the result of a lack of reports on South-Indian FH but it 
may also reflect the genetic heterogeneity of the Indian population living in the 
UK.  
One of the limitations of this study is a low patients recruitment rate. Although 
reasons for patients refusal to participate in this study were not recorded, 
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previous genetic studies demonstrated reduced participation among racial 
minorities (Sterling et al. 2006) mainly due to concerns about discrimination, 
confidentiality, or lack of confidence in researchers. A weakness of the study 
was that pre-treatment TC measurements were not available for 5 out of 34 
participants, and pre-treatment TG levels were not recorded for 10 individuals. 
This was because some patients who met the criteria in other respects (e.g. 
personal family history of premature CHD) were referred to the lipid clinic 
whilst on diet or lipid-lowering medication, and it would not have been ethical 
to stop medication to collect data for this study. Another limitation to this 
project was that patients were not screened for large rearrangements in LDLR 
because of a high cost of the test. 
 
Although the need for development of a sensitive, reliable and inexpensive kit 
for a routine search for FH-causing variants specific to the Indian population 
has been emphasized (Ashavaid et al. 2000),  many more studies on this 
ethnic group will be required since no common FH mutations have been 
identified, apart from the p.Pro685Leu. Results of this study suggest high 
genetic heterogeneity of FH mutation in patients of Indian descent, which may 
limit the development of a population-specific FH mutation detection assay.  
 
The consanguineous family from Mumbai was found to carry two predicted 
FH-causing variants, in different parts of the LDLR gene. The severely 
affected family proband was homozygous for a splice site mutation in intron 
11 of the gene, c.1705+1G>C. This variant has been previously observed in a 
Japanese family, where a heterozygous proband manifested with multiple 
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xanthomas. Proband’s parents were both heterozygous for the mutation, with 
cholesterol levels about 3 fold lower (~7.7 mmol/l) in comparison to the 
proband. Four other family members were identified to carry a novel variant, 
p.Asn316Lys, located in exon 7 of LDLR, which codes for the first part of the 
EGF precursor homology domain. SIFT, PolyPhen and the Mutation Taster in 
silico tools consistently predicted the variant to have a damaging effect on the 
protein. However the effect of p.Asn316Lys on lipid levels in the family was 
not consistent. The 23 years old proband’s cousin, a carrier of the 
p.Asn316Lys variant, had plasma lipids within the normal range (TC=5.4 
mmol/l, LDL-C=3.63 mmol/l), whereas the cousin’s father who was found to 
be a compound heterozygote for the p.Asn316Lys and c.1705+1G>C, 
manifested heterozygous FH lipid levels (TC=7.7 mmol/l), which was about 3 
fold lower than his brother (TC=20 mmol/l) – also compound heterozygote. 
Therefore the data suggests that the variant p.Asn316Lys is benign, however 
the extreme TC level in FH14 remains unexplained thus further investigation 
is required. Patient FH14 is likely to carry another LDL-rising variant outside of 
the screened region. Sanger sequencing of the entire PCSK9 coding region in 
FH11 and FH14 patients did not identify any LDL-lowering or LDL-raising 
alleles. If resources were available, whole exome sequencing of both samples 
would be recommended as an informative experiment to identify additional 
causes. 
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V. CHAPTER FIVE - LDL-C SNPs score analysis for 
polygenic hypercholesterolaemia 
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5.1. Introduction 
The FH mutation detection rate in DFH patients varies between 60-90% 
(Graham et al. 2005, Taylor et al. 2010b, Futema et al. 2013), suggesting that 
there are other genetic causes, located outside of the currently screened 
regions, which are yet to be identified. Recent report provided new evidence 
that a substantial proportion of individuals with a clinical diagnosis of FH 
inherit a combination of small-effect changes in several genes (polygenic) 
rather than a large-effect mutation in a single gene (monogenic) (Talmud et al. 
2013). The proposed molecular test for polygenic hypercholesterolaemia uses 
findings of the Global Lipid Genetic Consortium (GLGC) meta-analysis of 
genome-wide association studies, which identified several loci where common 
variants affect LDL-C concentration (Teslovich et al. 2010), and results of 
another study that showed that a proportion of individuals carrying several 
LDL-C-raising single nucleotide polymorphisms (SNPs) have LDL-C 
concentrations that exceed the Simon Broome FH diagnostic LDL-C threshold 
of 4.9 mmol/l (Talmud et al. 2009).  
In this chapter, LDL-C SNPs scores, derived from 12 common LDL-C-raising 
SNPs in 11 genes (two in APOE), were calculated for patients with European 
ancestry who had the clinical diagnosis of definite familial 
hypercholesterolaemia and were included in the whole exome sequencing 
project, as discussed in Chapter Seven, and compared with those of healthy 
men and women of European ancestry from the UK Whitehall II (WHII) cohort 
study. The aim was to test the hypothesis that familial hypercholesterolaemia 
can be caused by an accumulation of common small-effect LDL-C-raising 
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alleles. Identifying patients with low LDL-C SNPs score would help to increase 
the chance of finding novel monogenic causes of FH when analysing the 
whole exome sequencing data (Chapter Seven). In addition, this study 
intended to validate the findings using three independent cohorts from 
Canada, Greece and Holland, which in total included 109 mutation positive 
and 122 mutation negative FH patients. 
 
5.2. Results 
5.2.1. Healthy comparison cohort 
A healthy comparison group of white men and women was drawn from the UK 
Whitehall II study (WHII), discussed in section 2.3.2. Genotypes of 3020 
individuals were used for the final LDL-C gene score comparison. Baseline 
characteristics of the WHII study are shown in Table 26. 
Frequencies of the 12 SNPs used for the score calculations in the FH cohort 
and the WHII study are shown in Table 27.  
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Table 26 
Baseline characteristics of the LDL-C score control cohort, the WHII study. 
Pre-treatment TG levels were not available.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  WHII (n=3020) 
% male 76% (2308/3020) 
Age (years) 49.0 ± 6.0 
Pre-treatment TC (mmol/l) 6.4 ± 1.1 
Pre-treatment LDL-C (mmol/l) 4.4 ± 1.0 
Post-treatment LDL-C (mmol/l) 4.4 ± 1.0 
Post-treatment HDL-C (mmol/l) 1.4 ± 0.4 
Post-treatment TG (mmol/l) 1.4 ± 1.1 
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Table 27 
LDL-C gene score calculations with observed minor allele frequencies in the studied cohort and the WHII control. Weights for risk 
alleles were acquired from (Teslovich et al. 2010), and from (Bennet et al. 2007) for APOE genotypes. 
 
Chromosome Gene 
Minor 
allele 
Common 
allele 
Weight for score 
calculation 
Minor allele frequency 
 
FH 
(n=109) 
WHII controls 
(n=3020) 
rs2479409 1 PCSK9 G* A 0.052 0.38 0.35 
rs629301 1 CELSR2 G T* 0.15 0.14 0.21 
rs1367117 2 APOB A* G 0.1 0.38 0.33 
rs4299376 2 ABCG8 G* T 0.071 0.42 0.32 
rs1564348 6 SLC22A1 C T* 0.014 0.25 0.17 
rs1800562 6 HFE A G* 0.057 0.06 0.07 
rs3757354 6 MYLIP T C* 0.037 0.18 0.21 
rs11220462 11 ST3GAL4 A* G 0.05 0.16 0.13 
rs8017377 14 NYNRIN A* G 0.029 0.52 0.48 
rs6511720 19 LDLR T G* 0.18 0.04 0.13 
rs429358 19 APOE C T .. 0.2 0.15 
rs7412 19 APOE T C .. 0.01 0.08 
ε2ε2 19 APOE .. .. -0.9 .. .. 
ε2ε3 19 APOE .. .. -0.4 .. .. 
ε2ε4 19 APOE .. .. 0.2 .. .. 
ε3ε3 19 APOE .. .. 0 .. .. 
ε3ε4 19 APOE .. .. 0.1 .. .. 
ε4ε4 19 APOE .. .. 0.2 .. .. 
*Risk allele (LDL-rising)  
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The mean weighted LDL-C gene score of the WHII participants was 0.90 (SD 
0.23), and WHII individuals in the bottom decile (decile 1) of the LDL-C gene 
score distribution had a mean LDL-C concentration of 3.76 mmol/l (0.95), 
whereas those in the top decile (decile 10) had a mean LDL-C concentration 
of 4.9 mmol/l (0.99), the diagnostic cutoff point for familial 
hypercholesterolaemia. Participants from WHII in decile 10 of the LDL-C 
score distribution had a much higher likelihood than those in decile 1 of 
having observed LDL-C concentrations above the UK NICE recommended 
diagnostic threshold of 4.9 mmol/l, with 146 (50%) of 292 individuals in decile 
10 having observed LDL-C concentrations of greater than the Simon Broome 
FH criteria cutoff, compared with 35 (12%) of 295 individuals in decile 1, as 
demonstrated in Table 28.  Thus the top decile cutoff of LDL-C weighted 
score for the WHII population (1.16) was used as a lowest threshold for 
polygenic hypercholesterolaemia.  
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Table 28 
LDL-C gene scores in WHII cohort by deciles and its correlation with LDL-C level.  
 
LDL-C weighted score in 
WHII controls 
Measured LDL-C 
(mmol/L) in WHII 
controls, mean (SD) 
WHII controls with 
LDL-C >4.9 mmol/L 
 
Mean (SD) Range Measured 
Decile 1 0.43 (0.14) -0.5 to 0.58 3.76 (0.95) 36/299 (12%) 
Decile 2 0.66 (0.04) 0.58 to 0.73 3.99 (0.88) 43/296 (15%) 
Decile 3 0.77 (0.03) 0.73 to 0.81 4.21 (0.96) 71/300 (24%) 
Decile 4 0.85 (0.02) 0.81 to 0.88 4.34 (0.95) 85/298 (29%) 
Decile 5 0.91 (0.02) 0.88 to 0.93 4.36 (0.94) 80/300 (27%) 
Decile 6 0.96 (0.01) 0.94 to 0.98 4.48 (0.91) 96/298 (32%) 
Decile 7 1.00 (0.01) 0.98 to 1.02 4.50 (1.00) 102/295 (35%) 
Decile 8 1.05 (0.02) 1.02 to 1.08 4.56 (0.93) 96/292 (33%) 
Decile 9 1.12 (0.02) 1.08 to 1.16 4.68 (1.05) 120/294 (41%) 
Decile 10 1.23 (0.06) 1.16 to 1.46 4.90 (0.99) 148/295 (50%) 
*decile 1 used as reference 
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5.2.2. Familial Hypercholesterolaemia cohort 
LDL-C SNPs score calculations were performed for the whole exome 
sequencing cohort (studied further in Chapter Seven), which contained 14 
DFH mutation negative samples from the Oxford FH study (Chapter Three). 
Complete genotypes of all 12 LDL-C-rising SNPs were obtained for 109 
samples. There were 15 samples for which the score could not be attained 
because of insufficient DNA. Out of the 109 genotyped FH samples 21 were 
found to carry an FH mutation, missed by the initial mutation screening 
methods, which was revealed by the whole exome sequencing analysis. 
Mutation positive samples were treated separately from the 88 mutation 
negative FH patients.  Overall, 29 of the genotyped mutation negative 
individuals had a gene score above the 1.16 cutoff. The distribution of the 
scores in the mutation negative FH patients and the WHII study is shown in 
Figure 33. In the mutation positive patients’ group two samples had high gene 
score, of whom one had an LDLR mutation in exon 11 (c.1690A>C 
(p.N564H)) found on the same allele as a 9bp deletion in exon 17 
(c.2393_2401del9 (p.L799_V801del)), which together have been 
demonstrated as not fully-penetrant (Mozas et al. 2000), the other was 
positive for a deletion of a consensus splice site at the 5’ of exon 5,  c.695-
6_698del, which has not been examined in vivo to confirm its likely effect on 
splicing. 
The mean LDL-C gene score for the FH mutation negative group was 1.08, 
which was significantly higher than 0.9 for the WHII study (p < 2.2x10-16), and 
0.96 for the FH mutation positive group (p = 0.006), as shown in Figure 2. The 
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overall difference between the groups was significant (ANOVA, p = 1.33x10-
12).  
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Figure 33 
Distribution of the LDL-C SNPs score in mutation negative DFH patients (in purple) and in the healthy WHII cohort (in grey). Red 
line indicates the LDL-C score top decile cutoff for WHII. 
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Figure 34 
Comparison of the LDL-C SNPs score between the control WHII population 
(n=3020), the FH mutation positive individuals (n=21), and the FH mutation 
negative individuals (n=83) in a standard boxplot (the minimum, lower 
quartile, median, upper quartile and maximum). The overall difference 
between the groups was highly significant (ANOVA, p < 2.2 x10-16). Dashed 
red line indicates the top decile cutoff for the WHII cohort (=1.16). 
 
 
NS = not significant 
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5.2.3. FH replication cohort 
For validation of the LDL-C SNPs score association three independent 
cohorts of FH patients were studied. The replication cohort included 78 adult 
FH individuals from Canada, composed of 39 patients with an identified FH 
mutation and 39 mutation negative patients. Two groups of FH children were 
also studied, which included 130 patients from Greece and 23 patients from 
Holland. Baseline characteristics of the validation cohorts are shown in Table 
29. There was no tendon xanthomas observed in children cohorts. Only one 
person of the mutation negative adults was diagnosed with definite FH, using 
the Simon Broome criteria.  
The highest mean LDL-C SNPs score was observed in the mutation negative 
FH children from the Dutch cohort (1.04), followed by the mutation negative 
FH children cohort from Greece (1.00).  The LDL-C gene score difference 
between the mutation negative FH patients from Canada and the healthy 
WHII population was not statistically different although the mutation negative 
FH individuals had the highest mean score in this cohort. The summary of the 
findings in the individual validation cohorts is shown in Table 30. 
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Table 29 
Baseline characteristics of the LDL-C score replication cohorts. A. FH Canada 
adults cohort; B. FH Greece children cohort; C. FH Holland children cohort.  
 
 
 A. Canada FH M+ Canada FH M- 
Number   39 39 
Percent male 43.2 43.2 
Age (years) 47.5±11.7 48.3±11.9 
Percent with tendon xanthoma 20.5 2.6 (1 person) 
Total cholesterol (mmol/L) 9.35±2.43 7.40±2.13 
LDL-C (mmol/L)  7.36±2.17 5.24±2.03 
HDL-C (mmol/L) 1.25±0.35 1.24±0.34 
Triglyceride (mmol/L)  1.73±1.02 2.05±0.99 
   
 
M+ = mutation positive 
M- = Mutation negative 
NA = not applicable 
 
 
 
 
 
 B. Greece FH M+ Greece FH M- 
Number   70 60 
Percent male 61.4 55 
Age (years) 6.9±0.45 8.7±0.38 
Percent with tendon xanthoma 0 0 
Total cholesterol (mmol/L) 7.9±0.16 6.4±0.09 
LDL-C (mmol/L)  5.8±0.17 4.2±0.09 
HDL-C (mmol/L) 1.5±0.04 1.7±0.04 
Triglyceride (mmol/L)  ± ± 
   C. Holland FH M+ Holland FH M- 
Number   0 23 
Percent male NA 43.5 
Age (years) NA 11.7±3.6 
Percent with tendon xanthoma NA 0 
Total cholesterol (mmol/L) NA 6.15±0.72 
LDL-C (mmol/L)  NA 4.32±0.68 
HDL-C (mmol/L) NA 1.36±0.35 
Triglyceride (mmol/L)  NA 0.85±0.50 
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Table 30 
Summary of LDL-C gene score results in the replication FH cohorts.  
 
 
 
 
 
 
NA = not applicable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Replication FH cohort 
    Greece Holland Canada 
FH/M- 
N 60 23 39 
Mean score 1.00 1.04 0.96 
FH/M+ 
N 70 0 39 
Mean score 0.93 NA 0.92 
WHII 
N 3020 3020 3020 
Mean score 0.90 0.90 0.90 
t-test 
FH/M- vs. FH/M+ 0.02 NA 0.50 
FH/M- vs. WHII 3.318x10-6 0.0002 0.14 
FH/M+ vs. WHII 0.20 NA 0.60 
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There were 122 mutation negative and 109 mutation positive FH patients in 
the validation studies, when combined. Mutation negative FH individuals had 
significantly higher LDL-C gene score than the healthy WHII population (0.99 
vs.0.89, p < 4.8 x10-7). The mutation negative patients group had also higher 
gene score than mutation positive FH patients (0.99 vs. 0.93, p < 0.009). 
Although the FH mutation positive patients had higher mean LDL-C gene 
score than the WHII population the difference was not statistically different. 
The LDL-C SNPs score distribution in the replication study is shown in Figure 
35.  In the mutation negative patients group there were three individuals with 
relatively low LDL-C gene score, which suggests that they do carry an FH 
variant with strong effect, which has not been yet identified. The boxplot 
shown in Figure 36 summarises the difference between groups in the 
replication cohort.  
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Figure 35 
Distribution of the LDL-C SNPs score in A. mutation negative FH patients 
from the replication cohorts combined (in red); B. mutation positive FH 
patients from the replication cohorts combined (in purple) and in the healthy 
WHII cohort (in green). Dashed red line indicates the LDL-C score top decile 
cutoff (1.16) for WHII. 
 
 
 
 
 
A. 
B. 
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Figure 36 
Comparison of the LDL-C SNPs score between the control WHII population 
(n=3020), the FH mutation positive individuals from replication cohorts 
combined (n=109), and the FH mutation negative individuals from the 
replication cohorts combined (n=122) in a standard boxplot (the minimum, 
lower quartile, median, upper quartile and maximum). Dashed red line 
indicates the top decile cutoff for the WHII cohort (=1.16).  
 
 
 
 
NS = not significant 
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5.3. Discussion 
The major finding of this chapter supports results reported in the original study 
(Talmud et al. 2013) demonstrating that the phenotype of familial 
hypercholesterolaemia can be caused by a collection of common genetic 
variants of mild LDL-C-raising effect. Using the top decile of LDL-C gene 
score for the healthy cohort as a cutoff, the cumulative effect of risk alleles 
was shown to be the likely cause of hypercholesterolaemia in a significant 
proportion (25%) of the examined patients. A high gene score was also 
observed in two patients with considerably mild LDLR mutations, which 
demonstrates that common polymorphisms can contribute to the presentation 
of an individual carrying a mild FH mutation with LDL-C levels above the 
diagnostic threshold. However, it is possible that the LDL-C gene score cutoff 
of 1.16 for polygenic hypercholesterolaemia is too stringent. Thus using the 
9th decile cutoff of 1.08, in which a 41% of WHII individuals had LDL-C above 
the 4.9 mmol/l (mean LDL-C = 4.68 ±1.05mmol/l) FH diagnostic level, could 
be more appropriate. By doing so, the phenotype would be explained in an 
additional nine mutation-negative patients. 
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VI. CHAPTER SIX - Use of targeted exome 
sequencing as a diagnostic tool for Familial 
Hypercholesterolaemia. 
 
 
 
 205 
6.1. Introduction 
The clinical phenotype of FH is known to be due to mutations in three genes 
encoding proteins involved in the clearance of LDL-C from the plasma, LDLR, 
APOB and PCSK9. There are over 1,200 different LDLR mutations (Usifo et 
al. 2012) but only one common APOB (c.10580G>A, p.R3527Q) and one 
PCSK9 (c.1120G>T, p.D374Y) mutation, reported in the UK population 
(Humphries et al. 2006a). While LDLR/APOB/PCSK9 mutations cause a 
dominant pattern of inheritance, an autosomal recessive 
hypercholesterolaemia (ARH) has also been observed. The locus for ARH 
was mapped to a chromosome one gene, the LDLRAP1, in which both 
homozygous and compound heterozygous mutations can be found (Garcia et 
al. 2001). 
In most laboratories FH mutation screening includes use of commercially 
available kits, designed to test for the most common mutations, such as 
ElucigeneTM FH20 (Gen-Probe Life Sciences, UK) and LIPOchip® (Progenica 
Biopharma, Spain), and SALSA MLPA probemix (MRC-Holland) for large 
gene rearrangements (deletions or duplications), which account for 4-5% of all 
FH mutations (Taylor et al. 2010a). However, in the UK, due to the highly 
heterogeneous nature of the population this approach is not fully effective, 
and many patient samples require screening the LDLR promoter and coding 
regions, splice sites, and splice branch points for causative mutations, and in 
the diagnostic laboratory this is currently performed using Sanger sequencing.  
Because of the time and labour of these methods, there has been interest in 
next generation sequencing (NGS) technology for the diagnosis of genetic 
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disorders. However, whether NGS is ready for clinical use has been 
questioned (Desai and Jere 2012). Main limitations of the technology include 
the requirement for complex data analysis, significant computing infrastructure 
with respect to data analysis and storage and legal and ethical issues 
associated with incidental findings from acquiring whole exome data. In the 
research laboratory a four-phased approach is used to screen FH patients to 
identify the causative mutation, using the commercially available ARMS 
(Amplification Refractory Mutation System) kit, which tests for 20 the most 
common UK mutations, followed by High Resolution Melting (HRM) to detect 
changes within the coding region and splice sites of FH genes, followed by 
Multiplex Ligation-dependent Probe Amplification (MLPA), for the detection of 
large LDLR gene rearrangements, and finally Sanger sequencing (Graham et 
al. 2005, Whittall et al. 2010a, Humphries et al. 2006c). Using standard 
molecular diagnostic techniques, an FH-causing mutation can be detected in 
20-30% of PFH patients and in 60-80% of DFH patients (Taylor et al. 2010b). 
This chapter presents results of is a pilot study, based on the analysis of the 
first UK10K project data release, which included whole exome sequencing 
results for 48 unrelated FH patients. The aim of this project was to identify and 
demonstrate advantages and limitations of the whole exome sequencing 
approach as a tool for molecular diagnosis of FH. In addition, the sensitivity 
problems of the current FH mutation screening methods were discussed. 
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6.2. Results 
6.2.1. Patients characteristics 
48 unrelated familial hypercholesterolaemia patients were selected from the 
Simon Broome FH register (Neil et al. 2004). Patients were diagnosed using 
the UK Simon Broome criteria as DFH on the basis of the presence or history 
of tendon xanthomas. The entire promoter and coding region, including splice 
sites, of the LDLR gene were screened by the High Resolution Melting 
method, as previously described (Whittall et al. 2010a), on the Rotor-Gene 
(6000) realtime rotary analyser. Patients were screened for presence of the 
APOB mutation, p.(R3527Q), using a restriction enzyme digest (Mamotte and 
van Bockxmeer 1993), and the entire coding region of the PCSK9 were 
examined by HRM (Humphries et al. 2006c). Fragments with a shifted melting 
curve were analysed further by direct sequencing. Screening for large 
rearrangements within the LDLR gene was done using the MLPA (Taylor et 
al. 2009) SALSA P062 LDLR kit from MRC-Holland (Amsterdam). 195 non-FH 
Caucasian samples, sequenced in parallel with the FH cohort, as a part of the 
UK10K rare disease arm project 
(http://www.uk10k.org/studies/rarediseases.html), were used as controls. 
None of these subjects had disorders known to affect plasma lipid levels.   
6.2.2. Gene coverage 
Overall, the mean read depth for the whole exome sequence was 72x, with 
78.9% of the exome covered at least 20x. 55.8% of the targeted sequence 
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was covered 50x or more. A highly significant negative correlation between 
the G/C content and the exome depth was observed in the FH genes 
(p=4.9x10-14), as shown in Figure 37, which was reflected in poor coverage of 
promoter regions.
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Figure 37 
The negative correlation of the median read depth and the GC content for 
each targeted exon of the four FH genes (LDLR, APOB, PCSK9 and 
LDLRAP1).  
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6.2.3. LDLR analysis 
The average read depth of LDLR exons varied from 136x, for exon 12, to 4x, 
for exon 18, as shown in Figure 38. Using a 16x coverage threshold, which 
would give a 99% probability of observing a rare allele at least 3 times, all 
except exon 1 and 18 showed adequate coverage.  Exons 3 and 4 contain the 
largest number of reported FH-causing mutations (Usifo et al. 2012) and both 
of these exons are well covered (mean depth 92 and 57, respectively).   
As shown in Table 31, in 14 out of the 48 samples, a FH-unique variant in the 
LDLR was called, in 11 of these the variant has been previously reported to 
be FH causing (Usifo 2012).  
 211 
Figure 38 
The exonic coverage of FH genes: APOB, LDLR, LDLRAP1 and PCSK9 in a standard boxplot (the minimum, lower quartile, 
median, upper quartile and maximum for each gene exon). The horizontal dashed line indicates the 16x coverage, when the 
probability of observing a rare allele at least 3 times is 99%. The additional Y-axis describes GC content (0.4= 40%, 0.5= 50%, etc.) 
for a given exon, shown as     . 
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Table 31 
Summary of pathogenic single nucleotide changes and small 
deletions/insertions in the FH genes. ‘Depth’ refers to the coverage depth; 
‘Quality’ values are Phred-like quality scores generated by SAMtools. 
 
 
 
 
 
 
 
Gene 
No. 
samples 
Nucleotide 
change 
Functional 
effect 
Depth Quality Comments 
LDLR 
      
 
1 c.326G>A p.(C109Y) 43 506 known FH mutation 
 
1 c.1690A>C p.(N564H) 36 343 known FH mutation 
 
1 c.1823C>T p.(P608L) 82 1214 known FH mutation 
 
1 c.2054C>T p.(P685L) 20 135 known FH mutation 
 
1 c.2479G>A p.(V827I) 65 749 known FH mutation 
 
2 c.682G>T p.(E228X) 13 155 known FH mutation 
 
1 c.1048C>T p.(R350X) 60 816 known FH mutation 
 
1 c.1150C>T p.(Q384X) 20 275 known FH mutation 
 
1 c.1685G>A p.(W562X) 41 701 known FH mutation 
 
1 c.2140+1G>A Splicing 22 258 known FH mutation 
 
1 c.695-6_698del Splicing 36 1543 novel 
 2 c.1776_1778del p.(G592del) 148 2634 novel 
APOB 
      
 
1 c.10277G>A p.(A3426V) 192 2785 novel 
 2 c.10580C>T p.(R3527Q) 161 2144 known FH mutation 
PCSK9 
      
 
1 c.1027G>C p.(D343H) 51 44 false positive 
 1 c.1028A>C p.(D343A) 50 201 false positive 
LDLRAP1       
  1 c.432_433insA p.(A145KfsX26) 90 2186 heterozygous 
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All of the LDLR variants were confirmed to be correct by Sanger sequencing 
of duplicate DNA samples (not shown). The variants included five different 
missense mutations and five nonsense mutations. The two novel LDLR 
variants included: c.695-6_698del and c.1776_1778del (p.(G592del)). The 
c.695-6_698del is predicted to cause a frameshift and a premature stop 
codon by altering LDLR splicing, as demonstrated in Figure 39. The deletion 
of Glycine at residue 592 is predicted to disrupt packaging of the LDL-R 
propeller blades in the EGF domain, which could affect displacement of the 
ligand from the ligand-binding region, shown in Figure 40. Of these 14 
mutations, all should have been detected by the initial screening protocol, 
except for c.695-6_698del, where the change was located in the primer 
sequence used for PCR.
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Figure 39 
In silico, splice site predictions using BDGP prediction tools 
(http://www.fruitfly.org/seq_tools/splice.html) (Reese et al. 1997). A: Wild type 
LDLR scores for the acceptor/donor splice sites. B: LDLR mutation (c.695-
6_698del) removes the exon 5 acceptor site and potentially activates an 
upstream cryptic site (c.695-457/8). 
A. 
B. 
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Figure 40 
Conservation score calculated over the entire available crystal structure of the 
LDL-R protein. Red shows high conservation, purple- moderate conservation, 
blue- poor conservation and black- no conservation. A. LDL-R protein 
displaying the calcium molecules (black spheres) and labeled regions 
including Glycine 592. B. Glycine 592 is on the surface of the protein and is 
highly conserved (see inset ‘i’). 
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Copy Number Variations (CNVs) calling was performed using the 
ExomeDepth package, which identified one deletion of exons 11 to 12 (c. 
1587-?_1845+?del), and two duplications, of exons 3 to 8 (191-
?_1186+?dup), and exons 13 to 15 (c.1846-?_2311+?dup), as shown in 
Figure 41. These variants affect a substantial part of the gene and are 
predicted to cause a frameshift. All CNVs were confirmed by MLPA 
experiment, of which results are presented in Figure 42. 
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Figure 41 
Copy Number Variants (CNVs) in the LDLR gene. A: Heterozygous 
duplication of exons 3 to 8. B: Heterozygous deletion of exons 11 and 12. C: 
Heterozygous duplication of exons 13 to 15. All identified by ExomeDepth in 
the exome sequencing data. The crosses show the ratio of 
observed/expected number of reads for the test sample. The grey shaded 
region shows the estimated 99% confidence interval for this observed ratio in 
the absence of CNV call. The presence of contiguous exons with read count 
ratio located outside of the confidence interval is indicative of a heterozygous 
deletion or duplication in a sample. Exons 1 and 18 were excluded from the 
analysis (not shown on the graph) as they did not reach the threshold of 100 
for the total number of reads. 
 
 
 
 
A. 
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B. 
C. 
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Figure 42 
MLPA results quantified by the fluorescence peak heights for the tested 
sample (blue) and normalised control (red). Red arrows mark peaks, in which 
the sample/control difference was significant. A: Heterozygous duplication of 
exons 3 to 8 in sample HYP5002209. B: Heterozygous deletion of exons 11 
and 12 in sample HYP5062217. C: Heterozygous duplication of exons 13 to 
15 in sample HYP5062219. 
 
 
 
 
 
 
 
A. 
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B. 
C. 
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6.2.4. APOB analysis 
The mean read depth of APOB exons was 93. Exons 26 and 29 were covered 
on average 135x, whereas exon 1 was covered only once (Figure 38). Two 
individuals were found to carry the FH-causing APOB mutation in exon 26, the 
p.(R3527Q), which were confirmed by Sanger sequencing. There were no 
nonsense or frameshift mutations observed in the gene sequence. One novel 
non-synonymous variant was found in exon 26 of APOB, the p.(A3426V), 
which was unique to the FH cohort. The variant was predicted as ‘Tolerated’, 
‘Benign’ and ‘Polymorphism’ by SIFT, PolyPhen and Mutation Taster, 
respectively. Four other FH-unique non-synonymous variants were observed 
outside of the ligand-binding domain, as shown in . The functional impact of 
these variants as predicted by PolyPhen/SIFT/Mutation Taster was not 
consistent and whether or not these are FH causing is unclear. There were no 
CNVs found within the APOB gene. 
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Table 32 
Summary of novel APOB variants, located outside of exons 26 and 29. 
‘Depth’ refers to the depth coverage; ‘Quality’ values are Phred-like quality 
scores generated by SAMtools. D- damaging; B-benign; T-tolerated; N- 
polymorphism. 
 
Nucleotide 
change 
Functional 
effect 
Depth Quality PolyPhen SIFT 
Mutation 
Taster 
c.148C>T p.(R50W) 139 181 D D N 
c.1199G>A p(.R400H) 35 100 B D N 
c.2938G>A p.(A980T) 29 198 B T N 
c.3931A>C p.(K1311Q) 68 170 B D N 
 
 
 
6.2.5. PCSK9 analysis 
The mean read depth of the PCSK9 exons was 23. Of these, only 58% of the 
gene coding sequence had the mean coverage higher than 16, whereas 
exons 1, 6, 10, 11, and 12 were covered 4x on average (Figure 38).  Exon 7, 
where the common UK FH-causing mutation (c.1120G>T, p.(D374Y)) occurs, 
was covered 36x. Two novel non-synonymous variants were called by the 
exome sequencing, c.1027G>C and c.1028A>C, both present in the same 
sample. However, despite the high read depth (51x and 50x), and the high 
number of read count for the novel alleles (19 and 26), presented in Figure 
43, the Sanger sequencing did not confirm the variants. There were no CNVs 
observed in PCSK9
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Figure 43 
Intergrative Genomic Viewer image of the coverage of PCSK9 exon 7 region containing two false positive variants c.1027G>C and 
c.1028A>C. These artifacts were probably created during the amplification step in the sequence capture process. 
PCSK9	c.1027	
C:19	(37%)	
G:31	(61%)	
A:1	(2%)	
PCSK9	c.1028	
A:24	(48%)	
C:26	(52%)	
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6.2.6. LDLRAP1 analysis 
The average read depth of LDLRAP1 was 36, with all except exons 1 and 9, 
covered above the 16x threshold (Figure 38). The LDLRAP1 variant analysis 
was performed using a homozygosity-based strategy, and the presence of 
compound heterozygote variants was also assessed. There were no 
homozygous or compound heterozygous functional changes within the gene 
in any of the individuals. One patient was found to be heterozygous for a 
known Sicilian/Sardinian ARH mutation, the c.432_433insA, p.(A145KfsX26), 
which is a frame shift mutation resulting in a truncated peptide formation 
(Garcia et al. 2001, Barbagallo et al. 2003). Further analysis of this sample 
showed no other pathogenic variants in known FH genes, which could 
contribute to the phenotype. CNV calling did not detect large rearrangements 
in the LDLRAP1. 
6.3. Discussion 
The exome sequencing results exposed sensitivity problems with the current 
FH mutation screening methods used in our research laboratory.  Overall, the 
standard variant detection process already in place (HRM, MLPA and Sanger 
sequencing) did not detect 17 LDLR mutations (including 3 CNVs) and 2 
APOB mutations. Although the HRM has proved to be efficient at detecting 
FH variants (Whittall et al. 2010a), its sensitivity decreases in some gene 
regions, depending on the nucleotide composition of the fragment. Re-
examining previous results for the samples with a LDLR or APOB variant 
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called by the NGS, we observed that most of the variants showed a melting 
curve shift during the HRM assay, but Sanger sequencing of the identified 
gene region did not detect any heterozygous changes in the sequence 
despite being repeated several times (i.e. only the predicted wild-type 
sequence was obtained).  After the exome sequencing, the Sanger 
sequencing was repeated on a duplicate DNA sample and the predicted 
mutations were confirmed to be present, validating the exome sequencing 
and variant calling. Although Sanger sequencing is considered to be the gold 
standard mutation-detection method, a combination of PCR artefacts and the 
human error aspect in the protocol appears to be the main reason for the false 
negative calling in the original screening.  
 
Two novel variants in LDLR were identified, a deletion of 10 bp on boundary 
of intron 4 and exon 5, which is predicted to cause a frameshift resulting in a 
premature stop codon by altering LDLR splicing, and a three bp deletion 
which deletes Glycine at residue 592, which is predicted to disrupt packaging 
of the LDL-R propeller blades in the EGF domain. Both of these variants are 
not found in dbSNP, the 1000 Genomes or the NHLBI Exome Sequencing 
Project, and are highly likely to be FH-causing, although further work is 
required to confirm this. 
 
APOB codes for one of the largest human proteins, which is the major 
component of the LDL-C responsible for binding to the LDL-receptor 
(Innerarity et al. 1987). The actual binding site for the receptor, the B-site 
(residues 3386–3396), has been mapped to a region encoded by exon 26 of 
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the APOB, which is the longest coding exon known (7572 bps) (Boren et al. 
1998). In addition, the C-terminus encoded by exon 29 of the gene was 
proposed to function as a modulator of the receptor binding (Boren et al. 
1998). Therefore our variant analysis strategy prioritised novel variants 
located in exons 26 and 29 of the gene, as these are more likely to cause the 
FH phenotype. In this study, there was only one novel variant identified in the 
exon 26 of APOB, the c.10277G>A (p.(A3426V)), which was not observed 
previously by the dbSNP, the 1000 Genomes or the NHLBI Exome 
Sequencing Project. The variant was not present in the 195 non-FH exomes 
from the UK10K project, which were processed using the same pipeline, 
increasing the likelihood that it is in fact disease causing. The novel 
p.(A3426V) variant is located near to the LDL-receptor-binding site (B-site), 
and close to the known FH mutation p.(R3527Q), and although it does not 
alter the charge at the site, it may produce a conformational change affecting 
the LDL-R/ApoB interaction. This requires further experiments since the 
current in silico prediction tools are not able to assess protein-protein 
interactions. We will also examine whether or not the variant co-segregates 
with the disease. Four other novel APOB variants were identified in this group 
of patients in the N-terminal part of the protein. Although these variants are 
less likely to influence LDL clearance from the blood, since the N-terminal 
region of the protein is not involved in interacting with the LDL-R, some of the 
variants are predicted as damaging by Polyphen or SIFT. Future work 
includes the assessment of novel identified variants, which will involve family 
co-segregation and functional assays. 
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There were no FH-causing mutations identified in the control cohort at this 
stage of the study. Further data releases, analysed in Chapter Seven, which 
included whole exome sequencing data for almost 2,000 controls revealed 
several FH-causing variants, which included two APOB p.R3527Q mutations 
and six previously published  LDLR variants, which would be considered as 
pathogenic. This finding demonstrates that WES has a potential for the 
identification and reporting of incidental findings, as recently recommended by 
the American College of Medical Genetics and Genomics (Green et al. 2013).  
Most of the sequencing data generated for Mendelian disorders are focused 
on the exome, which constitutes around 1% of the whole human genome. 
Prediction tools for the analysis of non-synonymous changes are well 
established and widely used to estimate the deleteriousness of amino acid 
changes. However, since the majority of human variations are located in the 
non-coding regions ('A map of human genome variation from population-scale 
sequencing'  2010), concern about the bias towards variants in the protein-
coding sequence was highlighted (Cooper and Shendure 2011). Proving the 
pathogenic effect of promoter variants requires use of functional assays. To 
date, there are 13 LDLR promoter variants predicted to be causal (in revision 
(Khamis A 2012)). Disappointingly, but not surprisingly given they were not 
targeted, the exome sequencing data generated by the SureSelect Human All 
Exon (Agilent) assay, had negligible coverage of the gene promoter regions, 
which can lead to false negative conclusions. Further updates of the human 
exome capture assay should include coverage of the LDLR promoter 
sequences, which can cause autosomal dominant disease by altering gene 
regulation. 
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The SureSelect Human All Exons capture assay is a standard product, which 
proved to be efficient at detecting mutations within the LDLR and the APOB 
genes. In this sample, 78.9% of exome bases were covered at least 20 times, 
which is in line with the product description ~80%. For both, LDLR and APOB, 
the majority of the coding sequence was covered more than the 16x threshold 
to achieve an estimated 99% chance of seeing a real variant (present in a 
heterozygous state) of at least 3 times, and overall 19 mutations, were found 
by high throughput DNA sequencing, which had been missed by conventional 
methods in our research laboratory. This indicates increased sensitivity for 
NGS, which can be due both to the method used and to the reduced human 
intervention and the highly automated protocol. However, as with many PCR-
based methods, exome sequencing has some limitations when it comes to 
amplification of highly repetitive regions or sequences rich in GC content. A 
highly significant negative correlation between the G/C content and the exome 
depth was observed in the FH genes (p=4.9x10-14), as shown in Figure 37. 
Specifically, only 58% of the PCSK9 gene was covered more than 16x, 
producing unreliable results for variant calling in a significant proportion of the 
gene’s coding region. If a read depth threshold of 30x was considered to be 
required for complete certainty of variant calling, at which the sensitivity to 
detect heterozygous variants was shown to be 100% (Choi et al. 2009), exons 
that would be insufficiently covered would also include exons 1, 14 and 18 of 
LDLR, exons 2 and 5 of PCSK9, and exons 2, 3 and 7 of LDLRAP1. Thus, 
although the quality of the produced data is good, validation of called variants 
in poorly covered regions is still necessary. There were two novel non-
synonymous PCSK9 variants called by the exome sequencing, which were 
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not confirmed by the capillary sequencing. Despite their sufficient coverage 
(51x and 50x), the variants were wrongly called due to inadequate variant 
calling settings. In later data releases, the variant calling was optimized and 
both variants did not pass filtering criteria. Applying more stringent filters to 
the raw data increases the specificity of the calling. However it may also lead 
to false negative results, since not all of the exome’s regions are equally 
covered. Newer versions of the SureSelect assay show markedly improved 
coverage of exons that were previously poorly covered (unpublished data), so 
we can expect the sensitivity of exome sequencing to improve. 
The Agilent SureSelect assay was efficient in capturing the exon-intron 
junctions, covering on average 80-100bps of the intronic regions. This was an 
advantage over our current screening protocol, and enabled us to detect a 
novel variant, the c.695-6_698del, which is partially positioned on the 
annealing site for the sequencing primer routinely used in our lab.  
The methodology behind the ExomeDepth package (Plagnol et al. 2012) 
proved to be robust and enabling the use of the exome data, which are 
composed of short sequence reads for exonic regions, for the  detection of 
large gene rearrangements, which are known in the LDLR to be usually due to 
intronic Alu sequence misparing (Lehrman et al. 1987a, Lehrman et al. 
1987b). The method was shown to allow identification of heterozygous CNVs 
within the LDLR gene, which were missed by the currently used MLPA. 
However, in order to maximise the sensitivity and to minimise the noise 
created by technical variability between samples, CNV analysis by 
ExomeDepth requires quality data of well-matched exomes (>6 samples), i.e. 
sequenced under the exact same conditions. 
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The greater time efficiency of the exome sequencing is a significant 
advantage over the current screening methods. Although each called variant 
currently needs to be individually confirmed by Sanger sequencing before a 
mutation report can be prepared, analysing a number of patients in parallel, in 
a short period of time, is likely to be an efficient way forward for screening of 
heterogeneous FH patients. More importantly, limited use of manual checks 
and human intervention reduce the issues of possible human error. The cost 
efficiency of NGS is also increasing. The development of novel approaches of 
gene-targeted sequencing, using Illumina MiSeq platform, reduces not only 
the costs of sequencing itself but also the time spent on data analysis and 
computer storage requirements. The possibility of designing custom 
amplicons for each disease, recently offered by Illumina TruSeq Custom 
Amplicon or Agilent HaloPlex products, will also improve the capture of 
promoters and other regulatory regions, which could be omitted in WES. 
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VII. CHAPTER SEVEN - Whole exome sequencing of 
no LDLR/APOB/PCSK9 mutation definite Familial 
Hypercholesterolaemia patients. 
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7.1. Introduction 
The importance of identifying an FH-causing variant, which has clinical utility in 
providing an unequivocal diagnosis (Humphries et al. 2008), has been 
emphasized by the National Institute of Clinical Excellence (NICE), which in 
2008 recommended  cascade testing using  DNA information for finding the 
affected relatives of a patient (Wierzbicki et al. 2008). The risk of early CHD can 
be significantly reduced by statin treatment (Neil et al. 2008), and genetic 
information has been demonstrated to complement the management of treated 
patients (Humphries et al. 2006c).  
However, an FH-causing mutation can be detected in 63-87% of DFH patients, 
thus in a proportion of patients the cause of high LDL-C remains unexplained. 
The majority of FH patients inherit a mutation in LDLR (Usifo et al. 2012). The 
APOB variant (c.10580G>A, p.(Arg3527Gln)) accounts for 5-12% of UK FH 
cases (Graham et al. 2005, Taylor et al. 2010b, Futema et al. 2013) whereas a 
gain-of-function mutation in PCSK9, (c.1120G>T, p.(Asp374Tyr)), can be found 
in roughly 1.7% of FH patients (Taylor et al. 2010b). In the past few years, 
several loci have been reported to co-segregate with FH in family linkage 
studies, however to date this has not led to the identification of a specific causal 
gene (Cenarro et al. 2011, Marques-Pinheiro et al. 2010, Wang et al. 2011). It is 
likely that there are novel FH mutations located in unknown genes influencing 
lipid metabolism and that their discovery may contribute to the identification of 
novel treatment targets. In order to find novel causes of FH the whole exomes 
of 125 unrelated DFH patients were sequenced at a high depth. The expected 
frequency of an FH-causing mutation in a novel gene was lower than the gain-
 233 
of-function mutation in PCSK9 (1.7%), reasoning that a higher frequency would 
give researchers more power and led to the discovery earlier on. Patients were 
also assessed for polygenic hypercholesterolaemia, which is discussed in 
Chapter Three.  
7.2. Results 
The overall workflow of the whole exome sequencing data analysis is shown in 
Figure 44. All copy number variants called in the FH cohort can be found here: 
https://github.com/marta10/PhD_Thesis_MF/tree/master/cnvs_results .
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Figure 44 
Novel FH gene discovery pipeline. To increase the chance of detecting true 
FH-causing variants with a strong effect and reducing the noise, samples with 
a mutation in LDLR or APOB  (apart from novel APOB variants of unknown 
effect) or those with a high LDL-C gene score (discussed in Chapter Five) 
were removed from the analysis. Remaining variants were filtered by their 
frequency and functional effect and compared against controls. Genes with 
more than 4 rare functional variants in controls were filtered out. Remaining 
variants were manually assessed and false positive calls were removed. 
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7.2.1. Variants in known FH genes 
Firstly, variants in known FH genes were analysed (Figure 44). The coverage 
of LDLR, APOB, PCSK9 and LDLRAP1 were discussed in Chapter Six. For 
the LDLR ten individuals were carrying a missense mutation, five a nonsense 
mutation, three had small deletions, and two individuals had intronic changes 
known to affect splicing Table 33. Two of the variants were novel, c.695-
6_698del and c.1776_1778del, and their effect was discussed in Chapter 
Four (Figure 39 and Figure 40). Analysis with ExomeDepth package for CNVs 
identified two large duplications and one deletion within the LDLR region, 
discussed in Chapter Four (Figure 41). For APOB two individuals carried the 
known FH mutation, c.10580G>A (p.R3527Q), and several rare and cases-
unique APOB variants, distributed across different gene exons, were identified 
(Table 34). Because APOB is highly polymorphic the overall number of rare 
variants was not significantly different in comparison to controls. PCSK9 had 
the lowest mean read depth (18x), with four exons (1, 5, 9, and 10) covered 
less than 10x. There were no FH-causing variants identified in this gene. 
Samples with an explained cause (FH mutation positive) were removed from 
further analysis. 
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Table 33 
Summary of the identified LDLR mutations and their in silico predicted effect, including calculated LDL-C gene scores for the 
mutations carriers (presented in bold are the gene scores that are above the top decile cutoff for the control population).  
Mutation 
type/Exon 
Mutation Gene Score PolyPhen SIFT Mutation Taster 
Missense 
     4 c.326G>A (p.C109Y) 1.03 Probably damaging Not tolerated Disease Causing 
4 2X    c.502G>C (p.D168H) 0.91, N/A Probably damaging Not tolerated Disease Causing 
4 c.681C>G (p.D227E) N/A Probably damaging Not tolerated Disease Causing 
9 2X    c.1196C>A (p.A399D) 1.03 and 1.07 Possibly damaging Not tolerated Disease Causing 
11 c.1690A>C (p.N564H)1 1.17 Probably damaging Tolerated Disease Causing 
12 c.1823C>T (p.P608L) 1.09 Probably damaging Not tolerated Disease Causing 
14 c.2054C>T (p.P685L) 0.97 Probably damaging Not tolerated Disease Causing 
17 c.2479G>A (p.V827I) 0.92 Probably damaging Not tolerated Disease Causing 
Nonsense 
     4 2X    c.682G>T (p.E228*) 0.78 and 0.84 NA NA Disease Causing 
7 c.1048C>T (p.R350*) 1.11 NA NA Disease Causing 
8 c.1150C>T (p.Q384*) 0.65 NA NA Disease Causing 
11 c.1685G>A (p.W562*) 0.95 NA NA Disease Causing 
Indels 
     5 c.695-6_698del (Figure 39) 1.23 NA NA Disease Causing 
12 
2X c.1776_1778del p.G592del 
(Figure 40)  N/A NA NA Disease Causing 
Intronic 
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intron14 c.2140+1G>A 0.58 NA NA Disease Causing 
intron9 c.1359-31_1359-23 delinsCGGCT 0.92 NA NA NA 
      Large rearrangements 
    3_8 c.191-?_1186+?dup 1.03 10kb in frame duplication, peptide elongation 
11_12 c.1587-?_1845+?del N/A 4kb out of frame deletion, truncated protein 
13_15 c.1846-?_2311+?dup 0.92 7kb out of frame duplication, truncated peptide  
  
 
        
       
 
N/A - not available 
NA - not applicable 
1 – carrier of this variant also has a deletion in exon 17 of LDLR c.2393_2401del9 (p.L799_V801del)) 
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Table 34 
All rare APOB variants identified in the FH cases (updated Table 32), including in silico predictions of their effect and LDL-C gene 
scores for the corresponding variant carriers. Using in silico mutation prediction tools (PolyPhen2, SIFT, Mutation Taster) the 
variant located in exon 3 of APOB (c.148C>T (p.R50W) has been predicted to be pathogenic by all three algorithms. The mutant 
Tryptophan is bigger than the wild type Arginine and it is predicted to cause a loss of hydrogen bonds in the core of the protein, 
which may result in an incorrect folding. Other variants include c.598G>A (p.A200T), c.1199G>A (p.R400H), and c.G2700G>T 
(p.Q900H) in both cases the mutant differs in size and hydrophobicity from the wild type residue, which may affect the folding of the 
protein as well as the hydrophobic interactions within the protein’s core. The novel c.10277C>T (p.A3426V) variant is located near 
to the LDL-receptor-binding site (Boren et al. 1998), and although it has been predicted as benign/tolerated/polymorphism by the in 
silico tools, it may affect the LDL-R/ApoB interaction. 
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Exon Variant Gene Score PolyPhen SIFT MutationTaster ID 
 
3 
      
c.148C>T(p.R50W) 0.83 Probably Damaging Not Tolerated Disease Causing HYP5062228 
 
6 
      
c.598G>A (p.A200T) 0.98 Possibly Damaging Not Tolerated Polymorphism HYP5269576 
 
10 
      
c.1199G>A(p.R400H) N/A Benign Not Tolerated Polymorphism HYP5159267 
18       
c.G2700G>T (p.Q900H) 1.19 Probably Damaging Not Tolerated Polymorphism HYP5358899 
26       
c.10277C>T (p.A3426V) and 
1.17 
Benign Tolerated Polymorphism 
HYP5002222 
 
c.6639_6641delTGA (p.2213_2214delD) NA NA Disease Causing 
 
2 X     c.G10580G>A (p.R3527Q) 0.71 
and 1.01 
 
Probably Damaging Not Tolerated Disease Causing HYP5062226 
and HYP5062216 
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7.2.2. LDL-C gene score analysis 
Out of 109 FH samples (21 mutation positive, 88 mutation negative, remaining 
samples had insufficient DNA), genotyped for all 12 SNPs, 31 had a gene 
score above the 1.16 cutoff (results are demonstrated in Chapter Five), within 
which two samples, in addition to the high gene score, had an LDLR mutation, 
one in exon 11 (c.1690A>C (p.N564H)) found on the same allele as a 9bp 
deletion in exon 17 (c.2393_2401del9 (p.L799_V801del)), which have been 
demonstrated as not fully-penetrant (26). The other was a deletion of a 
consensus splice site at the 5’ of exon 5, c.695-6_698del, which has not been 
examined in vivo to confirm its likely effect on splicing.  
The mean LDL-C gene score for the FH mutation negative group was 1.08, 
which was significantly higher than 0.90 for the WHII study (p < 2.2x10-16), 
and 0.96 for the FH mutation positive group (p = 0.006). The overall difference 
between the groups was significant (ANOVA, p = 1.33x10-12).  Individuals 
with a gene score above the top decile cut-off for the WHII subjects (>1.16), 
were considered to have polygenic hypercholesterolaemia and excluded from 
further analysis 
7.2.3. Variants in GLGC LDL-associated genes 
Next, variants in genes identified through GWAS as being involved in 
determining levels of LDL-C in healthy individuals (Teslovich et al. 2010) were 
examined. A burden test on all rare functional variants in any gene singly or in 
all 25 genes combined showed no obvious candidate for a novel FH locus 
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(Table 35). In addition, there were no loss-of-function variants (i.e. premature 
stop codon formation, loss of a stop codon, frameshift indels, CNVs) observed 
in these genes.  
Chromosomal regions previously associated with FH in family linkage studies 
were also analysed (Cenarro et al. 2011, Marques-Pinheiro et al. 2010, Wang 
et al. 2011). There was no association of rare functional variants in any gene 
located within the associated loci. The p vales for each of the loci are shown 
in Appendix Table III. 
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Table 35 
Top p values of the rare functional variant association between cases and 
controls in the GLGC candidate genes. 
 
 
 
Gene Name 
Variant count in  
p value 
Cases (n=71) Controls (n=1926) 
MTTP 3 12 0.04 
NYNRIN 3 18 0.09 
KIAA1875 2 11 0.14 
CYC1 1 4 0.23 
HFE 1 4 0.23 
TOP1 1 4 0.23 
PVRL2 1 6 0.31 
SCAP 2 23 0.37 
LIPG 1 10 0.44 
ABCG8 1 17 0.62 
LIPC 1 18 0.64 
OSBPL7 1 19 0.65 
CELSR2 1 32 0.83 
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7.2.4. Whole exome analysis 
25 samples carrying a mutation in known FH genes and 29 with the LDL-C 
gene score above 1.16 were removed from further analysis.To interrogate the 
whole exome a burden test was performed between 71 cases and 1,926 
controls. There were 4,326 genes with one or more rare functional variant in 
cases. In order to remove calls less likely to influence the FH phenotype and 
to increase the detection power, further analysis were only limited to genes 
where a maximum of 4 rare functional variants were seen in the controls, 
based on the expected prevalence of FH of 1 in 500 in the general population, 
and therefore any gene with > 4 rare functional variants in the controls were 
excluded. The next step involved a visual validation of the quality of calls 
performed using the Human Genome 19 on the Integrative Genomic Viewer 
(IGV) (Thorvaldsdottir et al. 2013). In order to avoid false negative calls, data 
produced by a less stringent variant calling pipeline (using a single-sample 
calling) were searched for rare variants in the significant genes. An additional 
loss-of-function variant, a premature stop codon at the position c.244C>T 
(p.Q81*) was found in the CH25H gene, in an FH patient sample with a low 
LDL-C SNP score After adjusting for the false positives and false negatives, 
CH25H remained the top gene (p < 1.4x10-3) with three variants in the cases 
and two in the controls (Table 36). 
 244 
Table 36 
Summary of the genes and their variants, which shown a significant excess of rare functional variants in FH cases in comparison to 
the controls. 
 
Gene   Ch 
Number of variants in cases 
(n=71) 
Number of variants in 
controls (n=1,926) 
  p value 
CH25H 
 
10 3 2 
 
0.001 
 
Cases 
 
ENST00000371852:exon1:c.G568A:p.V190I; exon1:c.A716C:p.H239P; exon1:c.C244T:p.Q82X 
 
 
Controls 
 
ENST00000371852:exon1:c.T742G:p.C248G; exon1:c.C590A:p.P197Q 
 
TSPAN4 
 
11 3 3 
 
0.002 
 
Cases 
 
3X ENST00000397408:exon4:c.230_232del:p.77_78del 
 
 
 
Controls 
 
ENST00000346501:exon5:c.G389A:p.R130Q; 2X exon5:c.G439A:p.A147T 
 
HSPB7 
 
1 2 0 
 
0.003 
 
Cases 
 
2X ENST00000311890:exon2:c.199+7G>A 
 
 
 
Controls 
 
None 
  
 
KLRC1 
 
12 2 0 
 
0.003 
 
Cases 
 
ENST00000544822:exon5:c.G333C:p.Q111H; exon3:c.C178T:p.H60Y 
 
 
Controls 
 
None 
  
 
MOAP1 
 
14 3 4 
 
0.004 
 
Cases 
 
ENST00000556883:exon2:c.C707T:p.A236V; exon2:c.G476C:p.C159S; exon2:c.A182G:p.N61S 
 
 
Controls  
ENST00000556883:exon2:c.C655G:p.R219G; exon2:c.C627A:p.S209R; exon2:c.C264G:p.I88M; 
exon2:c.A919G:p.I307V 
RBM25 
 
14 3 4 
 
0.004 
 
Cases 
 
ENST00000261973:exon6:c.A454T:p.I152F; exon2:c.T50C:p.L17P; exon11:c.C1364A:p.A455D 
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Controls  
ENST00000261973:exon7:c.C671T:p.A224V; exon11:c.A1273G:p.R425G; exon18:c.G2392A:p.V798I; 
exon2:c.T7C:p.F3L 
ANP32E 
 
1 2 1 
 
0.008 
 
Cases 
 
ENST00000436748:exon3:c.G227C:p.S76T; ENST00000533654:exon4:c.A434G:p.K145R 
 
 
Controls 
 
ENST00000436748:exon6:c.G629T:p.R210L 
 
 
CABP5 
 
19 2 1 
 
0.008 
 
Cases 
 
ENST00000293255:exon4:c.C281A:p.T94N; exon3:c.G201A:p.M67I 
 
 
Controls 
 
ENST00000293255:exon3:c.A169C:p.M57L 
 
 
CELA2B 
 
1 2 1 
 
0.008 
 
Cases 
 
ENST00000375910:exon6:c.G576A:p.W192X; ENST00000422901:exon3:c.G271A:p.G91R 
 
 
Controls 
 
ENST00000375910:exon7:c.T739C:p.Y247H 
 
 
INSIG2 
 
2 2 1 
 
0.008 
 
Cases 
 
ENST00000245787:exon2:c.T89C:p.I30T; exon2:c.C236T:p.T79M 
 
 
Controls 
 
ENST00000245787:exon4:c.G376A:p.D126N 
 
 
KCTD7 
 
7 2 1 
 
0.008 
 
Cases 
 
ENST00000275532:exon4:c.G814A:p.V272M; exon4:c.C758T:p.S253L 
 
 
Controls 
 
ENST00000275532:exon4:c.G506A:p.R169Q 
 
 
MR1 
 
1 2 1 
 
0.008 
 
Cases 
 
ENST00000367579:exon5:c.A747T:p.E249D; exon4:c.C740T:p.P247L 
 
 
Controls 
 
ENST00000367579:exon4:c.G654A:p.W218X 
 
 
MRO 
 
18 2 1 
 
0.008 
 
Cases 
 
ENST00000436348:exon5:c.G578A:p.R193Q; exon5:c.G565A:p.V189I 
 
 
Controls 
 
ENST00000436348:exon3:c.A223G:p.S75G 
 
 
NR2E1 
 
6 2 1 
 
0.008 
 
Cases 
 
ENST00000368983:exon1:c.G136A:p.G46S; exon5:c.A634G:p.M212V 
 
 
Controls 
 
ENST00000368983:exon7:c.G1000A:p.V334I 
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NXT2 
 
X 2 1 
 
0.008 
 
Cases 
 
2X ENST00000218004:exon1:c.A82C:p.T28P 
 
 
 
Controls 
 
ENST00000218004:exon2:c.C155T:p.T52I 
 
 
PABPC1 
 
8 2 1 
 
0.008 
 
Cases 
 
ENST00000318607:exon9:c.A1250C:p.Q417P;exon10:c.G1364A:p.R455H 
 
 
Controls 
 
ENST00000523555:exon3:c.226+3A>G 
 
 
PODXL 
 
7 2 1 
 
0.008 
 
Cases 
 
ENST00000537928:exon3:c.G821A:p.R274K; exon5:c.A992G:p.H331R 
 
 
Controls 
 
ENST00000537928:exon8:c.C1246G:p.Q416E 
 
 
PUS3 
 
11 2 1 
 
0.008 
 
Cases 
 
ENST00000530811:exon1:c.T74C:p.V25A; exon2:c.T824C:p.L275P 
 
 
Controls 
 
ENST00000530811:exon4:c.945-8T>C 
 
 
TXNDC15 
 
5 2 1 
 
0.008 
 
Cases 
 
ENST00000511070:exon2:c.C130T:p.R44W; ENST00000507024:exon2:c.G91A:p.A31T 
 
 
Controls 
 
ENST00000358387:exon2:c.G534C:p.E178D 
 
 
WDR89 
 
14 2 1 
 
0.008 
 
Cases 
 
ENST00000394942:exon2:c.T821C:p.L274S; exon2:c.A553G:p.M185V 
 
 
Controls 
 
ENST00000394942:exon2:c.A860G:p.D287G 
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7.2.5. CH25H and INSIG2 variants 
CH25H codes for cholesterol 25-hydroxylase, known to catalyse the formation 
of the oxysterol - 25-hydroxycholesterol (25-HC) (Lund et al. 1998). The 
INSIG2 gene, which also exhibited an excess of rare functional variants in the 
FH cohort in comparison to the controls (p < 7.8x10-3) (Table 36), has been 
demonstrated to regulate the activity of SREBPs, a family of major lipid 
metabolism transcription factors, via direct biding of 25-HC (Radhakrishnan et 
al. 2007). Thus both genes, CH25H and INSIG2, are involved in the same 
pathway of cholesterol metabolism, as summarized in Figure 45.
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Figure 45 
CH25H and INSIG2 involvement in the regulation of SREBP activity (adapted from (Ikonen 2008)). CH25H catalyses the formation 
of 25-hydroxycholesterol from cholesterol. 25-hydroxycholesterol binds INSIG2 in the endoplasmic reticulum, which further 
prevents SCAP (SREBP cleavage activating protein) from transporting SREBP to the Golgi. Consequently, SREBP activity is 
inhibited and thus the expression of its target protein (including LDLR and HMG-CoAR) descreases.
 249 
There were three heterozygous variants found in CH25H, all confirmed by 
Sanger sequencing (Figure 46), of which one leads to a formation of a 
premature stop codon at residue 81, predicted to have a damaging effect on 
the protein, the second is affecting a well-conserved residue across species, 
c.568G>A (p.V190I), and third, c.716A>C (p.H239P), is altering  one of the 
crucial residues of the His Box 3 domain, known to play a crucial role, 
together with His Boxes 1 and 2, in the catalytic activity of CH25H (Fox et al. 
1994), as shown in Figure 47. Two rare functional variants were found in the 
control cohort, both being non-synonymous (p.P197Q and p.C248G). The 
p.P197Q is located in a conserved region of the protein however it is 
predicted as Tolerated/Benign/Neutral by SIFT/PolyPhen/Mutation Taster. 
The p.C248G variant affects a residue that is not conserved (Holmes et al. 
2011). 
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Figure 46 
Sanger sequencing confirmation of novel CH25H variants, A. c.716A>C 
(p.H239P) and c.568G>A (p.V190I); B. c.244C>T (p.Q81*). Primers used for 
the amplification of the region are highlighted in blue (A) and in purple (B).  
 
CH25H	sequencing	(order	#410822401)	
p.H239P	(c.716A>C)	(UK10K_HYP5231652)	
WT	(UK10K_HYP5231677)	
p.V190I	(c.568G>A)	(UK10K_HYP5231677)	
WT	(UK10K_HYP5231652)	
90966631 TYGTGTGGCACCTGCTGCACCACAAGGTGCCCTGGYTGTACCGCACCTTYCACAAGGTGC 90966572 
90966571 ACCACCRGAACTCGTCCTCGTTCGCRCTGGCAACGCAGTATATGAGCGTCTGGGAACTGT 90966512 
90966511 TTTCTTTGGGYTTCTTCGACATGATGAACGTCACACTGCTYGGGTGCCACCCGCTCACCA 90966452 
90966451 CCCTGACCTTCCACGTGGTCAACATCTGKCTTTCCGTGGAGGWCCACTCCGGCTACAAYT 90966392 
90966391 TCCCTTGGTCCACTCACAGACTGGTGCCCTTCGGGTGGTACGGGGGTGTGGTRCACCACG 90966332 
90966331 ACCTGCATCACTCTCACTTTAACTGCAACTTCGCTCCRTACTTTACACACTGGGACAAAA 90966272 
90966271 YACTGGGAACRCTGCGRACTGCATCTGTCCCAGCGCRRTGATGTGGCTGCGGTGGGTGCC 90966212 
90966211 CCTAAGAMTCGGGACTGCTRTGCCTTTCACACTTGAATGAAGAGAAACACCTGAGCTATA 90966152 
90966151 TATTTTTTTAAAGCAACTAACTTATTRCTTTATGTTTATCTATGAAAACCATAGATAAAA 90966092 
90966091 TCTGATGCATTTTTGTAATCTGACAAAGTAATTTACATACTGTTTGTGTATCAATACAAT 90966032 
*Primers:	
CH25H	_01F	/	CH25H_02R	
	
A. 
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CH25H	sequencing	(order	#4108796)	
*Primers:	
CH25H	_03F	/	CH25H_04R	
	
p.A80A	(c.243G>T)	and	p.Q81*	(c.244C>T)	(UK10K_HYP5159267)	 WT	(UK10K_HYP5002218)	
B. 
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Figure 47 
Schematic representation of the intronless CH25H gene and the localisation of novel variants identified in the FH cohort. CH25H 
encodes an enzyme, cholesterol 25-hydroxylase, known to be spanning the endoplasmic reticulum membrane, with two domains 
(including the N terminal) located outside of the membrane (in light grey), three 20 amino acid long transmembrane regions, and 
two domains positioned inside the membrane, which contain three His boxes, essential for the catalytic activity of the enzyme 
(Holmes et al. 2011)
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Sanger sequencing also confirmed two rare functional variants in the INSIG2 
gene called in the cases, both non-synonymous changes (Figure 48). A 
mutation prediction report generated by Project HOPE (Venselaar et al. 2010) 
highlighted that the c.89T>C (p.I30T) variant will cause an empty space in the 
core of INSIG2 because of the size differences between the wild type 
Isoleucine and the smaller mutant - Threonine.  The other variant, c.236C>T 
(p.T79M), located in the transmembrane domain of INSIG2 is predicted to 
have an effect on the hydrophobic interactions within the core of the protein or 
with the membrane lipids, because the mutant Methionine is more 
hydrophobic than the wild type Threonine. One rare missense variant was 
found in INSIG2 in the controls (p.D126N), which was predicted as 
Tolerated/Probably Damaging/Disease Causing (by SIFT/PolyPhen/Mutation 
Taster). 
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Figure 48 
Sanger sequencing confirmation of novel INSIG2 variants, c.236C>T 
(p.T79M) and c.89T>V (p.I30T). Primers used for the amplification of the 
region are highlighted in yellow. 
 
118853948 ATCATGTATTAGATACACATTAATTTCTTTTTTCTTATCTCTTGCAGGATTTCTGGTAGG 118854007 
118854008 TCCTACTTTAGGACAAGATGTGGTACCGTTGAAGCGTCAGTCTTTGATTCACAGACAGTT 118854067 
118854068 GAGCTTTTCAGCTGGGAAGCCTTTCCATTTTTTTTTTTTTAACGGCTTTCTGAACCTATG 118854127 
118854128 AAACCATGGCAGAAGGAGAGACAGAGTCACCTGGGCCCAAAAAGTGTGGCCCATATATTT 118854187 
118854188 CATCTGTCACTAGCCAGAGTGTGAACTTGATGATTCGAGGAGTAGTGCTATTTTTTATTG 118854247 
118854248 GAGTATTTCTTGCATTAGTGTTAAATTTACTTCAGATTCAGAGAAATGTGACGCTCTTTC 118854307 
118854308 CACCTGATGTGATTGCAAGCATCTTTTCTTCTGCATGGTGGGTACCCCCATGCTGTGGCA 118854367 
118854368 CGGCTTCAGGTATGTGTAGGATGTTTCTGTAATGCTTAGAAAGGAAATAGGGTAAATGAG 118854427 
118854428 TATGGACGTTGTCTGAGCAATAAACCTTTTTAAAAAAGAAAATATATTTATTGAGATATA 118854487 
118854488 ATTTAGGTATAATACACTGGACCCGTTTGAATTGAACAACTTGATGTGTTTAGGCAAATG 118854547 
INSIG2	sequencing	(order	#4103758)	
p.T79M	(c.236C>T)	(UK10K_HYP5231650)	
WT	(UK10K_HYP5002210)	
WT	(UK10K_HYP5231650)	
p.I30T	(c.89T>C)	(UK10K_HYP5002210)	
*Primers:	
INSIG2_01F	/	INSIG2_02R	
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7.2.6. Re-sequencing of CH25H 
Additional 160 unrelated FH patients, from independent cohorts studied in 
Chapter Three (Greece, Canada, Holland, South-Indian) who had LDL-C 
gene score below 1.16 cutoff for polygenic hypercholesterolaemia, were 
sequenced for changes within the CH25H gene. The gene was found to be 
highly conserved, with two common polymorphisms (MAF 0.19, and 0.20), 
which do not affect the amino acid composition of the protein.  
7.3. Discussion 
This study identified 25 mutations in known FH genes (23 in LDLR and 2 in 
APOB), which were missed by the current screening protocol. This finding 
confirmed that LDLR locus is highly heterogeneous and mutations within this 
gene account for the majority of FH causes. The need for an update of current 
screening methods has been previously discussed in Chapter Six. In addition 
to the known FH mutations, six novel APOB variants were identified, 
distributed across different exons, in five patients. The pathogenicity of these 
variants remains to be tested, however their very low frequency and absence 
from the control cohorts can indicate a damaging effect. Most of the current 
mutation screening strategies for FH are focused on a selected region of exon 
26 of APOB, because of its established function (Boren et al. 1998). The 
whole exome sequencing enabled to extent the analysis to the entire coding 
sequence of the gene, by which novel variants, unique to the FH cohort, were 
found.  
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Rare functional variants in genes associated with LDL-C levels in the GWAS 
meta-analysis were not significantly overrepresented in the FH cohort, when 
compared to controls. This suggests that rare variants that have a major effect 
on function in these genes known to have common LDL-C variants of modest 
effect are unlikely to be a common cause of FH.  
Although we found no evidence that rare variants in the LDL-C associated 
genes identified by GWAS were causing FH, the cumulative effect of common 
LDL-rising alleles in these genes was shown to be the likely cause of high 
LDL-C in a significant proportion (25%) of the examined patients. A gene 
score above the top decile for a healthy population cutoff (1.16) was also 
observed in two patients with considerably mild LDLR mutations, which 
demonstrates that common polymorphisms can contribute to the presentation 
of an individual carrying a mild effect FH mutation with LDL-C levels above 
the diagnostic threshold, as discussed in Chapter Five. 
 
Genes CH25H and INSIG2 are the strongest candidates for novel FH loci 
among the final 19 genes, showing the excess of rare functional variants, 
based on the available literature on functions of the proteins for which they 
code. CH25H encodes 25-cholesterol hydroxylase, which catalyses the 
formation of 25-HC from cholesterol. It has been demonstrated that both 
cholesterol and 25-HC can regulate the function of SREBP, a transcription 
factor known to regulate the expression of several key players in the lipid 
metabolism (Adams et al. 2004, Shao and Espenshade 2012). It is known that 
the regulation of SREBP activity depends on binding of 25-HC to INSIG2, 
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encoded by the INSIG2 gene (Radhakrishnan et al. 2007). The recently 
updated GLGC GWAS study, with > 180,000 individuals had now identified an 
association at the genome wide level of LDL-C with an INSIG2 gene variant 
(MAF = 0.08) (Willer et al. 2013b). A previous GWAS shown an association of 
INSIG2 SNP with bone mineral density (Estrada et al. 2012). The CH25H 
variants identified in this study have not been observed in 1000 Genomes, 
6500ESP and 69CG or the 1,926 control exomes. An additional novel variant 
has been found in the CH25H re-sequencing cohort of 160 FH patients. The 
possible effect of this promoter variant (c.-58C>T) on the expression of 
CH25H remains to be tested in the future work. CH25H is located in close 
proximity (<7 Kb) to the LIPA gene. A common (MAF= 0.38) intronic SNP 
(rs1412444) in LIPA has been shown to be associated with CHD in two 
independent GWAS (Wild et al. 2011, 'A genome-wide association study in 
Europeans and South Asians identifies five new loci for coronary artery 
disease'  2011), however the SNP is not in LD with the region surrounding 
CH25H (Figure 49). Homozygous mutations in LIPA are known to cause 
cholesterol ester storage disease due to deficiency of lysosomal acid lipase 
(LAL) (Patrick and Lake 1969). A recent case report described a patient with a 
homozygous splice site junction mutation in LIPA gene who was initially 
diagnosed with autosomal recessive hypercholesterolaemia (Stitziel et al. 
2013). None of the CH25H rare variant carriers had an additional rare variant 
in LIPA, thus the CH25H variants could not mark a causative haplotype in this 
region, although variants in the intragenic region remain undiscovered. 
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Figure 49 
Linkage disequilibrium (LD) region of LIPA SNP (rs1412444), which was 
shown to be associated with CHD. The variant does not share LD with any 
common variant in CH25H and its surrounding region. Plot was generated 
using SNAP tool (http://www.broadinstitute.org/mpg/snap/ldsearch.php). 
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In summary, in 125 DFH unrelated patients without an identified mutation by 
conventional screening methods, the analyses identified 25 disease-causing 
variants in already known FH loci, as well as six previously unreported APOB 
variants in five patients. LDL-C gene score analysis found that 31 (29 
mutation negative) patients had SNP score in top decile of the general 
population and therefore had a definite polygenic aetiology, and an additional 
five had a potential functional variant in CH25H or INSIG2. This means that 
explanation for the FH phenotype is still lacking in 50% of the patients. This 
suggests that some causal variants could be missed at different stages of the 
data processing or analysis. The variant calling pipeline used for this study 
was carefully optimised for the majority of the exome regions, though some 
calls in poorly covered regions could be missed. There is a possibility that 
there are genetic causes located outside of the protein coding region, 
affecting protein expression, posttranscriptional stability, or altering gene 
splicing. Also, it is possible that the LDL-C gene score cutoff of 1.16 for 
polygenic hypercholesterolaemia is too stringent. Thus using the 9th decile 
cutoff of 1.08, in which a 41% of WHII individuals had LDL-C above the 4.9 
mmol/l (mean LDL-C = 4.68 ±1.05mmol/l) FH diagnostic level, could be more 
appropriate. By doing so, the phenotype would be explained in an additional 
nine mutation-negative patients. Finally because the burden test results are 
dependent on the number of associated variants and variants diluting the 
signal, it is possible that novel FH mutations are located in a highly 
polymorphic gene, in which it is difficult to pick up the true mutation.    
Thus overall, no major novel locus for FH was detected, with no gene having 
a functional variant in more than 3 patients. This suggests that the genetic 
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cause of FH in these unexplained cases is likely to be very heterogeneous, 
which complicates the novel gene discovery and diagnostic process.  
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VIII. CHAPTER EIGHT – General Discussion 
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8.1. Challenges of mutation prediction 
The findings of this thesis show that, in the UK, the spectrum of FH mutations 
is markedly heterogeneous, and novel LDLR variants continue to be 
discovered. These results highlight the need for more advanced tools 
enabling a quick and decisive assessment of the functional effect of a variant 
on the protein. The already existing bioinformatic tools, such as PolyPhen, 
SIFT, Mutation Taster, and Project HOPE provide an evaluation of the 
variant’s effect, based on multiple sequence alignments, and examining the 
degree of conservation of amino acid residues, Bayes classifiers, which 
predict the effect using the variant frequencies provided by large databases 
(including the 1000 Genomes Project and the Human Gene Mutation 
Database  (HGMD)), or on the comparison of the physicochemical 
characteristics of the wild type and the substituted amino acids. The 
algorithms have proven to be accurate for prediction of the majority of human 
mutations and are optimized for high-throughput analysis of next generation 
sequencing data. However, the existing in silico tools are mainly designed to 
assess the effect of non-synonymous changes. Results of Chapter Three 
show that roughly 20% of the observed LDLR mutations are small insertions 
or deletions, 2% are variants located within or in close proximity to a splicing 
site, and 2% occur in the promoter region. The effect of such nucleotide 
changes cannot be examined by the tools mentioned above. Although some 
of the small insertions/deletions cause a frameshift and usually do not require 
further investigations, novel approaches examining the protein structure 
and/or interactions with other molecules are essential. A recently published 
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report on the UCL FH mutation database (Usifo et al. 2012) makes a use of 
the Single Amino Acid Polymorphism database (SAAPdb) (Hurst et al. 2009), 
which enables visualization of the structural effects of the studied variant. 
However, this method is limited to proteins that have an established crystal 
structure, therefore cannot be used for examining changes within, for 
example, the transmembrane domain of LDLR. Other advanced analytic tools 
of protein structure and conservation include ScoreCons (Lees et al. 2010), 
Jalview (Waterhouse et al. 2009) and PyMol (http://www.pymol.org). This 
structural analysis requires in-depth knowledge of the physiochemical 
interactions between amino acids, advanced bioinformatics skills and 
appropriate computing equipment, thus at the moment it is not widely 
available for clinical use.  
The ability to predict the functional effect of a variant is especially important in 
the next generation sequencing era. The rapid development of high-
throughput technologies over the past decade led to the discovery of 
thousands of variants, however identifying which are causal is not always 
successful. The Gene Ontology (GO) (http://www.geneontology.org) project 
can also provide an important tool for the analysis of next generation 
sequencing data. The GO project utilizes already published functional 
information to annotate genes and gene products. The information is 
incorporated in many different bioinformatics tools, which allows for the 
analysis of, for example, protein-protein interactions, or protein pathway 
networks. The GO project aims to completely annotate twelve reference 
genomes and biological systems, however currently only the Cardiovascular 
and Renal annotation projects are funded.  
 264 
The analysis of variants that may potentially affect the correct splicing of pre-
mRNA is still rather laborious. Currently available in silico tools, such as 
Human Splicing Finder (Desmet et al. 2009), compare the strength of the 
splice donor or acceptor sites and the branch points in the wild type and 
mutated state, by analyzing the length between the acceptor and the donor 
sites, the conservation of splicing factors motifs, and the frequency of the 
tested variant, however they cannot account for the complexity of a cellular 
environment, thus in some cases the results may be misleading. Although the 
preferred method for analyzing the effect of splice site variants is the direct 
analysis of mRNA from an appropriate tissue from a patient and a control, the 
genetic material may not always be available due to several different reasons, 
such as difficult tissue access. An in vivo approach, which employs a 
‘minigene’ system has been developed to predict the potential consequence 
of splice site variants. The method applies minigene-based technologies used 
for alternative splicing analysis (Vibe-Pedersen et al. 1984). Any genomic 
region of interest- for example, an exon with part of its intronic flanking 
regions- can be amplified from normal or affected individuals and cloned into 
the minigene, forming a plasmid. The plasmid is then transfected in to an 
appropriate cell line where it is transcribed and the resulting mRNA can be 
analysed by Real-Time PCR (RT-PCR). This exon-trapping method was 
shown to be effective at correctly identifying the variant’s effect in vivo and it 
can be used to analyse complex exonic/intronic regions (Baralle et al. 2003, 
Cooper 2005, Kishore et al. 2008). The minigene system is currently being 
tested for LDLR splice variants at the UCL Cardiovascular Genetics lab.  
 265 
In a small proportion of FH patients the LDLR gene has no defect and the 
defective plasma clearance of LDL particles due to a defect in ApoB can be 
examined by analyzing the mutant:wild type ratios of ApoB in the plasma. 
Authors of a recent report ((Thomas et al.) published online on 13 Jun 2013) 
applied mass spectrometry technology to analyse a novel APOB variant, 
p.R50W, which was also identified in this project as a potential FH mutation 
(Chapter Seven). The authors demonstrated, that in the patients plasma, 
there was 2.5-3.5 fold more of the mutated ApoB peptide in comparison to the 
wild type ApoB peptide. The abundance of the two peptides was quantified 
using synthetic peptides. The finding was supported by a family co-
segregation of the variant, which overall demonstrated that the ApoB p.W50 
has a significant impact on the plasma LDL clearance. This method can be 
adapted for assessing other APOB variants, however it requires a 
multidisciplinary collaboration.  
It is widely accepted that one of the main criteria to evaluate the pathogenicity 
of a variant in an autosomal dominant disorder is a family co-segregation 
analysis (Cotton and Scriver 1998). However, in some instances segregation 
analysis of the phenotype with a single variant may give misleading results, 
for example, the co-segregation of the novel LDLR variant (p.Asn316Lys) in 
the Indian Family, as demonstrated in Chapter Four. Further analysis of the 
polygenic effect of common variants (discussed in Chapter Five) or the effect 
of rare LDL-lowering variants (such as variants in PCSK9) should be 
considered before a final conclusion is made. 
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8.2. Application of LDL-C SNPs score 
This thesis provides the first validation of the findings of the study (Talmud et 
al. 2013), which demonstrated that in a proportion of FH patients raised LDL-
C may have a polygenic cause. This is an important step in the translational 
research of hypercholesterolaemia. The LDL-C SNPs score analysis can be 
used to identify hypercholesterolaemic patients who don’t have a monogenic 
cause, which is vital for the efficacy of cascade testing. It is expected that less 
than 50% of relatives of patients with polygenic hypercholesterolaemia will be 
affected (i.e. have LDL-C levels above the diagnostic cut-off for relatives 
(Starr et al. 2008)), which would compromise cascade testing for FH. 
Conversely, in individuals in the lower two deciles of the LDL-C SNPs score, it 
is extremely unlikely that their elevated cholesterol levels can be explained by 
a polygenic mechanism, suggesting that they are more likely to have a novel 
monogenic cause, yet to be identified. Therefore using the gene score 
information may increase the probability of finding novel rare FH variants with 
a strong effect.  Furthermore, combining the LDL-C SNPs score information 
with the FH mutation information for the mutation positive patients can help to 
explain the LDL-C level variability between patients, which consequently may 
help to decide on the appropriate LDL-C lowering therapy.  
Finally, it is important to compare the impact of a polygenic vs. a monogenic 
cause of hypercholesterolaemia on the development of atherosclerosis. For 
example, future studies should use non-invasive methods such as 
computerised tomography (CT) angiography and carotid intima media 
thickness (cIMT) ultrasound measures to examine the extent of the 
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progression of atherosclerosis in patients with similar LDL-C levels but a 
polygenic vs. a monogenic cause. 
8.3. Novel FH loci 
The whole exome sequencing analysis described in Chapter Seven did not 
identify a single 4th FH locus causing high LDL-C levels in patients negative 
for mutations in LDLR, APOB, PCSK9 and LDLRAP1. Nonetheless, several 
novel variants, which are likely to cause FH, were discovered. The strongest 
candidates for further functional study include variants in CH25H and INSIG2 
genes. Both genes encode proteins which function in the pathway of SREBP 
regulation. Although proving that mutations in CH25H and INSIG2 can cause 
FH requires further investigation, this finding can be important for the 
discovery of novel drug targets for the LDL-lowering therapy.  However, if the 
identified five variants (three in CH25H and two in INSIG2) are shown to be 
FH-causing, their frequency is very low, and consequently the overall FH 
mutation detection rate will not increase significantly. This finding also 
suggests the possibility that there are genetic causes located outside of the 
protein coding region, or that the cause of hypercholesterolaemia is 
multifactorial, i.e. due to interactions of several environmental factors or 
environment-gene interactions. Thus, altogether the analysis demonstrate that 
the FH aetiology is much more heterogeneous, than previously thought. 
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Table I 
 
Summary of methods used for the initial FH mutation screening, before whole exome sequencing. 
 
 
Sample ID 
Original study 
cohort 
Reference LDLR 
MLPA 
for 
LDLR 
APOB PCSK9 
UK10K_HYP5231659 Australian FH 
(Hooper et al. 
2012) 
all exons and 
promoter by Big 
Dye Terminator 
chemistry 
(Applied 
Biosystems) 
sequencing 
yes 
fragment of exon 
26, and exon 29 
by Big Dye 
Terminator 
chemistry (Applied 
Biosystems) 
sequencing 
exon 7 by Big 
Dye Terminator 
chemistry 
(Applied 
Biosystems) 
sequencing 
UK10K_HYP5231660 Australian FH 
UK10K_HYP5231661 Australian FH 
UK10K_HYP5231662 Australian FH 
UK10K_HYP5231663 Australian FH 
UK10K_HYP5231664 Australian FH 
UK10K_HYP5231665 Australian FH 
UK10K_HYP5231666 Australian FH 
UK10K_HYP5231667 Australian FH 
UK10K_HYP5231668 Australian FH 
UK10K_HYP5231669 Australian FH 
UK10K_HYP5231670 Australian FH 
UK10K_HYP5231671 Australian FH 
UK10K_HYP5231672 Australian FH 
UK10K_HYP5231673 Australian FH 
UK10K_HYP5231674 Australian FH 
UK10K_HYP5269604 Israeli FH 
None 
all exons and 
promoterby 
SSCP 
no 
APOB fragment of 
exon 26 by SSCP 
no 
UK10K_HYP5269605 Israeli FH 
UK10K_HYP5269606 Israeli FH 
UK10K_HYP5269607 Israeli FH 
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UK10K_HYP5269608 Israeli FH 
UK10K_HYP5269609 Israeli FH 
UK10K_HYP5358903 Israeli FH 
UK10K_HYP5358904 Israeli FH 
UK10K_HYP5358905 Israeli FH 
UK10K_HYP5358906 Israeli FH 
UK10K_HYP5231679 Italy FH 
(Bertolini et al. 
2013) 
all exons and 
promoter by 
Sanger 
sequencing 
yes 
 c.9216 to c.11788 
+152 nt of intron 
26 by Sanger 
sequencing 
all exons by 
Sanger 
sequencing 
UK10K_HYP5231676 Italy FH 
UK10K_HYP5231677 Italy FH 
UK10K_HYP5231678 Italy FH 
UK10K_HYP5269570 Nothern Ireland FH 
(Graham et al. 
1999) 
all exons and 
promoter by 
TTGE/DDGE 
yes 
RFLP for 
p.R3527Q 
no 
UK10K_HYP5269571 Nothern Ireland FH 
UK10K_HYP5269572 Nothern Ireland FH 
UK10K_HYP5269573 Nothern Ireland FH 
UK10K_HYP5269574 Nothern Ireland FH 
UK10K_HYP5269575 Nothern Ireland FH 
UK10K_HYP5269576 Nothern Ireland FH 
UK10K_HYP5269577 Nothern Ireland FH 
UK10K_HYP5269578 Nothern Ireland FH 
UK10K_HYP5269581 Nothern Ireland FH 
UK10K_HYP5159271 Oxford FH 
(Futema et al. 
2013) 
all exons and 
promoter by 
HRM 
yes 
fragment of exon 
26 by HRM and 
ARMS 
ARMS for 
p.D374Y 
UK10K_HYP5159272 Oxford FH 
UK10K_HYP5159273 Oxford FH 
UK10K_HYP5159274 Oxford FH 
UK10K_HYP5159275 Oxford FH 
UK10K_HYP5231650 Oxford FH 
UK10K_HYP5231651 Oxford FH 
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UK10K_HYP5231652 Oxford FH 
UK10K_HYP5231653 Oxford FH 
UK10K_HYP5231654 Oxford FH 
UK10K_HYP5231655 Oxford FH 
UK10K_HYP5231656 Oxford FH 
UK10K_HYP5231657 Oxford FH 
UK10K_HYP5231658 Oxford FH 
UK10K_HYP5159266 RFH 
(Taylor et al. 
2010b) 
all exons and 
promoter by 
SSCP or Sanger 
sequencing 
yes 
ARMS for 
p.R3527Q 
ARMS for 
p.D374Y 
UK10K_HYP5159267 RFH 
UK10K_HYP5159268 RFH 
UK10K_HYP5159269 RFH 
UK10K_HYP5159270 RFH 
UK10K_HYP5002209 SBBHF 
(Whittall et al. 
2010b, Mamotte 
and van 
Bockxmeer 1993, 
Humphries et al. 
2006b, Taylor et al. 
2009)  
all exons and 
promoter by 
HRM 
yes 
RFLP for 
p.R3527Q 
all exons by 
HRM 
UK10K_HYP5002210 SBBHF 
UK10K_HYP5002211 SBBHF 
UK10K_HYP5002212 SBBHF 
UK10K_HYP5002213 SBBHF 
UK10K_HYP5002214 SBBHF 
UK10K_HYP5002215 SBBHF 
UK10K_HYP5002216 SBBHF 
UK10K_HYP5002217 SBBHF 
UK10K_HYP5002218 SBBHF 
UK10K_HYP5002219 SBBHF 
UK10K_HYP5002220 SBBHF 
UK10K_HYP5002221 SBBHF 
UK10K_HYP5002222 SBBHF 
UK10K_HYP5002223 SBBHF 
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UK10K_HYP5002224 SBBHF 
UK10K_HYP5002225 SBBHF 
UK10K_HYP5002226 SBBHF 
UK10K_HYP5002227 SBBHF 
UK10K_HYP5002228 SBBHF 
UK10K_HYP5002229 SBBHF 
UK10K_HYP5002230 SBBHF 
UK10K_HYP5002231 SBBHF 
UK10K_HYP5002232 SBBHF 
UK10K_HYP5062209 SBBHF 
UK10K_HYP5062210 SBBHF 
UK10K_HYP5062211 SBBHF 
UK10K_HYP5062212 SBBHF 
UK10K_HYP5062213 SBBHF 
UK10K_HYP5062214 SBBHF 
UK10K_HYP5062215 SBBHF 
UK10K_HYP5062216 SBBHF 
UK10K_HYP5062217 SBBHF 
UK10K_HYP5062218 SBBHF 
UK10K_HYP5062219 SBBHF 
UK10K_HYP5062220 SBBHF 
UK10K_HYP5062221 SBBHF 
UK10K_HYP5062222 SBBHF 
UK10K_HYP5062223 SBBHF 
UK10K_HYP5062224 SBBHF 
UK10K_HYP5062225 SBBHF 
UK10K_HYP5062226 SBBHF 
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UK10K_HYP5062227 SBBHF 
UK10K_HYP5062228 SBBHF 
UK10K_HYP5062229 SBBHF 
UK10K_HYP5062230 SBBHF 
UK10K_HYP5062231 SBBHF 
UK10K_HYP5062232 SBBHF 
UK10K_HYP5269585 SBBHF 
UK10K_HYP5269589 SBBHF 
UK10K_HYP5269595 SBBHF 
UK10K_HYP5269597 SBBHF 
UK10K_HYP5269598 SBBHF 
UK10K_HYP5269601 SBBHF 
UK10K_HYP5269602 SBBHF 
UK10K_HYP5315266 SBBHF 
UK10K_HYP5315268 SBBHF 
UK10K_HYP5315271 SBBHF 
UK10K_HYP5315273 SBBHF 
UK10K_HYP5315275 SBBHF 
UK10K_HYP5358898 SBBHF 
UK10K_HYP5358899 SBBHF 
UK10K_HYP5358900 SBBHF 
UK10K_HYP5358901 SBBHF 
UK10K_HYP5358902 SBBHF 
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Table II 
Sequences of primers used for HRM product amplification. 
 
Gene Fragment Forward Reverse Forward primer 5' - 3' Reverse primer 5' - 3' Region Covered 
LDLR Prom FH110 FH130 CAGCTCTTCACCGGAGACCC ACCTGCTGTGTCCTAGCTGG c.-298 - c.-62 
LDLR Exon 1 FH544f FH545r AATCACCCCACTGCAAACTC  GGGCTCCCTCTCAACCTATT  c.-139 - c.67+23 
LDLR Exon 2 FH112 FH132 TTGAGAGACCCTTTCTCCTTTTCC GCATATCATGCCCAAAGGGG c.68-10 - c.190+6 
LDLR Exon 3 E3HRMfor E3HRMrev TCAGTGGGTCTTTCCTTTGAG CAGGACCCCGTAGAGACAAA c.191-28 - c.313+58 
LDLR Exon 4(1) FH504 F0 FH505 R0 TGGTGTTGGGAGACTTCACA CACTCATCCGAGCCATCTTC c.314-35 - c.519 
LDLR Exon 4(2) FH506 F1 FH507 R1 AAGTGCATCTCTCGGCAGTT CCCCTTGGAACACGTAAAGA c.377 - c.557 
LDLR Exon 4(3) FH508 F2 FH509 R2 AGCTTCCAGTGCAACAGCTC CATACCGCAGTTTTCCTCGT c.474 - c.679 
LDLR Exon 4(4) FH510 F3 FH511 R3 TGTTCCAAGGGGACAGTAGC AAATCACTGCATGTCCCACA c.586 - c.694+60 
LDLR Exon 5 FH116 FH136 AGAAAATCAACACACTCTGTCCTG GGAAAACCAGATGGCCAGCG c.695-8 - c.817+5 
LDLR Exon 6 FH117 FH137 TCCTCCTTCCTCTCTCTGGC TCTGCAAGCCGCCTGCACCG c.818-8 - c.940+8 
LDLR Exon 7 FH118 FH138 GGCGAAGGGATGGGTAGGGG GTTGCCATGTCAGGAAGCGC c.941-38 - c.1060+36 
LDLR Exon 8 FH567 FH568 CTAGCCATTGGGGAAGAGCC TGCCTGCAAGGGGTGAGGC c.1061-31 - c.1186+30 
LDLR Exon 9 FH9 FH28 TCCATCGACGGGTCCCCTCTGACCC AGCCCTCATCTCACCTGCGGGCCAA c.1187-26 - c.1358+25 
LDLR Exon 10 FH10 FH29 AGATGAGGGCTCCTGGTGCGATGCC GCCCTTGGTATCCGCAACAGAGACA c.1359-26 - c.1490 
LDLR Exon 10 FH11 FH141 GATCCACAGCAACATCTACTGGACC AGCCCTCAGCGTCGTGGATA c.1475 - c.1586+5 
LDLR Exon 11 FH122 FH142 TCCTCCCCCGCCCTCCAGCC GCTGGGACGGCTGTCCTGCG c.1587-28 - c.1705+7 
LDLR Exon 12 FH13 FH32 GCACGTGACCTCTCCTTATCCACTT CACCTAAGTGCTTCGATCTCGTACG c.1706-10 - c.1845+10 
LDLR Exon 13 FH550f FH551r AGAGGGTGGCCTGTGTCTC TCCACAAGGAGGTTTCAAGG c.1846-47 - c.1987+29 
LDLR Exon 14 FH265 FH145 GAATCTTCTGGTATAGCTGAT GCAGAGAGAGGCTCAGGAGG c.1988-39 - c.2140+46 
LDLR Exon 15 FH16 FH146 GAAGGGCCTGCAGGCACGTGGCACT GTGTGGTGGCGGGCCCAGTCTTT c.2141-26 - c.2311+2 
LDLR Exon 16 FH127 FH147 CCTTCCTTTAGACCTGGGCC CATAGCGGGAGGCTGTGACC c.2312-23 - c.2389+32 
LDLR Exon 17 FH128 FH148 GGGTCTCTGGTCTCGGGCGC GGCTCTGGCTTTCTAGAGAGGG c.2390-33 - c.2547+10 
LDLR Exon 18 FH129 FH149 GCCTGTTTCCTGAGTGCTGG TCTCAGGAAGGGTTCTGGGC c.2548-35 - c.2607 
PCSK9 Exon 7 FH433 FH434 CCCTCTCTTGGGCTCCTTTCT AAAGGGGCTGTTAGCATCACG c.997-27 - c.1180+29 
APOB Exon 26 FH521 FH522 TGTCAAGGGTTCGGTTCTTT GGGTGGCTTTGCTTGTATGT c.10516 - c.10745 
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Table III 
Gene burden test results for genes in loci associated with FH in family linkage studies. 
 
 
Chromosomal 
region 
Gene name 
Number of rare functional variants 
p value 
cases (n=71) controls (n=1926) 
21q22 (Wang et 
al. 2011) 
KRTAP10-
11 2 2 0.02 
 
PFKL 2 4 0.03 
 
DSCR8 1 0 0.05 
 
KRTAP11-1 1 0 0.05 
 
ERG 2 8 0.09 
 
KRTAP19-8 1 1 0.10 
 
LRRC3 2 10 0.13 
 
RCAN1 1 2 0.15 
 
SIM2 1 2 0.15 
 
SYNJ1 3 24 0.16 
 
CBR1 2 15 0.22 
 
COL18A1 3 30 0.24 
 
ZNF295 2 17 0.26 
 
C21orf59 1 5 0.27 
 
C21orf90 1 5 0.27 
 
ETS2 1 5 0.27 
 
C21orf56 1 6 0.31 
 
KRTAP12-4 1 6 0.31 
 
PKNOX1 1 6 0.31 
 
PCNT 5 68 0.33 
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BACH1 1 7 0.35 
 
MX1 1 7 0.35 
 
BRWD1 2 24 0.39 
 
PRDM15 2 25 0.41 
 
HLCS 1 9 0.41 
 
PRMT2 1 9 0.41 
 
DOPEY2 3 43 0.43 
 
SUMO3 1 10 0.44 
 
MX2 1 11 0.47 
 
TTC3 2 29 0.48 
 
AIRE 1 13 0.53 
 
TRPM2 2 35 0.58 
 
ABCG1 1 16 0.60 
 
FTCD 1 17 0.62 
 
ITSN1 1 20 0.67 
 
LSS 1 20 0.67 
 
DSCAM 1 21 0.69 
 
COL6A2 1 23 0.72 
 
C21orf2 1 24 0.74 
 
TRAPPC10 1 24 0.74 
 
TSPEAR 1 24 0.74 
 
UMODL1 1 30 0.81 
 
ITGB2 1 33 0.84 
 
MCM3AP 1 36 0.86 
 
URB1 1 57 0.95 
     16q22 (Marques- CMTM2 2 3 0.02 
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Pinheiro et al. 
2010) 
 
HSF4 2 6 0.06 
 
KCTD19 2 7 0.08 
 
CES4A 2 8 0.09 
 
CMTM4 1 2 0.15 
 
TMEM208 1 3 0.19 
 
CMTM3 1 5 0.27 
 
DPEP3 1 5 0.27 
 
TMCO7 1 5 0.27 
 
PLEKHG4 2 19 0.30 
 
C16orf48 1 6 0.31 
 
CDH16 2 20 0.32 
 
CES3 1 11 0.47 
 
CDH3 1 13 0.53 
 
COG4 1 14 0.55 
 
GFOD2 1 16 0.60 
 
TSNAXIP1 1 17 0.62 
 
FHOD1 1 19 0.65 
 
SLC12A4 1 19 0.65 
 
FUK 1 23 0.72 
     8q24 (Cenarro et 
al. 2011) WISP1 3 25 0.17 
 
ST3GAL1 1 8 0.38 
 
ZFAT 2 28 0.46 
     3q25 (Wang et HPS3 3 15 0.06 
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al. 2011) 
 
ZBBX 2 8 0.09 
 
NMD3 1 1 0.10 
 
TRIM59 1 1 0.10 
 
MLF1 2 11 0.14 
 
ANKUB1 1 2 0.15 
 
IL12A 1 2 0.15 
 
OTOL1 2 13 0.18 
 
C3orf80 1 3 0.19 
 
WWTR1 1 4 0.23 
 
SLITRK3 2 17 0.26 
 
SMC4 1 6 0.31 
 
B3GALNT1 1 9 0.41 
 
MFSD1 1 9 0.41 
 
SI 2 35 0.58 
 
MED12L 2 36 0.59 
 
MECOM 1 24 0.74 
 
IGSF10 1 34 0.84 
 
